WO2003084940A1 - Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors - Google Patents

Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors Download PDF

Info

Publication number
WO2003084940A1
WO2003084940A1 PCT/IB2003/001330 IB0301330W WO03084940A1 WO 2003084940 A1 WO2003084940 A1 WO 2003084940A1 IB 0301330 W IB0301330 W IB 0301330W WO 03084940 A1 WO03084940 A1 WO 03084940A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
ethyl
hydrazino
trifluoroacetate
cyanothiazolidine
Prior art date
Application number
PCT/IB2003/001330
Other languages
French (fr)
Other versions
WO2003084940B1 (en
Inventor
Alangudi Sankaranarayanan
Original Assignee
Alangudi Sankaranarayanan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alangudi Sankaranarayanan filed Critical Alangudi Sankaranarayanan
Priority to AU2003214534A priority Critical patent/AU2003214534B2/en
Priority to MXPA04009784A priority patent/MXPA04009784A/en
Priority to KR10-2004-7015994A priority patent/KR20040105853A/en
Priority to EP03710113A priority patent/EP1492777A1/en
Priority to BR0308816-2A priority patent/BR0308816A/en
Priority to CA002481995A priority patent/CA2481995A1/en
Priority to JP2003582137A priority patent/JP2005532283A/en
Priority to TW092127020A priority patent/TW200511994A/en
Publication of WO2003084940A1 publication Critical patent/WO2003084940A1/en
Publication of WO2003084940B1 publication Critical patent/WO2003084940B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • Hoist JJ and Deacon CF Inhibition of the activity of Dipeptidyl -peptidase IV as a treatment of type 2 diabetes. Diabetes, 47:1663-1670, 1998.
  • the present invention relates to novel heterocyclic compounds useful for normalizing elevated blood glucose levels in diabetics and in treating disorders related to glucose intolerance.
  • These compounds are useful to control blood glucose level in diabetic patients and thereby delay the onset of vascular complications in diabetic patients and also transition to type II diabetes in impaired glucose tolerant patients.
  • These compounds are also useful in treating disorders related to glucose intolerance like Cushing's syndrome, hyperthyroidism, obesity, hyperglucagonemia, diseases like ulcers, HIV infection, disorders related to increased gastric emptying, acid secretion and hunger, autoimmune disorders like multiple sclerosis, rheumatoid arthritis and Grave's disease (Sedo and Kraml, 1994).
  • Diabetes mellitus is a clinically and genetically heterogenous group of disorders characterized by abnormally high levels of glucose in the blood.
  • the hyperglycemia is due to deficiency of insulin secretion or to resistance of body cells to the action of insulin, or to a combination of these.
  • Chronic hyperglycemia is a cause of heavy burden of morbidity and premature mortality from diabetic complications. These long-term complications can be delayed by improving glycemic control. None of the currently used medications is capable of reversing an ongoing failure of ⁇ -cell function and reduction in post prandial glucose peak represents an important target for therapeutic strategies.
  • pancreatic insulin secretion is predominantly controlled by blood glucose levels
  • incretins like the peptide GLP-1 derived from enteroinsular axis have an effect on insulin secretion and therefore on the blood glucose level. It is released from the gut in response to ingested nutrients, which acts on the pancreas to potentiate glucose- induced insulin secretion.
  • GLP-1 has beneficial effects in diabetic patients in normalizing elevated blood glucose levels (Hoist J and Deacon C, 1998).
  • GLP-1 has multifaceted actions, which include stimulation of insulin gene expression, trophic effects on ⁇ -cells, inhibition of glucagon secretion, promotion of satiety, and slowing of gastric emptying. Because of glucose dependency of the peptide and glucagonostatic actions, the glucose lowering effect is self-limiting, and the hormone, therefore does not cause hypoglycemia regardless of the dose.
  • the pathogenesis of type-2 diabetes ordinarily involves the development of insulin resistance associated with compensatory hyperinsulinaemia followed by progressive beta-cell impairment that results in decreasing insulin secretion and hyperglycemia.
  • Hyperglycemia itself causes additional inhibition of insulin secretion and more insulin resistance (glucose toxicity), which further accentuates_the hyperglycemia.
  • DPP-IV/ CD 26 Dipeptidyl-peptidase IV
  • Impaired glucose tolerance and impaired fasting glucose is present in a large population. These abnormalities progress to a large extent to overt diabetes. No therapy has been approved for the prevention or delay of type-2 diabetes in these patients.
  • Dipeptidyl Peptidase IV (DPP-IV) inhibitors addresses to a large extent the inadequacies of the presently available therapies. It targets not only the ⁇ -cell dysfunction but also insulin resistance and increased hepatic glucose output by liver.
  • the homeodomain transcription factor, PDX-1 is essential for the early development of the pancreas and the maintenance of the ⁇ -cell phenotype.
  • PDX-1 is known to regulate insulin, GLUT2 and islet amyloid precursor.
  • GLP-1 induces the differentiation of PDX-1 positive pancreatic epithelial cells into insulin- secreting cells.
  • GLP-1 stimulates the expression of transcription factor PDX-1 while stimulating ⁇ -cell neogenesis and may thereby be an effective treatment for diabetes.
  • GLP-1 and a long acting GLP-1 analogue exendin-4 stimulates both ⁇ -cell replication and neogenesis, resulting in increased ⁇ -cell mass and improved glucose tolerance in partial pancreatectomy rat model of type 2 diabetes (Gang et al, 1999).
  • GLP- 1 7 - 36 is one of the substrate for the circulating exopeptidase dipeptidyl peptidase IV (EC 3.4.14.5), a post proline cleaving enzyme with a specificity for removing Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of polypeptides and proteins.
  • DPP-IV is widely distributed in tissues like kidney, intestine and placenta, hepatocytes, epithelial cells of pancreatic duct, central nervous system, peripheral nervous system, endothelial cells of blood vessels (Rolf, 1999), and found as soluble enzyme in blood plasma. About 50% of the GLP-1 7 .
  • This N- terminally truncated form is not insulinotropic and acts as an antagonist at GLP-1 receptor.
  • GLP- 1 is rapidly degraded in the circulation, which results in clearance that exceeds cardiac output and an apparent half-life of 1-1.5 min.
  • the truncated metabolite is eliminated more slowly, with half-lives of 4-5 min for GLP-l 9 - 36 . It has been speculated that DPP-IV-mediated hydrolysis is the primary mechanism of inactivation of this hormone in vivo (Tina et al, 2001).
  • DPP-IV inhibitor Isoleucine thiazolidide (P-32/98)
  • Isoleucine thiazolidide P-32/98
  • GLP-1 9 - 36 an antagonist at GLP-1 receptor
  • Inhibition of circulating DPP-IV enhanced insulin secretion and improved glucose tolerance in response to oral glucose challenge in lean and obese fatty (fa/fa) rats. (Raymond et al, 1998). Also it has improved glucose tolerance in zucker fatty rats (Robert et al, 1999)
  • DPP-IV inhibitor NVP-DPP-728 i.e. l-[-2- ⁇ (5- cyanopyridin-2-yl) amino ⁇ ethylamino]acetyl-2-cyano-(S)-pyrrolidine inhibits DPP- IN activity and improves insulin secretion and glucose tolerance, through augmentation of the effects of endogenous GLP-1.
  • the improvement in prandial glucose homeostasis during DPP-IV inhibition by this molecule suggests that inhibition of this enzyme is a promising target for treating type 2 diabetes (Balkan et al, 2000)
  • this molecule showed potentiation of insulinotropic effects of GLP-1 in anaesthetized pig (Carolyn et al, 1998).
  • Dipeptidyl Peptidase IV (DPP - IV) is a proline specific protease and is involved in breaking peptide bonds before or after a proline residue. It plays an important role in the regulation of the life-time of biological active peptides like growth hormone releasing factor (GRF), Glucagon-like peptide - I (GLP-I), Gastric Inhibitory Polypeptide (GIP), Glucagon-like peptide - II (GLP-II), ⁇ -Casomorphin, morphiceptin, Human ⁇ europeptide Y, Human Peptide YY (Augustyns K. et al.
  • GRF growth hormone releasing factor
  • GLP-I Gastric Inhibitory Polypeptide
  • GLP-II Gastric Inhibitory Polypeptide
  • GLP-II Glucagon-like peptide - II
  • ⁇ -Casomorphin morphiceptin
  • Human ⁇ europeptide Y Human
  • DPP - IV is present on the surface of a subset of T-cells (lymphocytes) and has been recognized as CD 26 antigen.
  • Dipeptidyl peptidase-IV (DPP-IV) is a serine protease, which cleaves N- terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position.
  • DPP-IV is responsible for inactivating glucagon-like peptide- 1 (GLP-1). More particularly, DPP-IV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1.
  • GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal
  • DPP-IV inhibition appears to represent an attractive approach for treating non-insulin-dependent diabetes mellitus ( ⁇ IDDM).
  • ⁇ IDDM non-insulin-dependent diabetes mellitus
  • GLP-1 has multifaceted actions, which include stimulation of insulin gene expression, trophic effects on ⁇ -cells, inhibition of glucagon secretion, promotion of satiety, and slowing of gastric emptying, all of which contribute to normalizing elevated blood glucose levels (Hoist and Deacon, 1998). Because of glucose dependency of the peptide and glucagonostatic actions, the glucose lowering effect is self-limiting, and the hormone, therefore does not cause hypoglycemia regardless of the dose.
  • Type - II Diabetes Mellitus -
  • DPP - IV is involved in the degradation of GIP and GLP-I.
  • GIP and GLP-I are considered to be most important insulin-releasing hormones (incretins) comprising the enteroinsular axis.
  • the term enteroinsular axis refers to the signaling pathways between the gut and pancreatic islets that amplify the insulin response to absorbed nutrients.
  • Inhibition of circulating DPP - IV with orally administered lie-thiazolidine [DPP-IV inhibitor] enhanced insulin secretion and improved glucose tolerance in response to an oral glucose challenge in lean and obese Zucker rats.
  • the enhanced incretin response was greater in obese than in lean animals, with a more profound improvement in glucose tolerance (Pederson R. A, 1998). This was attributed to disruption of DPP - IV inactivation of GIP and GLP-I, resulting in amplification of enteroinsular axis.
  • DPP-IV inhibitors would have very little effect on subjects with normal blood glucose levels regardless of dose because its actions are glucose dependent (Qualmann C et al. 1995).
  • thyroxine and triiodothyronine treatment inhibits the delayed phase of glucose-mediated insulin secretion- triiodothyronine being fivefold more potent than thyroxine.
  • gluconeogenic precursor lactate and glycerol
  • lactate and glycerol are present in increased concentration in plasma.
  • phosphate oxidase increases the capacity for gluconeogenesis from glycerol.
  • hyperthyroidism leads to an increase in futile cycling of glucose, which could contribute to hyperglycemia.
  • Increased activity of several enzymes that could be implicated in the increase in gluconeogenesis have been seen in response to thyroid hormone, including glucokinase, pyruvate carboxylase, phospho-enolpyruvate carboxykinase, and glucose-6-phosphatase.
  • Obesity has been related to insulin resistance and hyperinsulinemia.
  • Visceral obesity is associated with specific changes in skeletal muscle morphology that correlate with insulin resistance and hyperinsulinemia, namely a reduction in capillary density and an increase in the proportion of 'white' or 'glycolytic' fibers which are less insulin sensitive than red (glycolytic) fibers.
  • TNF-alpha is secreted by adipose tissue and its circulating levels parallel total body fat mass. Circulating non-esterified fatty acid (NEFA) levels are raised in obese subjects, especially those with visceral obesity.
  • NEFA non-esterified fatty acid
  • NEFA are oxidised to acetyl CoA, which stimulates pyruvate carboxylase and therefore gluconeogenic production of glucose from pyruvate; hepatic glucose production therefore increases.
  • High NEFA level may also inhibit glucose utilization by skeletal muscle.
  • Increased acetyl CoA levels inhibit pyruvate dehydrogenase, thus decreasing glucose oxidation.
  • the combination of increased hepatic glucose output and reduced peripheral uptake effectively antagonises and would ultimately lead to hyperglycemia (Ronald T Jung, 1997). Glucose intolerance as a result of the above conditions can be managed better by the elevation of GLP-1 levels (as a result of DPP-IV inhibition).
  • Cushing's syndrome represents a distinctive constellation of clinical features associated with prolonged overproduction of impaired glucose tolerance, overt diabetes (in approximately 20%), loss of libido and impotence. Some of these abnormalities such as obesity, deranged glucose metabolism are directly attributable to increased glucocorticoids. These glucocorticoids stimulate gluconeogenesis in diabetes. Also, they increase amino acid uptake by the liver and kidney and increase the activity of enzymes required for gluconeogenesis and may lead to hyperglycemia (Ronald A DeLellius, 1989)
  • Glucose metabolism under the above conditions can be managed better by treatment with DPP-IV inhibitors.
  • DPP-IV inhibitors are reported to inhibit HIV infection such as pyrrolidine-2-nitriles and an irreversible cyclopeptide inhibitor (Nguyen C et al. 1998).
  • DPP-IV has been originally described to be a marker of activated T lymphocytes and lately DPP-IV/CD26 molecular identity has been proven
  • CD26/DPP-IN serves as an essential cofactor for HIN entry into CD cells and that its enzyme activity is an important condition for this function (Sedo A and Kraml J, 1994). Hence inhibition of DPP-IV could prove useful in the management of HIV infection.
  • DPP-IV / CD26 plays an important role in the immune system by a number of possible mechanisms. The exact mechanism remains to be elucidated, but a few examples are reported where DPP-IV inhibitors are useful immunosuppressahts in vivo. A dipeptide diphenyl phosphonate ester was able to abrogate acute rejection and prolong allograft cardiac survival (Korom S. et al. 1997). Role of DPP-IV inhibitors in ulcers, hyperglucagonemia, gastric emptying and hunger
  • DPP-IV inhibitors increase the level of GLP-1.
  • GLP-1 has multifaceted actions, which include stimulation of insulin gene expression, inhibition of glucagon secretion, promotion of satiety, inhibition of food intake and slowing of gastric emptying (Hoist JJ and Deacon CF, 1998).
  • GLP-1 also reduces gastric acid secretion (Michael A Nauck, 1999). Increase in gastric acid secretion is one the main reason for duodenal ulcers. By inhibiting gastric acid secretion, GLP-1 and therefore DPP-IV inhibitors may prove useful for the treatment of ulcers or can be used in combination with other antiulcer agents.
  • DPP-IV is involved in metabolic processing of morphiceptin.
  • Co- administration of a DPP- IV and the opiate peptide morphiceptin could be used in case of diarrhoea, as the experiment with DPP-IV deficient rats showed (Tiruppathi, C, et al., Am. J. Physiol. 1993).
  • GLP-2 DPP-IV hydrolysis of GLP-2 is responsible for its inactivation.
  • GLP-2 has recently been shown to display intestinal growth factor activity in rodents, raising the possibility that GLP-2 may be therapeutically useful for enhancement of mucosal regeneration in patients with intestinal disease (Drucker, D.J. et al. Diabetes 1998; 47:159).
  • a suitable DPP-IV inhibitor leads as a causal consequence to a reduced degradation of the neuropeptide Y(NPY) in the brain of mammals.
  • Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36).
  • NPY activity is prolonged thereby resulting among other things in functionally active NPY YI receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects (WO 02/34243 dated 02 May 2002 by PROBIODRUG AG).
  • DPP-IV is able to bind proteins of the extracellular matrix as a cell adhesion molecule. This has been inte ⁇ reted from the observation that the DPP-IV inhibitors interfere in vitro with the initial spreading of rat hepatocytes on a matrix consisting of fibronectin and collagen. Thus the DPP-IV inhibitors could also be used for the prevention/treatment of cancer metastasis and tumour colonization (WO 03/002595 dated 09 Jan 2003 by PROBIODRUG AG).
  • Free Radical Scavenging Activity It has been reported that compounds exhibiting free radical scavenging activity are useful in treatment of Neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Motor Neuron Disease, Prion Disease etc, (b) Diabetes and Diabetic Vascular Complications, (c) Intestinal Diseases such as Intestinal Ischemia, Radiation Enteritis, Inflammatory Bowel Disease, Gastric and Colorectal Cancers etc., (d) Liver Diseases such as Alcoholic Liver Disease, Chronic Hepatitis C etc., (e) Cancers such as Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Malignant Melanoma etc, (f) Cardiac Diseases such as Atherosclerosis, Myocardial Infarction, Ischemic Stroke, Endothelial Dysfunction etc., (g) Opthalmic Disorders such as Cataract formation, Macular degeneration etc., (h) HIV Diseases, (i) Respiratory Diseases such
  • Neuro-degenerative disorders such as Alzheimer's disease (A.D.), Parkinson's disease (P. D.), Huntington's disease (H.D.), Motor neuron disease (M.N.D), Prion disease
  • Oxidative stress induced by ROS damages essential components of the neurons, resulting ultimately in the neuronal death.
  • Oxidative stress is involved in various divergent events leading to neuronal damage, including an increase in membrane rigidity, DNA strand break, and impairment in glucose uptake.
  • Several potential sources of oxidative stress in different neurodegenerative disorders have been well identified (Munch G, et al. 1998).
  • Oxidative stress in diabetes is not yet fully understood but is thought to be due to mitochondrial dysfunction, direct enzyme inhibition by hyperglycemia, auto-oxidation of glucose, and activation of nicotinamide-adenine dinucleotide phosphate (NADPH)-oxidase.
  • Oxidative stress in diabetes is also increased due to weakened defenses due to reduced endogenous antioxidants.
  • the oxidative stress manifests itself as elevated concentrations of lipid peroxidation products, erythrocyte fragility, and decreases in the antioxidant enzyme systems (CAT, GSH Px, SOD). Recent studies also have shown a positive correlation between blood glucose concentration and oxidant-induced lymphocyte DNA damage (E.J. Harper The 24 th Annual WALTHAM ® /OSU SYMPOSIUM).
  • ROS are generated during glucose oxidation and formation of advanced glycation end products (AGE). Evidence has accumulated indicating that the generation of ROS plays an important role in the development of DVCs.
  • Many biochemical pathways associated with hyperglycemia such as advanced glycosylation, glucose auto oxidation, and polyol pathway can increase the production of free radicals. Hyperglycemia in diabetic patients leads to excess auto-oxidation of glucose thereby reducing molecular oxygen and yielding oxidizing intermediates such as superoxide ions (O " ), hydroxyl radicals (OH), and hydrogen peroxide (H 2 O ).
  • Oxidative stress is an important cause of tissue injury that occurs in inflammation and ischemia. Intestinal ischemia, radiation enteritis, inflammatory bowel disease, and promotion of gastric and colorectal cancers are some of the gastro-intestinal conditions where oxidative stress is implicated in the pathogenesis.
  • Alcoholic liver disease- Ethanol induces an increase in lipid peroxidation either by enhancing ROS or decreasing the level of endogenous antioxidants. Ethanol also induces variety of cytochrome P450 enzymes in microsomes and xanthine oxidases in cytosol. The role of these enzymes in the generation of oxidative stress has been well established in various studies (Ishii H, et al. 1997).
  • This fibrogenesis cascade characteristic of severe chronic hepatitis C e.g., oxidative stress, induction of c-myb, activation of stellate cells, and collagen gene expression
  • ROS reactive oxygen species
  • Oxidative damage to DNA is a result of interaction of DNA with ROS, in particular the hydroxyl radical.
  • the hydroxyl radicals produce multiple modifications in DNA.
  • Oxidative attack by OH radical on the deoxyribose moiety leads to the release of free bases from DNA, generating strand breaks with various sugar modifications and simple abasic (AP) sites
  • ROS also interact with and modify cellular protein, lipid, and DNA, which results in altered target cell function.
  • the accumulation of oxidative damage has been implicated in both acute and chronic cell injury including possible participation in the formation of cancer. Acute oxidative injury may produce selective cell death and a compensatory increase in cell proliferation.
  • ROS therefore, can have multiple effects in the initiation stage of carcinogenesis by mediating carcinogen activation, causing DNA damage, and interfering with the repair of the DNA damage.
  • Oxidative stress can activate redox-sensitive kinase cascades and transcription factors such as NF K B and AP-1, with resulting increases in the expression of factors associated with an inflammatory response and cellular proliferation.
  • NADH/NADPH oxidase There are three enzyme systems producing reactive oxygen species in the vascular wall: NADH/NADPH oxidase, xanthine oxidoreductase, and endothelial nitric oxide synthase (Zalba G.et al, 2000, Rosenfeld ME, 1998).
  • Atherogenesis is regarded as the outcome of interactions among multiple stimuli.
  • Endothelial dysfunction plays a key role in the development of atherosclerosis. Elevated homocysteine concentrations are associated with rapid onset endothelial dysfunction, which is another mechanism by which increased oxidative stress contributes to atherosclerosis.
  • Oxidation of low-density lipoprotein plays an important role at several steps in atherogenesis. Oxidative stress also activates NF JB, which induces expression of genes controlling cytokine expression and leukocyte adhesion to vascular wall. (Maxwell, et al. 1997).
  • Oxidative damage to lens of the eye with increase in age has a major contribution in cataract formation. Macular degeneration is also being recognized as a consequence of oxidative damage.
  • Oxidative stress may contribute to several aspects of HIV disease pathogenesis such as viral replication, inflammatory response, and decreased immune cell proliferation, loss of immune function, apoptosis, chronic weight loss.
  • Antioxidants may offer a promising treatment to HIV patients.
  • COPD Chronic obstructive pulmonary diseases
  • Oxidative stress is implicated in the pathogenesis of COPD, since it results in inactivation of anti proteinases, airspace epithelial injury, mucus hypersecretion, increased influx of neutrophils into the lungs, transcription factor activation and gene expression of pro-inflammatory mediators (MacNee W, et al. 2001).
  • Renal Disease ROS have been implicated not only in the genesis of different forms of renal disease, predominantly experimentally induced glomerulonephritis, but also in different forms of acute renal failure.
  • ROS ROS
  • the immune system is particularly sensitive to oxidative stress, primarily because immune cells rely heavily on cell-to-cell communication to work effectively. Peroxidation of cell membranes compromises membrane integrity and disrupts intracellular signaling.
  • Oxidative damage to lens of eye with increase in age has been a major contribution in cataract formation.
  • the following diseases can be treated or controlled :
  • COPD Chronic Obstructive Pulmonary Diseases
  • the first object of the present invention is to provide a new class of compounds which normalize elevated blood glucose levels in diabetic patients thereby delaying diabetic complications and preventing transition to type II diabetes in impaired glucose tolerant patients.
  • DPP-IV inhibitors enhance the level of active GLP-1, which would be advantageous in treating hyperglycemia. Added advantage is that there is no risk of hypoglycemia, since GLP-1 increases glucose mediated insulin secretion. Due to non-peptide nature of the compounds, they can be conveniently administered orally.
  • the increase in GLP-1 level in the active form provides for multifaceted action in respect of increase in insulin level, decrease in glucagon level, neogenesis of pancreatic ⁇ -cell, stimulation of insulin gene expression, and promotion of satiety, all of which contribute to beneficial effects in a diabetic patient.
  • Another object of the invention is to provide a method of treatment of a diabetic patient with glucose intolerance by administration of the compounds of the invention or pharmaceutically acceptable salts thereof either singly or in combination with drugs for anti-diabetic or other therapies for Cushing's syndrome, hyperthyroidism, HIV infection, obesity, ulcers, disorders related to hyperglucagonemia, gastric emptying and hunger in required dosage in admixture with pharmaceutically acceptable diluents, solvents, excepients, carriers or other media as may be appropriate for the purpose.
  • a further object of the invention is to provide a class of compounds having free radical scavenging activity which are useful for treatment of (a) Neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Motor Neuron Disease, Prion Disease etc, (b) Diabetes and Diabetic Vascular Complications, (c) Intestinal Diseases such as Intestinal Ischemia, Radiation Enteritis, Inflammatory Bowel Disease, Gastric and Colorectal Cancers etc., (d) Liver Diseases such as Alcoholic Liver Disease, Chronic Hepatitis C etc., (e) Cancers such as Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Malignant Melanoma etc., (f) Cardiac Diseases such as Atherosclerosis, Myocardial Infarction, Ischemic Stroke, Endothelial Dysfunction etc., (g) Opthalmic Disorders such as Cataract formation, Macular degeneration etc., (h) HIV Diseases, (i) Respir
  • Yet another object of the present invention is to provide a method of preparation of these compounds.
  • a still further object of the invention is to provide a pharmaceutical composition
  • a pharmaceutical composition comprising said compound in association with a pharmaceutical acceptable carrier, diluent or excepients.
  • Yet another object of the invention is to provide a method of treatment and/or prophylaxis of mammals including human beings for diseases relating to glucose intolerance and/or disease conditions caused by accumulation of free radicals in the body cells.
  • the present invention provides novel compounds represented by general formula (I), its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, which are useful for one or more of (i) normalizing elevated blood glucose levels in diabetes, (ii) treating disorders related to glucose intolerance and (iii) scavenging free radicals from body cells.
  • X is O, S, SO, SO 2 , NR7 or CHR1 ; n is null or 1 ; k is null or 1 ;
  • Z is O, S, and NR7 ;
  • Rl at two positions are independently selected from hydrogen or a substituted or unsubstituted group selected from linear or branched (C ⁇ -C ⁇ 2 )alkyl, (C 2 -C ⁇ )alkenyl, (C 3 -C )cycloalkyl, (C 5 -C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, wherein one or more heteroatoms are independently selected from O, N or S;
  • R2, R3, R4 and R7 are independently selected from hydrogen, perhaloalkyl, - (CO)NR8R9, -(CO)R8,-(CO)OR8, -SO2R8, -SOR8, substituted or unsubstituted groups selected from linear or branched (d-C ⁇ 2 )alkyl, (C 2 -C
  • R5 and R6 are independently selected from by hydrogen or a substituted or unsubstituted group selected from linear or branched (C ⁇ -C ⁇ 2 )alkyl, (C 2 -C ⁇ 2 )alkenyl, (C 3 .C 7 )cycloalkyl, (C 5 -C )cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl,aralkyl, heteroaryl,heteroaralkyl, wherein one or more heteroatoms are independently selected from O, N or S;
  • R8 and R9 are independently selected from hydrogen or a substituted and unsubstituted group selected from linear or branched (C t -C ⁇ )alkyl, alkoxyaryl, alkoxyalkyl, alkoxycycloalkyl, alkoxyaryl, perhaloalkyl, (C -C ⁇ )alkenyl, (C 3 -C ) cycloalkyl, perhalocycloalkyl, haloheterocycloalkyl, cyanoheterocycloalkyl, perhaloheterocycloalkyl, (C 5 -C 7 ) cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, perhaloaryl, perhaloheteroaryl;
  • substitutents are optionally and independently bridged by -(CO)-, - (CO)O, -(CO)NH-, -NH-, -NR8-, -O-, -S-, -(SO)-, -(SO2)-, -(SO2)NH-, -NH(SO2)-, - O(CO)- or -NH(CO)-; and are selected from halogen, hydroxy, nitro, cyano, amino, oxo, oxime, unsubstituted or substituted by R10 for the groups selected from linear or branched (C 1 -C8) alkyl, (C 3 -C )cycloalkyl, alkylcycloalkyl, perhaloalkyl, perhalocycloalkyl, aryl, aralkyl, alkylaryl, alkylheter
  • RIO is independently selected from halogen, hydroxy, nitro, cyano, amino, oxo or oxime, and pharmaceutically usable hydrates and salts thereof ;
  • R4 and R6 together form an optionally six or seven membered ring, which optionally contains two to three heteroatoms independently selected from O, S and NR7 with Rl as hydrogen, and Ni is attached to hydrogen.
  • aryl and heteroaryl ring includes up to two conjugated or fused ring systems.
  • Pharmaceutically acceptable salts forming part of this invention are intended to include not limited to salts of the carboxylic acid moiety such as alkali metal salts like Li, Na and K salts; alkaline earth metal salts like Ca and Mg salts; salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, trimethamine and the like; ammonium or substituted ammonium salts and aluminum salts.
  • alkali metal salts like Li, Na and K salts
  • alkaline earth metal salts like Ca and Mg salts
  • salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, trimethamine and the like
  • ammonium or substituted ammonium salts and aluminum salts such as sodium or substituted ammonium salts and aluminum salts.
  • Salts may be acid addition salts which defines but not limited to sulfates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, perhaloacetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzensulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
  • the invention also provides a process for preparation of the compounds as defined above.
  • the invention further provides pharmaceutical composition comprising compounds of the invention in association with a pharmaceutically acceptable carrier, diluent or excepient.
  • the invention also provides a method of treatment of mammals including human beings in disease conditions resulting from glucose intolerance and/or accumulation of free radical in the body cells by administering an effective compound of compounds of the invention to the subject in need thereof.
  • the invention further provides use of the compounds of invention in the manufacture of a medicament useful for treatment of diseases conditions resulting from glucose intolerance and/or accumulation free radical in the body cells.
  • Fig 1 This shows the effect of test compound (compound No. 95) on AUC in OGTT for the glucose load of 1 gm/kg in nSTZ induced diabetic rat.
  • Fig. 2 This shows the effect of test compound (compound No.95) pre-treatment on the glucose excursion.
  • the assay method is a modified method (as described by Welch et al, 1998) based on spectrophotometric determination of the product formed by penultimate proline cleaving activity of the enzyme.
  • Gly-Pro-pNA Glycine-Proline-p-nitroanilide Assay protocol involves incubation of the enzyme dipeptidyl peptidase IN with the test substance at 30° C for 30 min followed by addition of this reaction mixture to the substrate Gly-Pro-p ⁇ A that was equilibrated at 30° C for 2 min. The enzyme cleaves the substrate at penultimate proline and releases p-nitroanilide, the optical density of which is measured at 385 nm. The formation of p-nitroanilide will be reduced in the presence of inhibitor. Optical density is measured for 2 hours for every lO in using a spectrophotometer and N max is calculated to find the activity of new chemical entities.
  • the activity of molecule is expressed in terms of % inhibition. Atleast three different concentrations were tried out for each of the test substances. The percentage inhibitions for each of the concentrations were plotted and an IC 50 of the test compound was worked out. The enzyme inhibitory activity of different test compounds were compared based on the IC 50 values.
  • the percentage inhibition %I is calculated using the formula:
  • % I [(l-Vj/v 0 )]*100 where Vj and v 0 are the N max values with and without the test substance, respectively.
  • Enzyme solution Porcine DPP-IV (Sigma-Aldrich Germany) was used throughout the study. 0.4 mU in 80 ⁇ l of Tris. HCI buffer was prepared. Fresh solutions were prepared everyday for the assays.
  • inhibitor compound 95
  • vehicle vehicle
  • enzyme 280 ⁇ l of enzyme solution (0.4- mU/80 ⁇ l in Tris HCI buffer) was added to the eppendorf containing 70 ⁇ l solution of inhibitor or vehicle and mixed. This reaction mixture was incubated for 30 min at 30 °C. The 96 well plate containing substrate solution was thermally equilibrated in the spectrophotometer for 2 min at 30°C. Later 100 ⁇ l of the enzyme-inhibitor pre- incubation solution was added to respective wells in a 96 well plate. Each concentration of the inhibitor was tested in triplicates.
  • the rate of change in UV absorbance was measured at 385 nm, with respect to wells containing only 0.5 mM substrate in 45 mM phosphate buffer as blank at every 10 min for 2 hours after adding enzyme-inhibitor mixture to wells containing substrate solution.
  • mice Male STZ induced diabetic rats aged 10-12 weeks and weighing between 200-250gm were used for the study. These rats were treated with streptozotocin administered intraperitoneally on the day of birth at a dose of 90 mg/kg. They were maintained under standard conditions till the age of 10-12 weeks when they were used for the study.
  • Glucose solution (l gm/4ml of saline), Diethyl ether compound no. 95 (8mg/ml/kg), vehicle (lml/kg), Heparinized saline (lOOIU/ml), glucometer and strips
  • Method Animals were divided into two groups Group I: 8 hours fasted rats were treated with compound no. 95 vehicle (1 ml/kg, i.v.) 5 min before administration of glucose load.
  • Group II 8 hours fasted rats were treated with compound no. 95 (8mg/ ml/kg, i.v) 5 min before administration of glucose load.
  • blood glucose level was estimated by the glucose oxidase method using a LifeScan glucometer (Ca, USA). Blood glucose level at various time points was subtracted from the basal (0 min) reading. This was done to avoid changes in
  • AUC because of variation in basal glucose level.
  • the glucose excursion at various time points was plotted against time and the AUC was calculated.
  • the activity of compound no. 95 was expressed as % reduction in AUC as compared with that of its vehicle.
  • Table B Effect of compound no. 95 (8mg/ml/kg; i.v) pre-treatment on glucose excursions after a 1 gm/kg glucose load in nSTZ induced diabetic rats
  • DPPH radical solution 900 ⁇ l was added to an eppendorf tube. To it was added lOO ⁇ l of various concentrations of drug solutions in methanol.
  • control and test samples were recorded after incubation at 30°C for 30 minutes, at 515nm taking methanol as blank.
  • % Antioxidant activity 100-[O.D of test sample/O.D of control* 100] TABLE - 3
  • test compounds listed in the Table 3 above exhibit invitro (antioxidant) free radical scavenging activity. Excessive production of free radicals; reactive oxygen species (ROS) results in oxidative stress . Therefore, these molecules would be very effective in reducing oxidative stress by their ability to trap ROS. Antioxidants (free radicals scavengers) are reported to be effective in the management of various diseases linked with oxidative stress.
  • the novel compounds show Free Radical Scavenging Activity which is useful for (a) Neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Motor Neuron Disease, Prion Disease etc, (b) Diabetes and Diabetic Vascular Complications, (c) Intestinal Diseases such as Intestinal Ischemia, Radiation Enteritis, Inflammatory Bowel Disease, Gastric and Colorectal Cancers etc., (d) Liver Diseases such as Alcoholic Liver Disease, Chronic Hepatitis C etc., (e) Cancers such as Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Malignant Melanoma etc., (f) Cardiac Diseases such as Atherosclerosis, Myocardial infarction, Ischemic Stroke, Endothelial Dysfunction etc., (g) Opthalmic Disorders such as Cataract formation, Macular degeneration etc., (h) HIV Diseases, (i) Respiratory Diseases such as Chronic Obstructive Pulmonary
  • Oral glucose tolerance test is one of the methods to test pre-diabetic or diabetic condition and to evaluate insulin secretagogues and/or releasers.
  • Glucose level in the body is mainly controlled by insulin although many other factors contribute to insulin release.
  • Administration of glucose by oral route will increase the glucose level in the blood, which induces the release of insulin. This glucose stimulated insulin release is impaired in diabetes.
  • pretreatment with drugs that releases or stimulates insulin release before taking food/glucose the rise in glucose level can be controlled.
  • Figure-2 and Table-2 show a distinct decrease in the compound no. 95 treated animal's blood glucose values as compared to the corresponding vehicle treated group. This is also reflected in the decrease in AUC of glucose in compound no. 95 treated group as compared to vehicle group. From the graphs shown in figures 1 and 2 it is evident that compound no. 95 controls hyperglycemia and brings the glucose levels to normoglycemic range. Please note that the negative values do not represent hypoglycemia; it is only a fall below the basal hyperglycemic level. This could be explained by an increase in glucose mediated insulin secretion by compound no. 95. Hence, it is concluded that compound no. 95 would be a useful in the management of hyperglycemia in type II diabetes.
  • Free radicals along with AGE formation contributes to macroangiopathic (atherosclerosis, coronary artery disease) and microangiopathic (neuropathy, retinopathy, nephropathy) complication of diabetes.
  • the test compounds listed in Table-3 exhibit in vitro (antioxidant) free radical scavenging activity.
  • the novel compounds show free radical scavenging activity, which would be useful for treatment of diabetes and diabetic vascular complications (DVCs).
  • the DPP-IV inhibitors under study are preferably expected to not only control diabetes, but also to prevent diabetic complications by their antioxidant actions.
  • the compounds of the invention may be prepared by alternative synthetic routes as per Scheme I, II or III as described below:
  • the compounds of present invention may be prepared by the general methods as depicted in Scheme (I).
  • the starting amide compound of formula (1) i.e L — prolinamide is prepared in four steps from L-proline following the same methods as described in literature for the synthesis of (R)-(-)-thiazolidine-4-amide of formula (2) from the corresponding acid.
  • L-prolinamide (1) is then converted to l-chloroacetyl-2- cyanopyrrolidine of formula (3) in two steps which involves chloroacylation of the amide followed by dehydration [Ref. US pat -6124305 dated 26.09.00, WO- 0034241 dated 15.06.00 and US pat 601 1 155 dated 01.04.00].
  • Step-1 involves the reaction of thiazolidine amide of formula (2) with chloroacetylchloride in presence of a base such as potassium carbonate and an inert organic solvent like tetrahydrofuran at a temperature of from 0 °C to 20 °C for 2.5 to 3 hrs.
  • a base such as potassium carbonate
  • an inert organic solvent like tetrahydrofuran
  • Step 2 involves the dehydration of 3-chloroacetyl-thiazolidine-4-amide prepared in step-1, with 2-equivalents of trifluroacetic anhydride conducted in presence of an inert organic solvent such as tetrahydrofuran at a temperature preferably at 20 °C.
  • the second major component of the present invention i.e. N-2-substituted - tertbutyl carbazates of formulae (18) and (19), is prepared by the conventional manner.
  • the tert-butyl alkylidine carbazates of formula (17) is prepared by refluxing hexane or tetrahydrofuran solution of tert-butyl carbazate (15) with appropriate aldehyde or ketone of formula (16) in 1 :1 molar ratio for 2-4 hrs.
  • tert-butyl alkylidine carbazates of formula (17) is prepared by refluxing hexane or tetrahydrofuran solution of tert-butyl carbazate (15) with appropriate aldehyde or ketone of formula (16) in 1 :1 molar ratio for 2-4 hrs.
  • the alkylidine carbazates thus formed in the previous step is reduced to N-2 substituted -tert-butyl carbazates of formula (18) using metal hydrides like sodium borohydride or lithium aluminium hydride, preferably sodium borohydride and Sodium cyanoborohydride.
  • metal hydrides like sodium borohydride or lithium aluminium hydride, preferably sodium borohydride and Sodium cyanoborohydride.
  • the solvent used in the reaction is organic solvent like methanol or tetrahydrofuran at a temperature ranging from 25°C to 70°C for 4 to 20 hrs.
  • Piperazine-2-carboxylic acid dihydrochloride (20) is first protected by using usual protecting groups like Boc (tert-butyloxycarbonyl) or CBZ (benzyloxycarbonyl).
  • the protected acid (21) is subjected to coupling with L- prolinamide (J_) or (R)-(-)-thiazolidine-4-amide (2) to give the coupled products (23) or (24).
  • DCC dicyclohexylcarbodiimide
  • NOSU N-hydroxysuccinimide
  • DIEA diisopropylethyl amine
  • i.Et 3 N THF or DCM, -25° to 4°C, N 2 , 10-16 hrs. ii.Et 3 N, THF or DCM, Reflux, 6-10 hrs. iii.(CF 3 CO) 2 O, THF, Room temp. 2-4 hrs., iv.CF 3 COOH, THF, 5°C to Room temp. 0.5 to 2 hrs., v.Aqueous NaHCO 3 , vi.MeOH.HCl vii.Et 3 N,THF, -5° to 0°C, 1-2 hrs., N 2 , viii.Et 3 N, THF, 5° to 60°C, 12-18 hrs.
  • amide derivatives (36,37) can also be obtained by chlorocarbonylation of tert-butyl-carbazates (18) with trichloromethyl chloroformate (33) in presence of Et 3 N at a low temperature(-5° to 0° C), followed by coupling of the amides (1,2) with the chlorocarbonyl derivative of carbazates (38) in presence of Et 3 N / THF at a temperature ranging from 25° to 60°C for 8-12 hrs.
  • step-2 Product obtained in step-2 (0.25g, 0.68 mmol) is taken with trifluoroaceticacid (2.0 ml) at 0°C and allowed to stir at 5-l0°C for 10 minutes. Trifluoroaceticacid removed in vacuo and final traces of trifluoroaceticacid removed by stripping off with toluene and methanol respectively, gives white solid as a trifluoroacetate salt, final product. (Yield 0.179g, 69 %).
  • step-2 of example- 1 (0.6g, 1.57 mmol) was stirred with trifluoroacetic acid (5 ml) at 5-10°C for 10 minutes. Trifluoro acetic acid removed in vacuo. To the residue, added 5ml water and 5 ml saturated sodium carbonate solution, extracted with ethylacetate, evaporated to dryness yielded a mass. Resulting mass was refluxed in acetone (10ml) for 2 hrs. Excess solvent was removed in vacuo. Obtained mass was taken in methanol (15ml), cooled to 0°C, added sodium cyanoborohydride (8.1mmol, 0.30g) in portions, and stirred for 1 hr.
  • Example-3 1,1 -dioxo-3-[ 1 -oxo-2-(l -methylcyclohexyl)hydrazino)]ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 67).
  • Title compound is prepared by same method described in example- 1 using N-(4- methyl-cyclohexyl)ter-butyl carbazate and 3-chloro-acyl-4-cyanothiazolidine-l,l- dioxide (prepared as followed).
  • step-1 15.18 mmol as prepared in step-1 is added a solution of N-hydroxysuccinimide (1.75g, 15.21 mmol) in THF (20ml) and a solution of DCC (3.6g, 17.47 mmol) in
  • prolinamide derivative can be prepared by the following method.
  • step-3 Deprotection of the above compound as obtained in step-3 is done by stirring a solution of the compound (0.5g, 1.22 mmol) in CH 3 CN (10ml) with TFA (7ml) at room temperature for 2 hrs. Excess TFA and CH 3 CN removed in vacuo followed by stripping off with toluene and methanol respectively results in the formation of deprotected product as trifluoroacetate salt. (Yield 0.52g, 97.32%).
  • the compound is protected using di-tert-butyl dicarbonate (0.18g, 0.82 mmol) and NaOH (0.05g, 1.25 mmol) in the same way as described in step-1 and purified by column chromatography (50% ethyl acetate/hexane). (Yield 0.15g, 53.57%). This is finally deprotected using trifluoroacetic acid (2ml) resulting in the formation of the final product as trifluoroacetate salt. (Yield 0.1 lg, 53.92%).
  • step-1 To a solution of thiazolidine amide (0.66g, 5.0 mmol) and the product obtained in step-1 (1.96g, 7.10 mmol) in THF (30ml) is added a solution of triethylamine (1.6g, 15.84 mmol) in THF (10ml) dropwise at 5°C over a period of half an hr. Stirred at room temp, for 15 hrs, followed by refluxing for 1 hr.
  • Step-3 Trifluoroacetic anhydride (0.54g, 2.57 mmol) is added to a solution of the amide compound (0.80g, 2.15 mmol) as obtained in step-2, in THF (15ml) at 5°C and stirred at 30°C for 3 hrs. Excess solvents removed in vacuo, diluted with ethyl acetate, washed with aqueous 5% NaHCO 3 solution, dried (Na 2 SO 4 ) and concentrated. Crude material purified by column chromatography (20% ethyl acetate/ hexane). (Yield 0.43g, 56.48%).
  • the deprotection is done by stirring a solution of the cyano compound (0.43g,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

The invention discloses a novel series of compound represented by general formula (I), its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, solvates wherein X, n, k, z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (I) normalizing elevated blood glucose levels in diabetes, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals of mammals. The invention also discloses pharmaceutically acceptable composition comprising these compounds, method for preparation of the compounds as defined above and method of treating mammals including human beings by administering an effective amount of said compounds to a subject in need thereof. The invention further discloses use of these compounds in the manufacture of a medicament useful for treatment of different disease conditions as stated above.

Description

THIAZ0LIDINE-4-CARB0NITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYL-PEPTIDAS INHIBITORS
CROSS REFERENCE TO RELATED APPLICATIONS
5
This application claims benefit from U.S. provisional application No.60/370,224 filed April 08, 2002 which is incorporated herein by reference in its entirety.
Literature References
10
Augustyns K. et al. The unique properties of Dipeptidyl-peptidase IV (DPP-IN/ CD 26) and the therapeutic potential of DPP - IV inhibitors. Current Medical Chemistry 1999; 6:31 1-327
15 Bork Balkan and Xue Li : Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol regulatory Comp Physiol 279:R1449-R1454,2000.
Balkan B, Kwasnik L, Miserendino Rep, Hoist JJ, Li X: Inhibition of dipeptidyl 20 peptidase IV with ΝVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese zucker rats. Diabetologia 42:1324- 1331,1999.
Brubaker P.L. et al. Am. J. Physiol. 1997; 272:E1050.
25
Browne SE et al. Brain Pathology (1999) 9;147-163
Carolyn FD, Thomas EH, Jens JH: Dipeptidyl peptidase IV inhibition potentiates the 30 insulinotropic effect of glucagon-like peptide 1 in the anaesthetized pig. Diabetes 47:764-769,1998.
Doyle ME and Egan JM: Glucagon-like peptide- 1. Glucagon-like peptide 1. Recent Prog Horm Res 56:377-399,2001. Drucker, D.J. et al. Diabetes 1998; 47:159. Gang et.al., Diabetes, Vol.48, December, 1999; 2270-2276
Harold E Lebovitz, Pathogenesis of type-2 Diabetes; Drug Benefit Trends 12 (supp A): 8- 16, 2000
Harper E. J. The 24th Annual WALTHAM ®OSU SYMPOSIUM.
Hoist JJ and Deacon CF: Inhibition of the activity of Dipeptidyl -peptidase IV as a treatment of type 2 diabetes. Diabetes, 47:1663-1670, 1998.
Ishii et.al. Journal of Gastroenterology and Hepatology (1997) 12 (Suppl.), S272- S282
Korom S. et al. Transplantation 1997; 63:1495. MacNee W, Rahman I, Trends Mol Med 2001 Feb;7(2):55-62
Maxwell et. Al, Br J Clin Pharmacol 1997; 44:307-317.
Michael A Nauck: Is glucagons-like peptide 1 an incretin hormone. Diabetologia, 42:373-379, 1999.
Michael Berelowitz and lone A Kourides: Diabetes mellitus secondary to other endocrine disorders. In: Diabetes Mellitus: A fundamental and clinical text, second edition: Lippincott Williams & Wilkins, pg. 592-593,2000.
Munch G et.al, J Neural Transm (1998) 105:439-461
Nguyen C et al. J Med Chem 1998; 41 : 2100.
Pederson R. A, et al. Diabetes 1998; 47:1253
Qualmann C et al. Insulinotropic actions of intravenous glucagon-like peptide- 1 in the fasting state in healthy volunteers. Acta Diabetologica 1995; 32: 13-16 Raymond AP, Heather AW, Dagmar S, Robert PP, Christopher HSM, Hans-Ulrich D: Improved glucose tolerance in zucker fatty rats by oral administration of the dipeptidyl peptidase-IV inhibitor Isoleucine thiazolidide. Diabetes 47:1253- 1258,1998.
Robert PP, Hans-Ulrich D, Fred Rep, Jorn S, Heather AW, Francis L, Christopher HSM, Raymond AP: Improved glucose tolerance in rats treated with dipeptidyl peptidase-IV (CD26) inhibitor Ile-Thiazolidide. Metabolism 48:385-389,1999.
Ronald A DeLellis: The Endocrine system. In: Robbins pathologic basis of disease, fourth edition, W.B. Saunders international edition, pg.1254-1255,1989.
Ronald T Jung: Obesity and nutritional factors in the pathogenesis of non-insulin- dependent diabetes mellitus. In: Textbook of diabetes, second edition: Blackwell science, pg. 19.13-19.14, 1997.
Rosenfeld ME et.al. Arterioscler Thromb Vase Biol 1998 Sep;18(9):1506-13.
Sedo A and Kraml J: Dipeptidylpeptidase IV in cell proliferation and differentiation. Sborn lek, 95(4): 285-288, 1994.
Siegel EG, Scharf G, Gallwitz B, Mentlein Rep, Morys-Wortmann C, Folsch UR, Schmidt WE: Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur J Clin invest 29(7):610-614,1999.
Smith MA, Biochim Biophys Acta 2000 Jul 26; 1502(1): 139-144.
Tina Vilsboll, Thure Krarup, Carolyn F Deacon, Sten Madsbad, Jens J Hoist: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613,2001. Tiruppathi, C, et al., Am. J. Physiol. 1993; 265:G81-89.
Zalba G. Et.al, J physiol Biochem, 56(1) 2000; 57-64
BACKGROUND OF THE INVENTION
1. FIELD OF THE INVENTION
The present invention relates to novel heterocyclic compounds useful for normalizing elevated blood glucose levels in diabetics and in treating disorders related to glucose intolerance.
These compounds inhibit the enzyme DPP-IV, that degrade the peptide GLP-1, providing for enhanced levels of active GLP-1, a peptide which normalizes elevated blood glucose levels.
These compounds are useful to control blood glucose level in diabetic patients and thereby delay the onset of vascular complications in diabetic patients and also transition to type II diabetes in impaired glucose tolerant patients.
These compounds are also useful in treating disorders related to glucose intolerance like Cushing's syndrome, hyperthyroidism, obesity, hyperglucagonemia, diseases like ulcers, HIV infection, disorders related to increased gastric emptying, acid secretion and hunger, autoimmune disorders like multiple sclerosis, rheumatoid arthritis and Grave's disease (Sedo and Kraml, 1994).
These compounds also exhibit free radical scavenging activity which is useful in treatment of various disease condition caused by accumulation of free radicals in the body cells. 2. DESCRIPTION OF THE RELATED ART
Diabetes mellitus is a clinically and genetically heterogenous group of disorders characterized by abnormally high levels of glucose in the blood. The hyperglycemia is due to deficiency of insulin secretion or to resistance of body cells to the action of insulin, or to a combination of these. Chronic hyperglycemia is a cause of heavy burden of morbidity and premature mortality from diabetic complications. These long-term complications can be delayed by improving glycemic control. None of the currently used medications is capable of reversing an ongoing failure of β-cell function and reduction in post prandial glucose peak represents an important target for therapeutic strategies.
Although pancreatic insulin secretion is predominantly controlled by blood glucose levels, incretins like the peptide GLP-1 derived from enteroinsular axis have an effect on insulin secretion and therefore on the blood glucose level. It is released from the gut in response to ingested nutrients, which acts on the pancreas to potentiate glucose- induced insulin secretion. GLP-1 has beneficial effects in diabetic patients in normalizing elevated blood glucose levels (Hoist J and Deacon C, 1998). GLP-1 has multifaceted actions, which include stimulation of insulin gene expression, trophic effects on β-cells, inhibition of glucagon secretion, promotion of satiety, and slowing of gastric emptying. Because of glucose dependency of the peptide and glucagonostatic actions, the glucose lowering effect is self-limiting, and the hormone, therefore does not cause hypoglycemia regardless of the dose.
The pathogenesis of type-2 diabetes ordinarily involves the development of insulin resistance associated with compensatory hyperinsulinaemia followed by progressive beta-cell impairment that results in decreasing insulin secretion and hyperglycemia. Hyperglycemia itself causes additional inhibition of insulin secretion and more insulin resistance (glucose toxicity), which further accentuates_the hyperglycemia. (Augustyns K. et al. The unique properties of Dipeptidyl-peptidase IV (DPP-IV/ CD 26) and the therapeutic potential of DPP - IV inhibitors. Current Medical Chemistry 1999; 6:311-327) Most therapies used at present ultimately fail to control blood sugar level after
3-5 years. This is due to the progressive β-cell failure in the course of the disease and insulin is finally required in most type-2 diabetic patients.
Impaired glucose tolerance and impaired fasting glucose is present in a large population. These abnormalities progress to a large extent to overt diabetes. No therapy has been approved for the prevention or delay of type-2 diabetes in these patients.
Dipeptidyl Peptidase IV (DPP-IV) inhibitors addresses to a large extent the inadequacies of the presently available therapies. It targets not only the β-cell dysfunction but also insulin resistance and increased hepatic glucose output by liver.
Thus, it has a more holistic approach towards the treatment of type-2 diabetes. Furthermore, by stabilizing / reversing the progressive β-cell dysfunction, it would prevent the progression of the disease and for the same reason, it has the potential to prevent or delay the occurrence of overt diabetes in subjects with impaired fasting glucose and impaired glucose tolerance. (Pathogenesis of type-2 Diabetes; Harold E
Lebovitz, Drug Benefit Trends 12 (supp A):8-16, 2000).
The presently used antihyperglycemic drugs target either insulin resistance or β-cell dysfunction. Hence, there is a need to address both these pathologies together.
The homeodomain transcription factor, PDX-1 is essential for the early development of the pancreas and the maintenance of the β-cell phenotype. PDX-1 is known to regulate insulin, GLUT2 and islet amyloid precursor. Under conditions of sustained hyperglycemia, such as in the diabetic state, there is a downregulation of PDX-1 expression and a decrease in insulin secretion (Doyle and Egan, 2001). GLP-1 induces the differentiation of PDX-1 positive pancreatic epithelial cells into insulin- secreting cells. GLP-1 stimulates the expression of transcription factor PDX-1 while stimulating β-cell neogenesis and may thereby be an effective treatment for diabetes. GLP-1 and a long acting GLP-1 analogue exendin-4, stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in partial pancreatectomy rat model of type 2 diabetes (Gang et al, 1999).
GLP- 17-36 is one of the substrate for the circulating exopeptidase dipeptidyl peptidase IV (EC 3.4.14.5), a post proline cleaving enzyme with a specificity for removing Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of polypeptides and proteins. DPP-IV is widely distributed in tissues like kidney, intestine and placenta, hepatocytes, epithelial cells of pancreatic duct, central nervous system, peripheral nervous system, endothelial cells of blood vessels (Rolf, 1999), and found as soluble enzyme in blood plasma. About 50% of the GLP-17.36 amide released from the L cells is inactivated in the capillary bed surrounding these cells by DPP-IV. Furthermore, single pass through the liver inactivates a large fraction of the remaining active GLP - 1 (>40%) (Bork and Xue, 2000). Thus these two processes together with inactivation in the circulatory system and in other organs can be expected to inactivate or remove most of the GLP-1 released from the duodenum and intestine before the peptide can reach the pancreas in the active form. Hydrolysis of GLP-17.36 by DPP-IV yields the truncated oligopeptide GLP-19.36 and the dipeptide His- Ala. This N- terminally truncated form is not insulinotropic and acts as an antagonist at GLP-1 receptor. GLP- 1 is rapidly degraded in the circulation, which results in clearance that exceeds cardiac output and an apparent half-life of 1-1.5 min. The truncated metabolite is eliminated more slowly, with half-lives of 4-5 min for GLP-l9-36. It has been speculated that DPP-IV-mediated hydrolysis is the primary mechanism of inactivation of this hormone in vivo (Tina et al, 2001).
Because of rapid degradation, the effects of single injections of GLP-1 are short lasting and for a full demonstration of its anti-diabetogenic effects, continuous intravenous infusion is required. Therefore, it is proposed that the inhibition of DPP- IN, that elevate the levels of active GLP-1 and reduce the level of antagonistic metabolite, may be useful to treat impaired glucose tolerance and perhaps transition to type 2 diabetes. (Siegel et al (1999) reported that analogues of GLP-1 resistant to degradation by DPP-IV might help to realize the potential of GLP-1 in diabetes therapy.
DPP-IV inhibitor, Isoleucine thiazolidide (P-32/98), completely inhibited the formation of GLP-19-36, an antagonist at GLP-1 receptor, when it was incubated with 30 mM/L GLP-l7-36 and serum for 21 hours. Inhibition of circulating DPP-IV enhanced insulin secretion and improved glucose tolerance in response to oral glucose challenge in lean and obese fatty (fa/fa) rats. (Raymond et al, 1998). Also it has improved glucose tolerance in zucker fatty rats (Robert et al, 1999)
It is reported that a DPP-IV inhibitor NVP-DPP-728 i.e. l-[-2-{(5- cyanopyridin-2-yl) amino}ethylamino]acetyl-2-cyano-(S)-pyrrolidine inhibits DPP- IN activity and improves insulin secretion and glucose tolerance, through augmentation of the effects of endogenous GLP-1. The improvement in prandial glucose homeostasis during DPP-IV inhibition by this molecule suggests that inhibition of this enzyme is a promising target for treating type 2 diabetes (Balkan et al, 2000) Also this molecule showed potentiation of insulinotropic effects of GLP-1 in anaesthetized pig (Carolyn et al, 1998).
These data support a therapeutic approach of drug manipulation of plasma incretin activity by lowering glucose levels in ΝIDDM and other disorders involving glucose intolerance.
Dipeptidyl Peptidase IV (DPP - IV) is a proline specific protease and is involved in breaking peptide bonds before or after a proline residue. It plays an important role in the regulation of the life-time of biological active peptides like growth hormone releasing factor (GRF), Glucagon-like peptide - I (GLP-I), Gastric Inhibitory Polypeptide (GIP), Glucagon-like peptide - II (GLP-II), β-Casomorphin, morphiceptin, Human Νeuropeptide Y, Human Peptide YY (Augustyns K. et al. 1999) DPP - IV is present on the surface of a subset of T-cells (lymphocytes) and has been recognized as CD 26 antigen. Dipeptidyl peptidase-IV (DPP-IV) is a serine protease, which cleaves N- terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position. DPP-IV is responsible for inactivating glucagon-like peptide- 1 (GLP-1). More particularly, DPP-IV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Since the half-life for DPP-IV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10-fold) is anticipated from DPP-IN inhibition. Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, DPP-IV inhibition appears to represent an attractive approach for treating non-insulin-dependent diabetes mellitus (ΝIDDM). GLP-1 has multifaceted actions, which include stimulation of insulin gene expression, trophic effects on β-cells, inhibition of glucagon secretion, promotion of satiety, and slowing of gastric emptying, all of which contribute to normalizing elevated blood glucose levels (Hoist and Deacon, 1998). Because of glucose dependency of the peptide and glucagonostatic actions, the glucose lowering effect is self-limiting, and the hormone, therefore does not cause hypoglycemia regardless of the dose.
The exact biological functions of DPP - IV / CD 26 are still under investigation, but considerable evidence exists for the therapeutic potential of DPP-IV inhibitors.
Although a number of DPP-IV inhibitors have been described, all have limitations relating to potency, stability or toxicity. Accordingly, a great need exists for novel DPP-IV inhibitors, which do not suffer from the above-mentioned limitations.
Type - II Diabetes Mellitus: -
DPP - IV is involved in the degradation of GIP and GLP-I. GIP and GLP-I are considered to be most important insulin-releasing hormones (incretins) comprising the enteroinsular axis. The term enteroinsular axis refers to the signaling pathways between the gut and pancreatic islets that amplify the insulin response to absorbed nutrients. Inhibition of circulating DPP - IV with orally administered lie-thiazolidine [DPP-IV inhibitor] enhanced insulin secretion and improved glucose tolerance in response to an oral glucose challenge in lean and obese Zucker rats. The enhanced incretin response was greater in obese than in lean animals, with a more profound improvement in glucose tolerance (Pederson R. A, 1998). This was attributed to disruption of DPP - IV inactivation of GIP and GLP-I, resulting in amplification of enteroinsular axis.
DPP-IV inhibitors would have very little effect on subjects with normal blood glucose levels regardless of dose because its actions are glucose dependent (Qualmann C et al. 1995).
Hyperthyroidism and glucose intolerance
In patients with preexisting type I or type II diabetes mellitus, the presence of hyperthyroidism renders blood glucose management more difficult. Influences of thyroid hormone on insulin secretion and cellular metabolism have been implicated on the basis of in vitro and animal studies. In rats, thyroxine and triiodothyronine treatment inhibits the delayed phase of glucose-mediated insulin secretion- triiodothyronine being fivefold more potent than thyroxine.
In hyperthyroid states, gluconeogenic precursor (lactate and glycerol) are present in increased concentration in plasma. In rats, increased activity of mitochondrial glycerol, phosphate oxidase increases the capacity for gluconeogenesis from glycerol. It has also been shown in rats and pigs that hyperthyroidism leads to an increase in futile cycling of glucose, which could contribute to hyperglycemia. Increased activity of several enzymes that could be implicated in the increase in gluconeogenesis have been seen in response to thyroid hormone, including glucokinase, pyruvate carboxylase, phospho-enolpyruvate carboxykinase, and glucose-6-phosphatase. Studies in hyperthyroid patients report impairment in insulin suppression of hepatic glucose production. A recent study has also shown the inability to increase the insulin response appropriately to hyperglycemia and increased proinsulin levels, both fasting and in response to a meal (Michael Berelowitz and Lone A Kourides, 2000). Glucose intolerance as a result of hyperthyroidism can be better managed by enhancing the levels of GLP-1 a glucose dependent insulinotrophic agent.
Obesity and glucose intolerance
Obesity has been related to insulin resistance and hyperinsulinemia. Visceral obesity is associated with specific changes in skeletal muscle morphology that correlate with insulin resistance and hyperinsulinemia, namely a reduction in capillary density and an increase in the proportion of 'white' or 'glycolytic' fibers which are less insulin sensitive than red (glycolytic) fibers. TNF-alpha is secreted by adipose tissue and its circulating levels parallel total body fat mass. Circulating non-esterified fatty acid (NEFA) levels are raised in obese subjects, especially those with visceral obesity. In the liver, NEFA are oxidised to acetyl CoA, which stimulates pyruvate carboxylase and therefore gluconeogenic production of glucose from pyruvate; hepatic glucose production therefore increases. High NEFA level may also inhibit glucose utilization by skeletal muscle. Increased acetyl CoA levels inhibit pyruvate dehydrogenase, thus decreasing glucose oxidation. The combination of increased hepatic glucose output and reduced peripheral uptake effectively antagonises and would ultimately lead to hyperglycemia (Ronald T Jung, 1997). Glucose intolerance as a result of the above conditions can be managed better by the elevation of GLP-1 levels (as a result of DPP-IV inhibition).
Cushing's syndrome and glucose level
Cushing's syndrome represents a distinctive constellation of clinical features associated with prolonged overproduction of impaired glucose tolerance, overt diabetes (in approximately 20%), loss of libido and impotence. Some of these abnormalities such as obesity, deranged glucose metabolism are directly attributable to increased glucocorticoids. These glucocorticoids stimulate gluconeogenesis in diabetes. Also, they increase amino acid uptake by the liver and kidney and increase the activity of enzymes required for gluconeogenesis and may lead to hyperglycemia (Ronald A DeLellius, 1989)
Glucose metabolism under the above conditions can be managed better by treatment with DPP-IV inhibitors.
Role of DPP- IV in HIV infection
Prevention and treatment of HIV infection
The role of CD26 in HIV infection is also not completely clear yet, but seems to be important. Some DPP-IV inhibitors are reported to inhibit HIV infection such as pyrrolidine-2-nitriles and an irreversible cyclopeptide inhibitor (Nguyen C et al. 1998).
DPP-IV has been originally described to be a marker of activated T lymphocytes and lately DPP-IV/CD26 molecular identity has been proven
4+
CD26/DPP-IN serves as an essential cofactor for HIN entry into CD cells and that its enzyme activity is an important condition for this function (Sedo A and Kraml J, 1994). Hence inhibition of DPP-IV could prove useful in the management of HIV infection.
Immunosuppressant
It has been shown that DPP-IV / CD26 plays an important role in the immune system by a number of possible mechanisms. The exact mechanism remains to be elucidated, but a few examples are reported where DPP-IV inhibitors are useful immunosuppressahts in vivo. A dipeptide diphenyl phosphonate ester was able to abrogate acute rejection and prolong allograft cardiac survival (Korom S. et al. 1997). Role of DPP-IV inhibitors in ulcers, hyperglucagonemia, gastric emptying and hunger
DPP-IV inhibitors increase the level of GLP-1. GLP-1 has multifaceted actions, which include stimulation of insulin gene expression, inhibition of glucagon secretion, promotion of satiety, inhibition of food intake and slowing of gastric emptying (Hoist JJ and Deacon CF, 1998).
GLP-1 also reduces gastric acid secretion (Michael A Nauck, 1999). Increase in gastric acid secretion is one the main reason for duodenal ulcers. By inhibiting gastric acid secretion, GLP-1 and therefore DPP-IV inhibitors may prove useful for the treatment of ulcers or can be used in combination with other antiulcer agents.
Diarrhea
DPP-IV is involved in metabolic processing of morphiceptin. Co- administration of a DPP- IV and the opiate peptide morphiceptin could be used in case of diarrhoea, as the experiment with DPP-IV deficient rats showed (Tiruppathi, C, et al., Am. J. Physiol. 1993).
Mucosal Regeneration in patient with Intestinal Disease
DPP-IV hydrolysis of GLP-2 is responsible for its inactivation. GLP-2 has recently been shown to display intestinal growth factor activity in rodents, raising the possibility that GLP-2 may be therapeutically useful for enhancement of mucosal regeneration in patients with intestinal disease (Drucker, D.J. et al. Diabetes 1998; 47:159). The use of [Gly2] GLP-2, resistant to DPP-IV hydrolysis, increases small bowel weight in mice, predominantly due to a significant increase in villous height (Brubaker P.L. et al. Am. J. Physiol. 1997). Growth Hormone Deficiency
Since GRF is also degraded by DPP-IV, the use of a DPP-IV inhibitor together with GRF could be useful to treat children with growth hormone deficiency (Augustyns K. et al. 1999)
Neurological and Neuropsychological Disorders
Administration of a suitable DPP-IV inhibitor leads as a causal consequence to a reduced degradation of the neuropeptide Y(NPY) in the brain of mammals. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36), NPY activity is prolonged thereby resulting among other things in functionally active NPY YI receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects (WO 02/34243 dated 02 May 2002 by PROBIODRUG AG).
Cancers and Tumours
DPP-IV is able to bind proteins of the extracellular matrix as a cell adhesion molecule. This has been inteφreted from the observation that the DPP-IV inhibitors interfere in vitro with the initial spreading of rat hepatocytes on a matrix consisting of fibronectin and collagen. Thus the DPP-IV inhibitors could also be used for the prevention/treatment of cancer metastasis and tumour colonization (WO 03/002595 dated 09 Jan 2003 by PROBIODRUG AG).
Free Radical Scavenging Activity It has been reported that compounds exhibiting free radical scavenging activity are useful in treatment of Neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Motor Neuron Disease, Prion Disease etc, (b) Diabetes and Diabetic Vascular Complications, (c) Intestinal Diseases such as Intestinal Ischemia, Radiation Enteritis, Inflammatory Bowel Disease, Gastric and Colorectal Cancers etc., (d) Liver Diseases such as Alcoholic Liver Disease, Chronic Hepatitis C etc., (e) Cancers such as Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Malignant Melanoma etc, (f) Cardiac Diseases such as Atherosclerosis, Myocardial Infarction, Ischemic Stroke, Endothelial Dysfunction etc., (g) Opthalmic Disorders such as Cataract formation, Macular degeneration etc., (h) HIV Diseases, (i) Respiratory Diseases such as Chronic Obstructive Pulmonary Diseases, Asthma etc., (j) Renal Diseases such as Glomerulonephritis, Acute Renal Failure etc.
Neuro-degenerative disorders such as Alzheimer's disease (A.D.), Parkinson's disease (P. D.), Huntington's disease (H.D.), Motor neuron disease (M.N.D), Prion disease
As people age, their antioxidant levels diminish and these low levels are directly linked to the many diseases associated with aging such as Alzheimer's and Parkinson's disease. One of the leading hypotheses is that oxidative stress induced by ROS damages essential components of the neurons, resulting ultimately in the neuronal death. Oxidative stress is involved in various divergent events leading to neuronal damage, including an increase in membrane rigidity, DNA strand break, and impairment in glucose uptake. Several potential sources of oxidative stress in different neurodegenerative disorders have been well identified (Munch G, et al. 1998).
In A.D. mitochondrial dysfunction, amyloid beta mediated processes; transition metal accumulation and genetic factors are responsible for the redox imbalance (Smith MA, et al. 2000).
Point mutations in Superoxide Dismutase enzymes are known in the familial form of MND.
Disturbances of neuronal energy metabolism have been implicated as a pathogenetic mechanism for H.D. (Browne SE, et al. 1999) Diabetes and Diabetic Vascular Complications (DVCs)
The cause of oxidative stress in diabetes is not yet fully understood but is thought to be due to mitochondrial dysfunction, direct enzyme inhibition by hyperglycemia, auto-oxidation of glucose, and activation of nicotinamide-adenine dinucleotide phosphate (NADPH)-oxidase. Oxidative stress in diabetes is also increased due to weakened defenses due to reduced endogenous antioxidants. The oxidative stress manifests itself as elevated concentrations of lipid peroxidation products, erythrocyte fragility, and decreases in the antioxidant enzyme systems (CAT, GSH Px, SOD). Recent studies also have shown a positive correlation between blood glucose concentration and oxidant-induced lymphocyte DNA damage (E.J. Harper The 24th Annual WALTHAM®/OSU SYMPOSIUM).
ROS are generated during glucose oxidation and formation of advanced glycation end products (AGE). Evidence has accumulated indicating that the generation of ROS plays an important role in the development of DVCs. Many biochemical pathways associated with hyperglycemia such as advanced glycosylation, glucose auto oxidation, and polyol pathway can increase the production of free radicals. Hyperglycemia in diabetic patients leads to excess auto-oxidation of glucose thereby reducing molecular oxygen and yielding oxidizing intermediates such as superoxide ions (O "), hydroxyl radicals (OH), and hydrogen peroxide (H2O ). Free radicals accelerate the formation of advanced glycosylation end products (AGE), because fragmentation and conformational changes occurring during glycosylation and glucose oxidation have been shown to be dependent upon free radicals. AGEs in turn supply more free radicals; this process is termed as oxidative glycosylation or glycoxidation. These free radicals impair vascular relaxation by inactivating or quenching nitric oxide (NO) and also adversely affect the endothelial function. Evidence also suggests that Maillard reaction acts as an amplifier of oxidative damage in aging and diabetes. Intestinal diseases
Oxidative stress is an important cause of tissue injury that occurs in inflammation and ischemia. Intestinal ischemia, radiation enteritis, inflammatory bowel disease, and promotion of gastric and colorectal cancers are some of the gastro-intestinal conditions where oxidative stress is implicated in the pathogenesis.
Liver diseases
Alcoholic liver disease- Ethanol induces an increase in lipid peroxidation either by enhancing ROS or decreasing the level of endogenous antioxidants. Ethanol also induces variety of cytochrome P450 enzymes in microsomes and xanthine oxidases in cytosol. The role of these enzymes in the generation of oxidative stress has been well established in various studies (Ishii H, et al. 1997).
Chronic hepatitis C- Enhanced oxidative stress initiates a fibrogenesis cascade in the liver of patients with chronic hepatitis C. Evidences are coming up supporting an oxidative stress pathway leading to active fibrogenesis in chronic hepatitis C. This fibrogenesis cascade characteristic of severe chronic hepatitis C (e.g., oxidative stress, induction of c-myb, activation of stellate cells, and collagen gene expression) is stimulated by ROS.
Cancers
Oxidative damage to DNA is a result of interaction of DNA with ROS, in particular the hydroxyl radical. The hydroxyl radicals produce multiple modifications in DNA. Oxidative attack by OH radical on the deoxyribose moiety leads to the release of free bases from DNA, generating strand breaks with various sugar modifications and simple abasic (AP) sites ROS also interact with and modify cellular protein, lipid, and DNA, which results in altered target cell function. The accumulation of oxidative damage has been implicated in both acute and chronic cell injury including possible participation in the formation of cancer. Acute oxidative injury may produce selective cell death and a compensatory increase in cell proliferation. This stimulus may result in the formation of newly initiated preneoplastic cells and/or enhance the selective clonal expansion of latent initiated preneoplastic cells. Similarly, sublethal acute oxidative injury may produce unrepaired DNA damage and result in the formation of new mutations and, potentially, new initiated cells. ROS, therefore, can have multiple effects in the initiation stage of carcinogenesis by mediating carcinogen activation, causing DNA damage, and interfering with the repair of the DNA damage.
Benefits of various antioxidants in preventing or treating following cancers have been extensively studied.
1) Lung cancer
2) Colorectal cancer
3) Cervical cancer 4) Breast cancer
5) Malignant melanoma
Oxidative stress in cardiac diseases
Lifelong high levels of antioxidant nutrients are supposed to protect against the development of heart disease. High doses of antioxidants in the month following an acute heart attack have been shown to significantly reduce the number of deaths, as well as the extent of cardiac damage in non-fatal cases.
It is currently thought that increase in oxidative stress is involved in the pathophysiology of endothelial dysfunction that accompanies a number of cardiovascular risk factors including hypercholesterolemia, hypertension and cigarette smoking. It also plays a pivotal role in the evolution of clinical conditions such as atherosclerosis and heart failure. Oxidative stress can activate redox-sensitive kinase cascades and transcription factors such as NFKB and AP-1, with resulting increases in the expression of factors associated with an inflammatory response and cellular proliferation. There are three enzyme systems producing reactive oxygen species in the vascular wall: NADH/NADPH oxidase, xanthine oxidoreductase, and endothelial nitric oxide synthase (Zalba G.et al, 2000, Rosenfeld ME, 1998).
Atherogenesis is regarded as the outcome of interactions among multiple stimuli. Endothelial dysfunction plays a key role in the development of atherosclerosis. Elevated homocysteine concentrations are associated with rapid onset endothelial dysfunction, which is another mechanism by which increased oxidative stress contributes to atherosclerosis. Oxidation of low-density lipoprotein plays an important role at several steps in atherogenesis. Oxidative stress also activates NF JB, which induces expression of genes controlling cytokine expression and leukocyte adhesion to vascular wall. (Maxwell, et al. 1997).
Animal studies have provided evidence by suggesting that free radicals may promote thrombosis, directly damage vascular cells and other tissues, and interfere with vasomotor regulation with the clinical sequelae of myocardial infarction and ischemic stroke.
In tissues where oxygen supply becomes used up following ischemia, as in myocardial ischemia, the enzyme xanthine oxidase is changed to a form that has potential to reduce oxygen to superoxides. On readmission of oxygen e.g. by reperfusion there is a burst of free radical generation. ROS are formed at an accelerated rate in post-ischemic myocardium. Thus biochemical damage due to free radicals contributes to the ischemic injury. Oxidative stress also seems to be one of the mechanisms that may produce membrane defects and result in intracellular calcium overload, and cardiac contractile dysfunction in the stunned myocardium.
Macular degeneration and cataract
Oxidative damage to lens of the eye with increase in age has a major contribution in cataract formation. Macular degeneration is also being recognized as a consequence of oxidative damage.
HIV disease
Perturbation of anti-oxidant defense system has been observed in various tissues in HIV patients. Oxidative stress may contribute to several aspects of HIV disease pathogenesis such as viral replication, inflammatory response, and decreased immune cell proliferation, loss of immune function, apoptosis, chronic weight loss.
Antioxidants may offer a promising treatment to HIV patients.
Chronic obstructive pulmonary diseases (COPD)
Alteration in the alveolar and lung metabolism of glutathione is widely recognized as a central feature of many inflammatory lung diseases including COPD. These changes are a result of the alteration in the gene expression of the gamma- glutamyl cystine synthase (Gamma-GCS), the rate-limiting enzyme in glutathione synthesis. Oxidative stress is implicated in the pathogenesis of COPD, since it results in inactivation of anti proteinases, airspace epithelial injury, mucus hypersecretion, increased influx of neutrophils into the lungs, transcription factor activation and gene expression of pro-inflammatory mediators (MacNee W, et al. 2001).
Renal Disease ROS have been implicated not only in the genesis of different forms of renal disease, predominantly experimentally induced glomerulonephritis, but also in different forms of acute renal failure.
Asthma
Although the pathogenesis of asthma is not fully defined, a typical feature is an increase in the number of inflammatory cells in the lung. Such cells generate ROS, which are involved in the pathophysiology of asthma, including airway smooth muscle contraction, increased airway reactivity, and increased vascular permeability.
Effect of antioxidant status on immunologic function
The immune system is particularly sensitive to oxidative stress, primarily because immune cells rely heavily on cell-to-cell communication to work effectively. Peroxidation of cell membranes compromises membrane integrity and disrupts intracellular signaling.
Cataract:
Oxidative damage to lens of eye with increase in age has been a major contribution in cataract formation.
Thus, by scavenging the free radicals, the following diseases can be treated or controlled :
1) Neurodegenerative disorders
(a) Alzheimer's Disease
(b) Parkinson's Disease (c) Huntington's Disease
(d) Motor Neuron Disease
(e) Prion Disease 2) Diabetes and Diabetic Vascular Complications
3) Intestinal Diseases
(a) Intestinal Ischemia (b) Radiation Enteritis
(c) Inflammatory Bowel Disease
(d) Gastric and Colorectal Cancers
4) Liver Diseases (a) Alcoholic Liver Disease
(b) Chronic Hepatitis C
5) Cancers
(a) Lung Cancer (b) Colorectal Cancer
(c) Cervical Cancer
(d) Breast Cancer
(e) Malignant Melanoma
6) Cardiac Diseases
(a) Atherosclerosis
(b) Myocardial Infarction
(c) Ischemic Stroke
(d) Endothelial dysfunction
7) Opthalmic Disorders
(a) Cataract formation
(b) Macular degeneration
8) HIV Disease
9) Respiratory Diseases
(a) Chronic Obstructive Pulmonary Diseases (COPD) (b) Asthma
10) Renal Diseases
(a) Glomerulonephritis
(b) Acute Renal failure
OBJECTS OF THE INVENTION
The first object of the present invention is to provide a new class of compounds which normalize elevated blood glucose levels in diabetic patients thereby delaying diabetic complications and preventing transition to type II diabetes in impaired glucose tolerant patients.
These compounds exhibit in vitro DPP-IV inhibitory activity. DPP-IV inhibitors enhance the level of active GLP-1, which would be advantageous in treating hyperglycemia. Added advantage is that there is no risk of hypoglycemia, since GLP-1 increases glucose mediated insulin secretion. Due to non-peptide nature of the compounds, they can be conveniently administered orally. The increase in GLP-1 level in the active form provides for multifaceted action in respect of increase in insulin level, decrease in glucagon level, neogenesis of pancreatic β-cell, stimulation of insulin gene expression, and promotion of satiety, all of which contribute to beneficial effects in a diabetic patient.
Another object of the invention is to provide a method of treatment of a diabetic patient with glucose intolerance by administration of the compounds of the invention or pharmaceutically acceptable salts thereof either singly or in combination with drugs for anti-diabetic or other therapies for Cushing's syndrome, hyperthyroidism, HIV infection, obesity, ulcers, disorders related to hyperglucagonemia, gastric emptying and hunger in required dosage in admixture with pharmaceutically acceptable diluents, solvents, excepients, carriers or other media as may be appropriate for the purpose. A further object of the invention is to provide a class of compounds having free radical scavenging activity which are useful for treatment of (a) Neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Motor Neuron Disease, Prion Disease etc, (b) Diabetes and Diabetic Vascular Complications, (c) Intestinal Diseases such as Intestinal Ischemia, Radiation Enteritis, Inflammatory Bowel Disease, Gastric and Colorectal Cancers etc., (d) Liver Diseases such as Alcoholic Liver Disease, Chronic Hepatitis C etc., (e) Cancers such as Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Malignant Melanoma etc., (f) Cardiac Diseases such as Atherosclerosis, Myocardial Infarction, Ischemic Stroke, Endothelial Dysfunction etc., (g) Opthalmic Disorders such as Cataract formation, Macular degeneration etc., (h) HIV Diseases, (i) Respiratory Diseases such as Chronic Obstructive Pulmonary Diseases, Asthma etc., (j) Renal Diseases such as Glomerulonephritis, Acute Renal Failure etc.
Yet another object of the present invention is to provide a method of preparation of these compounds.
A still further object of the invention is to provide a pharmaceutical composition comprising said compound in association with a pharmaceutical acceptable carrier, diluent or excepients.
Yet another object of the invention is to provide a method of treatment and/or prophylaxis of mammals including human beings for diseases relating to glucose intolerance and/or disease conditions caused by accumulation of free radicals in the body cells.
SUMMARY OF THE INVENTION
The present invention provides novel compounds represented by general formula (I), its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, which are useful for one or more of (i) normalizing elevated blood glucose levels in diabetes, (ii) treating disorders related to glucose intolerance and (iii) scavenging free radicals from body cells.
Figure imgf000026_0001
( I ) wherein
X is O, S, SO, SO2, NR7 or CHR1 ; n is null or 1 ; k is null or 1 ;
Z is O, S, and NR7 ;
Rl at two positions are independently selected from hydrogen or a substituted or unsubstituted group selected from linear or branched (Cι-Cι2)alkyl, (C2-Cι )alkenyl, (C3-C )cycloalkyl, (C5-C7)cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, wherein one or more heteroatoms are independently selected from O, N or S;
R2, R3, R4 and R7 are independently selected from hydrogen, perhaloalkyl, - (CO)NR8R9, -(CO)R8,-(CO)OR8, -SO2R8, -SOR8, substituted or unsubstituted groups selected from linear or branched (d-Cι2)alkyl, (C2-C|2)alkenyl, (C3- C )cycloalkyl, (C5-C )cycloalkenyl, bicycloalkyl, amidino bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, wherein one or more heteroatoms are independently selected from O, N or S;
R5 and R6 are independently selected from by hydrogen or a substituted or unsubstituted group selected from linear or branched (Cι-Cι2)alkyl, (C2-Cι2)alkenyl, (C3.C7)cycloalkyl, (C5-C )cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl,aralkyl, heteroaryl,heteroaralkyl, wherein one or more heteroatoms are independently selected from O, N or S;
R8 and R9 are independently selected from hydrogen or a substituted and unsubstituted group selected from linear or branched (Ct-Cι )alkyl, alkoxyaryl, alkoxyalkyl, alkoxycycloalkyl, alkoxyaryl, perhaloalkyl, (C -Cι )alkenyl, (C3-C ) cycloalkyl, perhalocycloalkyl, haloheterocycloalkyl, cyanoheterocycloalkyl, perhaloheterocycloalkyl, (C5-C7) cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, perhaloaryl, perhaloheteroaryl;
wherein in the groups represented by Rl, R2, R3, R4, R5, R6, R7, R8 and R9 when substituted, the substitutents are optionally and independently bridged by -(CO)-, - (CO)O, -(CO)NH-, -NH-, -NR8-, -O-, -S-, -(SO)-, -(SO2)-, -(SO2)NH-, -NH(SO2)-, - O(CO)- or -NH(CO)-; and are selected from halogen, hydroxy, nitro, cyano, amino, oxo, oxime, unsubstituted or substituted by R10 for the groups selected from linear or branched (C1-C8) alkyl, (C3-C )cycloalkyl, alkylcycloalkyl, perhaloalkyl, perhalocycloalkyl, aryl, aralkyl, alkylaryl, alkylheteroaryl, aralkoxylalkyl, perhaloaryl, alkylheterocycloalkyl, heterocycloalkyl, perhaloheterocyclyloalkyl, heteroaryl, heteroaralkyl, alkylaryl, perhaloheteroaryl, acyl, acyloxy, acylamino, alkylamino, arylamino, aralkoxy, alkoxyalkyl, alkylthio, thioalkyl, arylthio, thioaryl, carboxylic acid or its derivatives, or sulfonic acid or its derivatives wherein the groups / substituents present on same or adjacent atoms such as carbon or nitrogen, together optionally and independently may form a five or a six or a seven membered ring optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from O, N or S;
and wherein
RIO is independently selected from halogen, hydroxy, nitro, cyano, amino, oxo or oxime, and pharmaceutically usable hydrates and salts thereof ;
with the proviso that,
if k is null, then R4 and R6 together form an optionally six or seven membered ring, which optionally contains two to three heteroatoms independently selected from O, S and NR7 with Rl as hydrogen, and Ni is attached to hydrogen.
As used herein, aryl and heteroaryl ring includes up to two conjugated or fused ring systems.
Pharmaceutically acceptable salts forming part of this invention are intended to include not limited to salts of the carboxylic acid moiety such as alkali metal salts like Li, Na and K salts; alkaline earth metal salts like Ca and Mg salts; salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, trimethamine and the like; ammonium or substituted ammonium salts and aluminum salts. Salts may be acid addition salts which defines but not limited to sulfates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, perhaloacetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzensulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
The invention also provides a process for preparation of the compounds as defined above. The invention further provides pharmaceutical composition comprising compounds of the invention in association with a pharmaceutically acceptable carrier, diluent or excepient.
The invention also provides a method of treatment of mammals including human beings in disease conditions resulting from glucose intolerance and/or accumulation of free radical in the body cells by administering an effective compound of compounds of the invention to the subject in need thereof.
The invention further provides use of the compounds of invention in the manufacture of a medicament useful for treatment of diseases conditions resulting from glucose intolerance and/or accumulation free radical in the body cells.
BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
Fig 1 : This shows the effect of test compound (compound No. 95) on AUC in OGTT for the glucose load of 1 gm/kg in nSTZ induced diabetic rat.
Fig. 2: This shows the effect of test compound (compound No.95) pre-treatment on the glucose excursion.
DETAILED DESCRIPTION OF THE INVENTION
The representative compounds of formula (I) as referred above are listed in
Table 1 below which can be conveniently prepared, by methods as described hereinafter. These compounds may exist both as diastereomeric mixtures or as the diastereomerically pure or enantiomerically pure compounds. FPP2857
Table-l : Representative Compounds
Figure imgf000030_0001
FPP2857
Figure imgf000031_0001
FPP2857
Figure imgf000032_0001
Figure imgf000033_0001
oo ΓM
£--
S-M
Figure imgf000034_0001
FPP2857
Figure imgf000035_0001
FPP2857
Figure imgf000036_0001
FPP2857
Figure imgf000037_0001
* This is part of the cyclic structure -R4 -R6 - ** This compound is obtained by reacting with lower isomer obtained during the reduction step. This compound is obtained by reacting with the upper isomer obtained during the reduction step. R2-R4 combine together to give -CH2-CH2-CH2-CH2-
The representative compounds of the invention listed in Table I can be identified by their following chemical names :-
(a) [2-Cyano- 1 -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate] (Compound No. 1). (b)[2-Cyano- 1 -(4-isopropyl-2-piperazinyl)-carbonyl-pyrrolidine bis trifluoroacetate] (Compound No. 2)
(c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 3)
(d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 4)
(e) 3-[l-Oxo-2-((2-(l,l-dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine (Compound No. 5)
(f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyrrolidine (Compound No. 6) (g) l-[l-Oxo-2-((2-(l ,l -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine (Compound No.7).
(h) 1 -[ 1 -Oxo-2-((l -(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No.8)
(i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 9)
(j) 1 -[ 1 -Oxo-2-(l -(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 10)
(k) l-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 11) (1) l-[l-Oxo-2-((l-(l-methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 12)
(m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine (Compound No. 13) (n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 14)
(o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 15)
(p) 3-[ 1 -Oxo-2-(( 1 -phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 16) (q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 17)
(r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 18)
(s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 19)
(t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 20)
(u) 3-[l -Oxo-2-((l -Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 21 ) (v) l-[l-Oxo-2-((l-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 22)
(w) 3-[l-Oxo-2-((l -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 23)
(x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 24)
(y) 3-[ 1 -Oxo-2-((l -(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 25).
(z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 26) (aa) 1 -[ 1 -Oxo-2-( 1 -(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate (Compound No. 27). ab) 3-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 28) ac) 3-[l-Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 29) ad) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 30) ae) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride] (Compound No. 31 ) af) [2-Cyano- 1 -( 1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride] (Compound No. 32) ag) [4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride] (Compound No. 33) ah) l-[l-Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 34) ai) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate] (Compound No. 35 aj) 3-[l-Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride (Compound No. 36) ak) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 37) al) l -[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine (Compound No. 38) am) 1 -[1 -Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)] ethyl-2- cyanopyrrolidine trifluoroacetate (Compound No. 39) an) l-[l-Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 40) ao) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 41) ap) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 42) aq) 3-[l-Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl] -4-cyanothiazolidine trifluoroacetate (Compound No. 43) ar) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 44) as) l-[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyrrolidino acetyl)] hydrazino] ethyl - 2-cyanopyrrolidine trifluoroacetate (Compound No. 45) at) 3-[l-Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate (Compound No. 46) au) 3-[l-Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate (Compound No. 47) av) l-[l-Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 48) aw) 3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 49) ax) l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine (Compound No. 50) ay) 3-[l-Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 51) az) 3-[l-Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl -4- cyanothiazolidine bis trifluoroacetate (Compound No. 52) ba) 3-[l-Oxo-2-[l-(4-methylcyclohexyl)-2-(l-(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine (Compound No. 53) (bb) 3-[l-Oxo-2- [l-(4-methylcyclohexyl)-2-(l-isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine (Compound No. 54) be) 3-[l-Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate (Compound No. 55) bd) 3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 56) be) 3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate (Compound No. 57) bf) 3-[l-Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate (Compound No. 58) bg) 3-[l-Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate (Compound No. 59) bh) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate (Compound No. 60) bi) 3-[l -Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 61) bj) 3-[l-Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate (Compound No. 62) bk) 3-[l-Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 63) bl) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 64) bm) 3-[l-Oxo-2-[l-(l-(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 65) bn) 3-[l -Oxo-2-(l -(1 -acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 66) bo) l l-Dioxo-3-[l-oxo-2-(l-(4-mefhylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 67) bp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine (Compound No. 68) bq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine (Compound No. 69) br) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 70) bs) 3-[ 1 -Oxo-2-[ 1 -methyl-2-( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine (Compound No. 71) bt) 3-[l-Oxo-2-(l-(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate (Compound No. 72) bu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyrrolidine trifluoroacetate (Compound No. 73) bv) 3-[ 1 -Oxo-2-( 1 -(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine (Compound No. 74) bw) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 75) bx) 3-[l-Oxo-2-(l-(l -(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 76) by)3-[ 1 -Oxo-2-(l -( 1 -(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate (Compound No. 77) bz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 78) ca) 3-[l-Oxo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 79) cb) 3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 80) (cc)3-[ 1 -Oxo-2-[ 1 -(1 -phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazol idine trifluoroacetate (Compound No. 81) cd) 3-[l-Oxo-2-(l-(l-(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 82) ce) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine (Compound No. 83) cf) 3-[ 1 -Oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl -4-cyanothiazolidine trifluoroacetate (Compound No. 84) eg) 3-[ 1 -oxo-2-[ 1 -( 1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4-cyano- thiazolidine trifluoroacetate (Compound No. 85) ch) 3-[ 1 -oxo-2-[ 1 -( 1 -(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 86) ci) 3-[ 1 -oxo-2-[ 1 -(1 (methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate (Compound No. 87) cj)3-[ 1 -oxo-2-[ 1 -( 1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 88) ck) 3-[ 1 -oxo-2-[ 1 -(1 -(moφholinocarbonyl)-piperidin-4-yl)-2-ethyl]hydrazino] ethyl - 4-cyanothiazolidine trifluoroacetate (Compound No. 89) cl) 3-[ 1 -oxo-2-[ 1 -(1 -(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 90) cm) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 91) en) 3-[ 1 -oxo-2-[ 1 -(1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 92) co) 3-[l-oxo-2-[l -(l-(4-fluorobenzyl)aminocyclohexan-4-yl)] hydrazino] ethyl -4- cyanothiazolidine bis-trifluoroacetate (Compound No. 93) cp) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate (Compound No. 94) cq) 3-[l-oxo-2-[(l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate (Compound No. 95) cr) 3-[ 1 -oxo-2-[ 1 -( 1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 96) cs) 3-[ 1 -oxo-2-[ 1 -( 1 -(methanesulphonyl)aminocyclohexan-4-yl)-2- ethyl]hydrazino]ethyl-4-cyanothiazolidine (Compound No. 97) ct) 3-[l-oxo-2-[(l -(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 98) cu) 3- [ 1 -oxo-2- [ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 99) cv)3-[l -oxo-2-[l-(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl -4- cyanothiazolidine trifluoroacetate (Compound No. 100) cw) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4-yl)]-2 ethylhydrazino]ethyl-4-cyanothiazolidine tris-hydrochloride (Compound No. 101) ex) 3-[ 1 -oxo-2-[- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No.102) cy) 3-[l-oxo-2-[l-(l-(2-oxo-2(-adamant-l-yl)amino ethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 103) cz) 3 -[ 1 -oxo-2- [ 1 -( 1 -(2-oxo-2(2 ,3 -dihydrobenzo( 14)dioxan-6-yl)aminoe thyl) piperidin-4-yl)]hydrazino]ethyl-4-cyano-thiazolidine bis- trifluoroacetate
(Compound No. 104) da) 3-[ 1 -oxo-2-[ 1 -(1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 105) db) 3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino] ethyl-4-cyanothiazolidine tris-trifluoroacetate (Compound No. 106) dc) 3-[ 1 -oxo-2-[ 1 -( 1 -(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 107) (dd)3 [ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 108) de) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4-yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate (Compound No. 109) df) 3-[ 1 -oxo-2-[ 1 -( 1 -( 1 -oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate (Compound No. 110) dg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex-1- yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate (Compound No. I l l) dh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No.1 12) di) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No.l 13) dj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride (Compound No. 114) dk)3-[- 1 -oxo-2-[ 1 -( 1 -(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride (Compound No. 115)
Assay of DPP-IV enzyme inhibitory activity.
The assay method is a modified method (as described by Welch et al, 1998) based on spectrophotometric determination of the product formed by penultimate proline cleaving activity of the enzyme.
The following equation explains the principle of the assay method:
Enzyme + Substrate Gly-Pro + pNA
(Dipeptidyl peptidase-IV) (Gly-Pro-pNA)
OD measured at 385 nm
Gly-Pro-pNA: Glycine-Proline-p-nitroanilide Assay protocol involves incubation of the enzyme dipeptidyl peptidase IN with the test substance at 30° C for 30 min followed by addition of this reaction mixture to the substrate Gly-Pro-pΝA that was equilibrated at 30° C for 2 min. The enzyme cleaves the substrate at penultimate proline and releases p-nitroanilide, the optical density of which is measured at 385 nm. The formation of p-nitroanilide will be reduced in the presence of inhibitor. Optical density is measured for 2 hours for every lO in using a spectrophotometer and Nmax is calculated to find the activity of new chemical entities. The activity of molecule is expressed in terms of % inhibition. Atleast three different concentrations were tried out for each of the test substances. The percentage inhibitions for each of the concentrations were plotted and an IC50 of the test compound was worked out. The enzyme inhibitory activity of different test compounds were compared based on the IC50 values.
The percentage inhibition %I, is calculated using the formula:
% I = [(l-Vj/v0)]*100 where Vj and v0 are the Nmax values with and without the test substance, respectively.
Reagents and their preparation:
Substrate solution: 0.5 mM in 45 mM phosphate buffer
Substrate used: Gly-Pro-p-nitroanilide (Source: Sigma-Aldrich Co. Germany) M. Wt of Gly-Pro-p-nitroanilide =328.8
3.288 mg substrate in 1 ml 45 mM phosphate buffer was prepared as stock solution. 0.25 ml of this stock solution was diluted to 5 ml to get 0.5 mM substrate solution (90 μl to be added in each well). The stock solution of the substrate was used within three days of preparation.
Enzyme solution: Porcine DPP-IV (Sigma-Aldrich Germany) was used throughout the study. 0.4 mU in 80 μl of Tris. HCI buffer was prepared. Fresh solutions were prepared everyday for the assays.
Inhibitor solution:
The compounds of the present invention were dissolved in their respective vehicles. E.g. 1. Compound Νo.95 (in MilliQ water) Mol. Wt. of Compound No.95 : 779
Various concentrations of inhibitor were used: 0.391μM, 0.781μM, and 3.125 μM.
Solutions of inhibitor were prepared and used on the same day.
Experimental Procedure:
Different concentrations of inhibitor (compound 95), vehicle, substrate and enzyme were prepared as per standard procedures. 280 μl of enzyme solution (0.4- mU/80 μl in Tris HCI buffer) was added to the eppendorf containing 70 μl solution of inhibitor or vehicle and mixed. This reaction mixture was incubated for 30 min at 30 °C. The 96 well plate containing substrate solution was thermally equilibrated in the spectrophotometer for 2 min at 30°C. Later 100 μl of the enzyme-inhibitor pre- incubation solution was added to respective wells in a 96 well plate. Each concentration of the inhibitor was tested in triplicates.
The rate of change in UV absorbance (in presence of various concentrations of the inhibitor) was measured at 385 nm, with respect to wells containing only 0.5 mM substrate in 45 mM phosphate buffer as blank at every 10 min for 2 hours after adding enzyme-inhibitor mixture to wells containing substrate solution.
Table 2:
The inhibitory activity of the compounds on DPP-IV enzyme activity
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Note : The IC50 values for compounds 1-32 as reported in the provisional specification No.60/370,224, which is incoφorated in the instant patent application by reference, were subjected to same experimental procedure as reported here to determine IC50 values. However, in view of an erronious dilution factor taken for calculation of IC50 values in the provisional specification, the reported figures, though showing the same trend of activity are 9.5 times of the figures reported above for the compounds 1,3,4,9,10,12-23 and 25-30 recalculated by using the correct dilution factor.
Invivo oral glucose tolerance studies
The anti-hyperglycemic effect of compound no. 95 (8mg/ml/kg, i.v) after an oral glucose load of lgm/kg was studied in STZ induced diabetic rats (modified method of Balkan et al 1999).
Animals: Male STZ induced diabetic rats aged 10-12 weeks and weighing between 200-250gm were used for the study. These rats were treated with streptozotocin administered intraperitoneally on the day of birth at a dose of 90 mg/kg. They were maintained under standard conditions till the age of 10-12 weeks when they were used for the study.
Materials: Glucose solution (l gm/4ml of saline), Diethyl ether compound no. 95 (8mg/ml/kg), vehicle (lml/kg), Heparinized saline (lOOIU/ml), glucometer and strips Method: Animals were divided into two groups Group I: 8 hours fasted rats were treated with compound no. 95 vehicle (1 ml/kg, i.v.) 5 min before administration of glucose load.
Group II: 8 hours fasted rats were treated with compound no. 95 (8mg/ ml/kg, i.v) 5 min before administration of glucose load.
In both groups, blood samples were taken before administration of vehicle/ compound no. 95 and glucose load for blood glucose estimation. Blood glucose level before administration of compound no. 95 or its vehicle was considered as -5 min reading. Blood glucose level before administration of glucose was considered as 0 min reading.
After 10, 20, 30, 45, 60, 75, 90, 120, 150 and 180 min of glucose administration, blood glucose level was estimated by the glucose oxidase method using a LifeScan glucometer (Ca, USA). Blood glucose level at various time points was subtracted from the basal (0 min) reading. This was done to avoid changes in
AUC because of variation in basal glucose level. The glucose excursion at various time points was plotted against time and the AUC was calculated.
The activity of compound no. 95 was expressed as % reduction in AUC as compared with that of its vehicle.
RESULTS:
The AUC for the group treated with compound no. 95 was found to be
413.3+134.6 mM*min and the AUC for the group treated with vehicle for compound no. 95 was found to be 1070.5+342.4 mM*min. compound no. 95 significantly (p<0.05) reduced the AUC values as compared to the group treated with their corresponding vehicle. Table A: Effect of compound no. 95 on AUC of glucose excursion in nSTZ induced diabetic rats.
Table - A
Figure imgf000053_0001
Values of AUC are Mean ±SD
a = PO.05 vs Vehicle for compound no. 95 group
Table B: Effect of compound no. 95 (8mg/ml/kg; i.v) pre-treatment on glucose excursions after a 1 gm/kg glucose load in nSTZ induced diabetic rats
Table - B
Figure imgf000053_0002
The results of the above analysis are also depicted in Figure 1 and Figure 2 of the drawings. Free Radical Scavenging activity:
l.Aim:
To determine the in-vitro free radical scavenging activity of compounds of general formula-I on 2,2,-diphenyl-l-picrylhydrazyl (DPPH)radical (Ref: W. Brand- Williams, M.E.Cuvelier, C. Berset "Use of a free radical method to evaluate antioxidant activity ", Lebensm.- Wiss.u.Technol.,1995,28,Nr.1:25-30).
2.Principle involved:
To evaluate the free radical scavenging activity of compounds they are allowed to react with stable radical DPPH . In its radical form, DPPH absorbed at the characteristic wave length of 515nm, but upon reduction by an antioxidant or radical scavenger (AH), the absoφtion disappears.
Equation:
a. DPPH + AH DPPH-H + A
(free radical) (antioxidant)
3. Reagents and Chemicals: DPPH' ( Sigma Aldrich)
Methanol (Merck)
4. Instrument used:
UV-visible spectrophotometer (Jasco) Quartz Microcuvette (1ml capacity) 5. Procedure:
Preparation of DPPH solution: 10" M solution of DPPH was prepared in methanol.
Preparation of drug solution:
Various concentrations (10mM,lmM, 0.5mM,0.25mM and 0.125mM) of drug solutions were prepared in methanol.
Preparation of Control solution:
900μl of DPPH radical solution was added to an eppendorf tube. To it was added lOOμl of methanol.
Preparation of Test solution:
900μl of DPPH radical solution was added to an eppendorf tube. To it was added lOOμl of various concentrations of drug solutions in methanol.
Measurement of absorbance (O.D):
The absorbance of control and test samples was recorded after incubation at 30°C for 30 minutes, at 515nm taking methanol as blank.
6. Calculation:
The percent antioxidant activity was calculated according to the formula: % Antioxidant activity = 100-[O.D of test sample/O.D of control* 100] TABLE - 3
IN-VITRO FREE RADICAL SCAVENGING ACTIVITY OF THE MOLECULES
USING DPPH FREE RADICAL
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
•The test compounds listed in the Table 3 above exhibit invitro (antioxidant) free radical scavenging activity. Excessive production of free radicals; reactive oxygen species (ROS) results in oxidative stress . Therefore, these molecules would be very effective in reducing oxidative stress by their ability to trap ROS. Antioxidants (free radicals scavengers) are reported to be effective in the management of various diseases linked with oxidative stress.
Also, the novel compounds show Free Radical Scavenging Activity which is useful for (a) Neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Motor Neuron Disease, Prion Disease etc, (b) Diabetes and Diabetic Vascular Complications, (c) Intestinal Diseases such as Intestinal Ischemia, Radiation Enteritis, Inflammatory Bowel Disease, Gastric and Colorectal Cancers etc., (d) Liver Diseases such as Alcoholic Liver Disease, Chronic Hepatitis C etc., (e) Cancers such as Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Malignant Melanoma etc., (f) Cardiac Diseases such as Atherosclerosis, Myocardial infarction, Ischemic Stroke, Endothelial Dysfunction etc., (g) Opthalmic Disorders such as Cataract formation, Macular degeneration etc., (h) HIV Diseases, (i) Respiratory Diseases such as Chronic Obstructive Pulmonary Diseases, Asthma etc., (j) Renal Diseases such as Glomerulonephritis, Acute Renal Failure etc.
Discussion of Test Results :
Oral glucose tolerance test is one of the methods to test pre-diabetic or diabetic condition and to evaluate insulin secretagogues and/or releasers. Glucose level in the body is mainly controlled by insulin although many other factors contribute to insulin release. Administration of glucose by oral route will increase the glucose level in the blood, which induces the release of insulin. This glucose stimulated insulin release is impaired in diabetes. By pretreatment with drugs that releases or stimulates insulin release before taking food/glucose, the rise in glucose level can be controlled.
Figure-2 and Table-2 show a distinct decrease in the compound no. 95 treated animal's blood glucose values as compared to the corresponding vehicle treated group. This is also reflected in the decrease in AUC of glucose in compound no. 95 treated group as compared to vehicle group. From the graphs shown in figures 1 and 2 it is evident that compound no. 95 controls hyperglycemia and brings the glucose levels to normoglycemic range. Please note that the negative values do not represent hypoglycemia; it is only a fall below the basal hyperglycemic level. This could be explained by an increase in glucose mediated insulin secretion by compound no. 95. Hence, it is concluded that compound no. 95 would be a useful in the management of hyperglycemia in type II diabetes.
Free radicals along with AGE formation contributes to macroangiopathic (atherosclerosis, coronary artery disease) and microangiopathic (neuropathy, retinopathy, nephropathy) complication of diabetes. The test compounds listed in Table-3 exhibit in vitro (antioxidant) free radical scavenging activity. The novel compounds show free radical scavenging activity, which would be useful for treatment of diabetes and diabetic vascular complications (DVCs).
The DPP-IV inhibitors under study are preferably expected to not only control diabetes, but also to prevent diabetic complications by their antioxidant actions.
Compound numbers 78, 95, 99, 104, 108 and 115 showed prominent dipeptidyl peptidase-IV inhibitory actions with their IC50's in the range of 88 to 250 nM. These compounds could be used to prevent the degradation of the insulinotrophic hormone GLP-1; and thereby elevate their circulating levels. These compounds are expected to exert their anti-hyperglycemic action in a glucose dependent way and hence the usual side effect of hypoglycemia observed with the classical sulphonylureas would not be observed.
Preparation of representaive compounds of the invention :
The compounds of the invention may be prepared by alternative synthetic routes as per Scheme I, II or III as described below:
SCHE E-I
Figure imgf000061_0001
BOCNHNhHj(15)
Route 1 : N-NH-BOC BCC-NH-NH-R4
R- (d) (17) (e) (18)
(16)
Route 2: R4-Br/(b) BOC-NHNH, BOC- H-NH-R4
(15) cr(f) (19) Reagents and conditions for Scheme - 1 :
[a] (I) Et3N, THF, K2CO3, CICH2COCl, 0-20°C, 2.5-3.0 hrs. (II) (CF3CO)2O / THF ;
[b] K2CO3, KI, THF, Reflux, 6-20 hrs.
[c] CF3COOOH, Room Temp., 10-20 min.
[d] Hexane / Reflux, 2-4 hrs.
[e] NaBH4, MeOH, Reflux, 4-20 hrs.
[f] Neat, Reflux.
[g] (i) Aldehyde/ketone, MeOH, Reflux, (ii) NaCNBH3, TiCl4, MeOH [h] (i) R8NHCOC1 or R8SO2Cl or R8COC1 , TEA, THF, 0-20°C (ii) [c]
Description:
The compounds of present invention may be prepared by the general methods as depicted in Scheme (I). The starting amide compound of formula (1) i.e L — prolinamide is prepared in four steps from L-proline following the same methods as described in literature for the synthesis of (R)-(-)-thiazolidine-4-amide of formula (2) from the corresponding acid.
Ref. US pat-6110949 dated 29.8.00, Doreen M et al, Bio.Org. Med. Chem. Lett. 6(22), 1996, 2745-48]. L-prolinamide (1) is then converted to l-chloroacetyl-2- cyanopyrrolidine of formula (3) in two steps which involves chloroacylation of the amide followed by dehydration [Ref. US pat -6124305 dated 26.09.00, WO- 0034241 dated 15.06.00 and US pat 601 1 155 dated 01.04.00].
In a similar manner, the another starting material 3-chloroacetyl-4-cyano thiazolidine of formula (4) is prepared by following two step reactions sequence. Step-1 involves the reaction of thiazolidine amide of formula (2) with chloroacetylchloride in presence of a base such as potassium carbonate and an inert organic solvent like tetrahydrofuran at a temperature of from 0 °C to 20 °C for 2.5 to 3 hrs. Step 2 involves the dehydration of 3-chloroacetyl-thiazolidine-4-amide prepared in step-1, with 2-equivalents of trifluroacetic anhydride conducted in presence of an inert organic solvent such as tetrahydrofuran at a temperature preferably at 20 °C. The second major component of the present invention i.e. N-2-substituted - tertbutyl carbazates of formulae (18) and (19), is prepared by the conventional manner. The tert-butyl alkylidine carbazates of formula (17) is prepared by refluxing hexane or tetrahydrofuran solution of tert-butyl carbazate (15) with appropriate aldehyde or ketone of formula (16) in 1 :1 molar ratio for 2-4 hrs. [ Ref. Dutta Anand S et.al., J.Chem. Soc.Perkin I, 1975, 1712-1720. Ghali N.I et al, J.Org.Chem. 46, 1981, 5413-5414 ].
The alkylidine carbazates thus formed in the previous step is reduced to N-2 substituted -tert-butyl carbazates of formula (18) using metal hydrides like sodium borohydride or lithium aluminium hydride, preferably sodium borohydride and Sodium cyanoborohydride. The solvent used in the reaction is organic solvent like methanol or tetrahydrofuran at a temperature ranging from 25°C to 70°C for 4 to 20 hrs.
On the other hand, direct alkylation of tert-butyl carbazate with alkyl or aryl halides preferably with the corresponding chlorides or bromides either in neat reaction condition or in presence of an inorganic base such as potassium carbonate and a catalyst such as potassium iodide in presence of THF provides carbazate derivatives of formula (19). Coupling of chloroacyl derivatives of formula (3) or (4) with the tert-butyl carbazate derivatives (18) or (19) in presence of K CO3 /KI in THF gives rise to hydrazinoacyl derivatives (11),(7),(12) or (8) which on deprotection using trifluoroaceticacid provides the final compounds (13), (9a),(14) or (10a) respectively as trifluoroacetate salts and further reaction of 9(a) or 10(a) with appropriate aldehyde followed by reduction using metal hydride like sodium borohydride or sodium cyanoborohydride in presence of catalytic compound of TiCl (Titanium tetrachloride) gives rise to compounds 9(b) or 10(b).
Similar reaction of 9(a) or 10(a) with appropriate acid chloride or sulfonyl chloride gives rise to respective compounds 9(c) or 10(c). Alternatively, the hydrazino derivatives (5) or (6) can be prepared from the corresponding chloroacyl derivatives (3) or (4) by reaction with tert-butyl carbazate itself. Alkylation of (5) or (6) with alkyl halides gives rise to penultimate intermediates (7) or (8) respectively.
Also, the reaction of compound (5) or (6) with appropriate carbamoyl chloride, sulphonyl chloride or acid chloride followed by deprotection with trifluroacetic acid gives rise to compound 5(a) or 6(a) respectively. SCHEME-2
Figure imgf000064_0001
21 , X= C4 32 , X = S
Reagents and conditions for Scheme - II : [a] : (Boc)2O, NaOH, Dioxan, H2O, 0°-25°C, 2-4 hrs; [b] : NOSU, DCC, DCM, THF, 0°-15°C, 3-5 hrs;
[c] HOBT, DCC, DIEA, DCM, -5°-25°C, 6-16 hrs; [d] DCM or THF, 5°-25°C, 12-22 hrs; [e] (CF3CO)2O, DCM or THF, Room Temp., 1-3 hrs; [f] CF3COOH, CH3CN, Room Temp., 3-4 hrs; [g] : R7Br, Et3N, K2CO3, THF, CH3CN or RBr, Et3N, THF, 0°-60°C, 1-25 hrs.
In an another embodiment of the present invention in which compounds, wherein the value of "k" mentioned in the general formula (I) is "null", then 1^ and R6 together form optionally six or seven membered ring optionally containing two or three heteroatoms independently selected from O, S and NR , with R\ is hydrogen, and Ni is attached to hydrogen. As described represented by the formula (II), compounds may be prepared by the general methods as depicted in Scheme-II.
Figure imgf000065_0001
(II) Piperazine-2-carboxylic acid dihydrochloride (20) is first protected by using usual protecting groups like Boc (tert-butyloxycarbonyl) or CBZ (benzyloxycarbonyl). The protected acid (21) is subjected to coupling with L- prolinamide (J_) or (R)-(-)-thiazolidine-4-amide (2) to give the coupled products (23) or (24). This can either be done by first dicyclohexylcarbodiimide (DCC) mediated coupling of the acid (21) with N-hydroxysuccinimide (NOSU) to form the active ester (22) followed by its reaction with the amides ( 1 or 2 ), or by direct coupling of the protected acid (21) with the amides ( \ or 2 ) in presence of 1-hydroxybenzotriazole (HOBT), DCC and the tertiaryamine like, diisopropylethyl amine (DIEA). Dehydration of the coupled products (23 or 24) using trifluroacetic anhydride as dehydrating agent provides the corresponding cyano derivatives (25 or 26). Deprotection of the compounds (25 or 26) in presence of trifluroacetic acid followed by regioselective functional ization of the deprotected compounds (27 or 28) at N-4 of piperazine ring using alkyl or aryl halides, or with acyl or sulphonyl halides yield the target compounds as represented by formula (29,30). They (29,30) can optionally be purified by reprotecting them at N-1 of the piperazine ring with a non-polar protecting group like Boc group, thereby, making these compounds more non polar, followed by deprotection of Boc group of this column purified intermediate using trifluroacetic acid results in the formation of final compounds as trifluroacetate salts 01,32). SCHEME-3
Boc-NH-NH-R4
Figure imgf000066_0001
(c)
Figure imgf000066_0002
39; X=CH, 41;X=CB, 40; X=S 42; X=S
1(e) 2. (f)
Figure imgf000066_0003
43; X=CH- 44; X=S Reagents and Conditions for Scheme -III:
i.Et3N, THF or DCM, -25° to 4°C, N2, 10-16 hrs. ii.Et3N, THF or DCM, Reflux, 6-10 hrs. iii.(CF3CO)2O, THF, Room temp. 2-4 hrs., iv.CF3COOH, THF, 5°C to Room temp. 0.5 to 2 hrs., v.Aqueous NaHCO3, vi.MeOH.HCl vii.Et3N,THF, -5° to 0°C, 1-2 hrs., N2, viii.Et3N, THF, 5° to 60°C, 12-18 hrs.
In a yet another embodiment of the present invention in which compounds described represented by the formula (III), wherein the value of "n" mentioned in the formula (I) is "null", may be prepared by the general methods as depicted in Scheme- Ill.
Figure imgf000067_0001
(III)
N-2-substituted tert-butyl carbazate (18) on reaction with 2,4,5- trichlorophenyl chloroformate (34), prepared from 2,4,5-trichlorophenol and trimethyl chloroformate (33) by the method as described in the literature, in presence of triethylamine as base results in the formation of carbazate derivatives (35). [Ref. Konakahara T et al, Synthesis, 1993, 103-106.]
The carbazate derivatives (35) on coupling with L-prolinamide (1) or thiazolidine amide (2) in presence of a tertiary amine as a base preferably triethylamine in an organic solvent like THF under reflux for 4-10 hrs. give the coupled products (36,37). These amide derivatives (36,37) can also be obtained by chlorocarbonylation of tert-butyl-carbazates (18) with trichloromethyl chloroformate (33) in presence of Et3N at a low temperature(-5° to 0° C), followed by coupling of the amides (1,2) with the chlorocarbonyl derivative of carbazates (38) in presence of Et3N / THF at a temperature ranging from 25° to 60°C for 8-12 hrs.
Subsequently usual dehydration of the amide derivatives (36,37) with trifluoroacetic anhydride in THF at a temperature from 5 to 30°C for 2-4 hrs. followed by deprotection of the corresponding cyano derivatives (39,40) with a deprotecting agent like trifluoroacetic acid at a temperature in the range of 5°C to 30°C for 0.5 to 2 hrs, results in the formation of the final compounds (41,42) as trifluoroacetate salts. They can optionally be purified by neutralizing with an aqueous alkali like sodium bicarbonate (aqueous), purifying the free base thus obtained by column chromatography followed by converting to hydrochloride salts (43,44) by treating with methanolic hydrochloric acid at 10°C to 20°C for 1 to 2 hrs.
Representative example of Scheme I: Example - 1
3-[l-Oxo-2- (-(1 -cyclohexyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate [ Compound No.21 ).
Step: 1
A solution of tert-butyl cyclohexylidine (8.0g, 37.7 mmol) in methanol (50ml) was warmed to 50°C and then added sodium borohydride (11.4g, 301.6 mmol) in portions over a period of 20 minutes. Refluxed for 8 hrs. Reaction mixture is concentrated in vacuo. Reaction mixture diluted with water and extracted with ethylacetate. Ethylacetate layer washed with water, dried (Na2 SO4), evaporated to dryness yielding the crude mass which is purified by column chromatography (5% ethyl acetate /hexane) gives N-cyclohexyl tert-butyl carbazate. (Yield 5.81g, 71.95 %). Step: 2
To a solution of carbazate derivative (0.535g, 2.5 mmol) thus formed in Stepl, and 3-chloroacyl-4 - cyanothiazolidine (0.475g, 2.5 mmol) (prepared in analogous manner as for corresponding pyrrolidine derivative) in THF (30 ml) is added K2CO3 (1.03g, 7.5 mmol) and KI (0.29g, 1.75 mmol). Reaction mixture is then refluxed for 6 hrs. Cooled, filtered, filtrate evaporated to dryness and the crude material purified by column chromatography (5 % ethylacetate/hexane). (Yield 0.45g, 48.9 %).
Step: 3
Product obtained in step-2 (0.25g, 0.68 mmol) is taken with trifluoroaceticacid (2.0 ml) at 0°C and allowed to stir at 5-l0°C for 10 minutes. Trifluoroaceticacid removed in vacuo and final traces of trifluoroaceticacid removed by stripping off with toluene and methanol respectively, gives white solid as a trifluoroacetate salt, final product. (Yield 0.179g, 69 %).
Example-2
3-[l-oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-4-cyanothiazolidine hydrochloride (Compound No. 36)
Product obtamed in step-2 of example- 1 (0.6g, 1.57 mmol) was stirred with trifluoroacetic acid (5 ml) at 5-10°C for 10 minutes. Trifluoro acetic acid removed in vacuo. To the residue, added 5ml water and 5 ml saturated sodium carbonate solution, extracted with ethylacetate, evaporated to dryness yielded a mass. Resulting mass was refluxed in acetone (10ml) for 2 hrs. Excess solvent was removed in vacuo. Obtained mass was taken in methanol (15ml), cooled to 0°C, added sodium cyanoborohydride (8.1mmol, 0.30g) in portions, and stirred for 1 hr. Reaction mixture was concentrated in vacuo, treated with water, extracted with ethylacetate. Dried organic layer was evaporated to dryness, yielding a mass, which is purified by column chromatography (15% ethylacetate / hexane). Free base was stirred with methanolic hydrochloric acid (2ml) for 15 min, solvent was removed in vacuo yielded hydrochloride salt. (200 mg, yield: 40%).
Example-3 1,1 -dioxo-3-[ 1 -oxo-2-(l -methylcyclohexyl)hydrazino)]ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 67).
Title compound is prepared by same method described in example- 1 using N-(4- methyl-cyclohexyl)ter-butyl carbazate and 3-chloro-acyl-4-cyanothiazolidine-l,l- dioxide (prepared as followed).
To stirred solution of 3-chloroacyl-4-cyanothiazolidine (0.50g, 2.6mmol) in dichloromethane added meta-perchlorobenzoic acid (0.91g, 5.2 mmol) in portions at 5-10°C. Reaction mixture was then stirred for 30 minutes and evaporated to dryness. Resulting crude mass was column chromatographed (20% ethylacetate / hexane) yielded desired compound (0.2g, yield: 30%).
Example-4
3-[l-oxo-2-(pyridizin-lyl)ethyl-4-cyanothiazolidine (Compound No. 83).
The solution of N+-benzyloxycarbonyl-N-ter-butyloxycarbonyl hydrazine (4g, 15mmol) and 1 ,4-diabromobutane (5.8g, 25.9mmol) in acetonitrile (50ml) was refluxed for 15 hrs in presence of potassium carbonate (4.2g, 30mmol). Reaction mixture was filtered, evaporated to dryness, purified by column chromatography (10%) ethylacetate-hexane, 4g, yield: 83%). The solution of obtained solid in 50% methanol-water (100ml) was stirred with 5%> palladium-charcoal (400mg) at 50 psi for 6 hrs, filtered evaporated, and purified by column chromatography (ethylacetate 1.9g, yield: 82%>). The solution of obtained N-ter-butyloxypyridazine (lg, 5.3mmol) was sitrred with 3-chloroacyl-4-cyanothiazolidine (1.5g, 7.8mmol) in tetrahydrofuran (60ml) at room temperature for 5 hrs in presence of cesium carbonate (2.6g, 7.8mmol) and then heated at 55°C for 30 hrs. Reaction mixture was filtered, evaporated, column chromatographed (35% ethylacetate-hexane) yielded desired product (0.4g, yield: 20%). Obtained product stirred with trifluoroacetic acid for 10 minutes at 5- 10°C. Trifluoroacetic acid removed in vacuo neutralised with aqueous sodium carbonate, extracted with ethylacetate. Dried organic layer was evaporated to dryness, purified by column chromatography (2% methanol / dichloromethane) yielded 90ml final compound (yield: 30%>).
Representative example of Scheme II:
Example - 5
2-Cyano-l-(4-isopropyl-2-piperazinyl)-carbonyl pyrrolidine trifluoroacetate
(Compound No.2).
Step-1
To an aqueous (100 ml) sodium hydroxide (4.0g, 100 mmol) solution of piperazine-2-carboxylic acid dihydrochloride (5g, 24.63 mmol) is added a solution of di-tert-butyl dicarbonate (1 l .Og, 50.45 mmol) in dioxan (50 ml) at 0°C over a period of half an hour. The reaction mixture is stirred at 0°C for 1 hr. followed by stirring at room temperature (25°C) for another 2 hrs. Neutralized (pH 6-7) with aqueous 2N HCI, extracted with ethyl acetate. Organic layer washed with brine solution, dried (Na SO4) and evaporated in vacuo to yield an oil which solidifies on cooling. (Yield 8.02g, 98.76%).
Step-2
Method-A
(i) To a dichloromethane (DCM, 40ml) solution of Boc-protected acid (5.0 lg,
15.18 mmol) as prepared in step-1 is added a solution of N-hydroxysuccinimide (1.75g, 15.21 mmol) in THF (20ml) and a solution of DCC (3.6g, 17.47 mmol) in
DCM (20ml) at 0°C in the order specified. Reaction mixture stirred at 0-5°C for 4-5 hrs, filtered, filtrate washed successively with water, aqueous sodium bicarbonate solution and finally with brine. Organic layer dried (Na SO4) evaporated in vacuo to give the product as white solid. (Yield 5.8g, 86.05%).
(ii) To a solution of the succinimide derivative (1.92g, 4.49 mmol) in DCM (20ml) as prepared in (i) of step-2, is added a solution of L-prolinamide (0.6g, 5.26 mmol). Reaction mixture stirred at 25°C for 16 hrs. washed with aqueous NaHCO3 solution and brine, dried (Na2SO4), evaporated in vacuo yielding a crude residue. Desired coupled product was isolated by column chromatography (40% ethyl acetate/hexane), (Yield 0.53g, 27.74%).
Method-B
Alternatively the above prolinamide derivative can be prepared by the following method.
DIEA (1.35g, 10.46 mmol), HOBT (1.40g, 10.37 mmol) sequentially added to piperazine acid (3.30g, 10 mmol) and L-prolinamide (1.14g, 10 mmol) in DCM (40ml) at 0°C. A solution of DCC (2.40g, 1 1.65 mmol) in DCM (30ml) is added slowly at 0°C over a period of 1 hr. Stirred another 1 hr. at 0°C and then at 25°C for 14 hrs. Filtered, DCM distilled off, diluted with ethyl acetate, washed sequentially with saturated aqueous solution of NaHCO3 and brine. Organic layer dried (Na2SO4), evaporated in vacuo purified by column chromatography (ethyl acetate). (Yield 2.6g, 61.03%).
Step-3
Prolinamide derivative (0.8g, 1.87 mmol) in THF (15 ml) is stirred with trifluoroacetic anhydride (TFAA) (1.5g, 7.14 mmol) at room temperature (25°C) for 4 hrs. Excess TFAA and THF is distilled off in vacuo, diluted with ethyl acetate, washed with aqueous sodium bicarbonate solution and brine. Organic layer dried (Na SO4), evaporated in vacuo and the required cyano compound purified by column chromatography (50% ethyl acetate/hexane). (Yield 0.6g, 78.32%). Step-4
Deprotection of the above compound as obtained in step-3 is done by stirring a solution of the compound (0.5g, 1.22 mmol) in CH3CN (10ml) with TFA (7ml) at room temperature for 2 hrs. Excess TFA and CH3CN removed in vacuo followed by stripping off with toluene and methanol respectively results in the formation of deprotected product as trifluoroacetate salt. (Yield 0.52g, 97.32%).
Step-5
To a solution of the deprotected compound (0.64g, 1.46 mmol) as obtained in step-4, in acetone (30ml), was added triethylamine (0.45g, 4.45 mmol), K CO3 (0.3g,
2.17 mmol) and isopropyl bromide (0.23g, 1.88mmol) and refluxed for 15 hrs. The reaction mixture is filtered and the filtrate is evaporated in vacuo to give the product as an oily residue. (Yield 0.2g, 54.51 %).
The crude material thus obtained is purified as follows:
The compound is protected using di-tert-butyl dicarbonate (0.18g, 0.82 mmol) and NaOH (0.05g, 1.25 mmol) in the same way as described in step-1 and purified by column chromatography (50% ethyl acetate/hexane). (Yield 0.15g, 53.57%). This is finally deprotected using trifluoroacetic acid (2ml) resulting in the formation of the final product as trifluoroacetate salt. (Yield 0.1 lg, 53.92%).
Representative example of Scheme III:
Example - 6
[4-Cyano-3-(l-cyclohexylhydrazino) carbonyl thiazolidine hydrochloride] (Compound No. 33). Step-1
A solution of trichloromethyl chloroformate (3.43g, 17.50 mmol) in THF (15ml) is added slowly at 0°C to a stirred solution of tert-butyl-cyclohexyl carbazate (2.5g, 11.68 mmol) in THF (15ml) under N2 atmosphere. Triethylamine (1.77g, 17.52 mmol) in THF (15ml) is next added at 0°C slowly over a period of 20 minutes. Stirred at 0°C for 1.5 hrs, THF distilled off, diluted with DCM (30ml), washed sequentially with water and 5%> aqueous citric acid solution. Organic layer dried (Na SO4) and removed in vacuo to give the product. (Yield 3.10g, 96.27%).
Step-2
To a solution of thiazolidine amide (0.66g, 5.0 mmol) and the product obtained in step-1 (1.96g, 7.10 mmol) in THF (30ml) is added a solution of triethylamine (1.6g, 15.84 mmol) in THF (10ml) dropwise at 5°C over a period of half an hr. Stirred at room temp, for 15 hrs, followed by refluxing for 1 hr. THF distilled off, diluted with ethyl acetate, washed successively with water and 5% aqueous citric acid, organic layer dried (Na SO4), evaporated in vacuo and crude material purified by column chromatography (50% ethyl acetate/hexane). (Yield 0.85g, 45.70%).
Step-3 Trifluoroacetic anhydride (0.54g, 2.57 mmol) is added to a solution of the amide compound (0.80g, 2.15 mmol) as obtained in step-2, in THF (15ml) at 5°C and stirred at 30°C for 3 hrs. Excess solvents removed in vacuo, diluted with ethyl acetate, washed with aqueous 5% NaHCO3 solution, dried (Na2SO4) and concentrated. Crude material purified by column chromatography (20% ethyl acetate/ hexane). (Yield 0.43g, 56.48%).
Step-4
The deprotection is done by stirring a solution of the cyano compound (0.43g,
1.21 mmol) with TFA (5ml) in THF (5ml) at 5°C for 1 hr. Excess solvents distilled off in vacuo, diluted with ethyl acetate, washed with saturated aqueous solution of
NaHCO3. Organic layer dried (Na2SO4), evaporated and the required pure compound is isolated as a free base after column chromatography (35% ethyl acetate/ hexane). (Yield 0.1 Og, 32.46%).
This is converted to its hydrochloride salt by treating with methanolic HCI at 10°C for 1 hr. and removing excess solvents in vacuo followed by crystallization from ether.
The following representative compounds may be prepared by following the synthetic route of Scheme I.
Example - 7
1-[1 -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 30)
Yield 60.6%; m.p. 138-140° C ; Mass (m/z) ■ 265 (M++1), 287 (M++Na) ; 'HNMR (400 MHz, CDC13) δ: 4.88-4.90 (m, 1H), 4.10-4.34 (m, 3H), 3.58-3.79
(m, 2H), 2.19-2.29 (m, 6H), 1.73-1.81(m, 4H), 1.54-1.57 (m, 6H); IR. (KBr, cm."1) : 3460, 3170, 2270, 1673, 1605, and 1524.
Example - 8
3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 29)
Yield 58.2%; m.p. 140-142° C ;
Mass (m/z) 283 (M++1), 267 ;
'HNMR (400 MHz, CDC13) 6: 5.27-5.29 (m, 1H), 4.13-4.57 (m, 4H), 3.49-3.75
(m, 4H), 1.82 (bs, 4H), 1.38 (bs, 4H), 0.98 (d, 3H,J=8Hz);
IR (KBr, cm."1) : 3460, 3175, 2250, 1670, 1605, and 1523. Example - 9
3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 28)
Yield 72.8%; m.p. 141-142° C ;
Mass (m/z) 283 ( M++l ) ;
'HNMR (400 MHz, d4-MeOH) δ 5.34-5.36 (t,lH,J=4Hz), 4.72- 4.74 (d,lH,J=8Hz), 4.64-4.66(d,lH,J=8Hz), 4.06-4.18 (m,2H), 3.39-
3.50(m,2H),2.04(bs,2H), 1.82(bs,2H), 1.70-1.73 (m,2H), 1.56-1.63 (m,7H) ;
IR (KBr, cm/1) : 3477, 3408, 2340, 1672, 1626,
1562, 1524.
Example - 10
1 -[ 1 -Oxo-2-(l -(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis-trifluoroacetate (Compound No. 27)
Yield 36.50% ;
Mass (m/z) 246 ( M+ +1),150,167 ;
'HNMR (400 MHz, c-U-MeOH^ 8.65-8.67 (d,lH, J=8Hz), 8.48-
8.52 (t,lH, J=8Hz), 7.79-7.81 (d,lH, J=8Hz), 7.58-7.62 (t,lH, J=8Hz),4.69-4.73
(t,lH, J=8Hz), 3.40-3.51 (m, 4H), 2.20-2.33 (m, 4H) ; IR (CCl4, cm."') 3445, 2248, 1677, 1519.
Example - 11
1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 26)
Yield 87.70% ; Mass (m/z) : 265 ( M+ +1),287 ( M++Na );
'HNMR (400 MHz, d4-MeOH)δ : 4.04 (bs,lH), 3.65-3.71 (m,lH),
3.48-3.55 (m,lH), 3.15-3.17 (m,lH),2.26-2.31(m,2H),2.18-2.22(t,2H,J=8Hz), 2.03- 2.05(m,2H), 1.86-1.89 (m,2H), 1.30-1.45 (m,7H), 0.92-0.94 (d,3H,J=8Hz) ;
IR (CC14, cm."') : 3400, 2248, 1676, 1454.
Example - 12
3- [ 1 -Oxo-2-(( 1 -(4-methyl)cyclohexyl)hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 25). [ ** This compound obtained by reacting with lower isomer obtained during the reduction step]
Yield 73.9% ; m.p. 89-90 -.oυ C ;
Mass (m/z) 283 ( M+ +1),305 ( M++Na ),
266;
'HNMR (400 MHz, j-MeOH) δ : 5.33-5.35 (t,lH,J=4Hz), 4.71- 4.73 (d,lH,J=8Hz), 4.64-4.66(d,lH,J=8Hz), 4.05-4.16 (m,2H), 3.38-3.40 (m,2H),
3.12-3.18 (m,lH), 2.01-2.03 (m,2H), 1.86-1.89 (m,2H), 1.36-1.43 (m,3H), 1.01-1.10
(m,2H), 0.93-0.95 (d,3H,J=8Hz);
IR (KBr, cm."') : 3477, 3403, 2340, 1670, 1629,
1567, 1523.
Example - 13
l-[l-Oxo-2-((l-Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 24)
Yield : 80.6% ;
Mass (m/z) : 331 ( M++Na ),283 'HNMR (400 MHz, d-j-MeOH) δ : 7.36-7.84 (m,5H), 4.72-4.75
(m,lH), 3.55-3.70(m,2H), 2.12-2.33 (m,6H);
IR (CC14, cm."') : 3444, 2337, 1639, 1424.
Example - 14
3 - [ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 23)
Yield 90.3% ; Mass (m/z) 243 ( M+ +1),225 ;
'HNMR (400 MHz, dt-MeOH) δ 5.34-5.36 (t,lH,J=4Hz), 4.75-
4.77 (d,lH,J=8Hz), 4.67-4.69 (d,lH,J=8Hz), 4.04 (bs,2H), 3.39-3.47 (m,3H), 1.36-
1.42(m,2H), 1.26-1.28 (d,3H,J=8Hz), 0.99-1.03 (t,3H,J=8Hz)
IR (CC14, cm."1) 3470,2340,1676,1632,1521
Example - 15
1-[1 -Oxo-2-((l-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 22) Yield 86.9% ;
Mass (m z) 225 ( M+ +1) ;
'HNMR (400 MHz, cU-MeOH) δ 4.79-4.80 (bs,lH), 3.98
(bs,2H),3.67-3.72 (m,lH), 3.49-3.56 (m,lH),2.18- 2.3 l(m,3H), 1.77-1.80(m,lH), 1.52-
1.54(m,l H), 1.35-1.38(m,2H), 1.28-1.30 (d,3H,J=8Hz), 1.00-1.04 (t,3H,J=8Hz) ; IR (CC14, cm."1) : 3441, 2280,1676, 1521.
Example - 16
3-[ 1 -Oxo-2-((l -Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 21)
Yield : 69% ; m.p. : 154 -155° C ; Mass (m z) 269 ( M+ +1), 291( M+ +Na)
'HNMR (400 MHz, αVMeOH) δ : 5.33 (t,lH,J=4Hz), 4.72-4.74
(d,lH,J=8Hz),4.64-4.66 (d,lH,J=8Hz), 4.02-4.12 (m,2H), 3.38-3.40 (d,2H,J=8Hz), 3.19-3.26 (m,l H), 1.92-2.01 (m,4H),1.69- 1.72 (m,lH),1.32-1.38 (m,4H), 1.22-1.24 (m,lH) ;
IR (KBr, cm."') 3172, 2342, 1676, 1608,1521.
Example - 17
l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 20)
Yield 81.7%: m.p. 148 -150υ C
Mass (m/z) 251 ( M+ +1), 273( M+ +Na), 225 ;
'HNMR (400 MHz,
Figure imgf000079_0001
4.81-4.84 (bs,lH), 3.99-4.03 (m,2H), 3.66-3.70 (m,lH), 3.50-3.55 (m,lH), 3.33-3.36 (m,lH), 3.18-3.22 (m,lH), 2.26-2.29 (m,lH), 2.18-2.23 (m,2H), 2.00-2.02 (m,2H), 1.90-1.90 (m,2H), 1.69-1.73 (m,lH), 1.35-1.41 (m,5H);
IR (KBr, cm."1) 3159, 2241, 1676, 1607, 1519.
Example - 18
3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 19)
Yield 48.3%: m.p. 136-137° C ;
Mass (m/z) 255 ( M+ +1), 277( M+ +Na) ;
'HNMR (400 MHz, --4-MeOH)δ 5.34-5.36 (t,lH,J=4Hz), 4.73-4.75 (d,lH,J=8Hz), 4.63-4.65 (d,lH,J=8Hz), 4.02-4.14 (m,2H), 3.65-3.69 (m,lH), 3.38- 3.39 (d,2H,J=4Hz), 1.98-2.02 (m,2H), 1.81-1.85 (m,2H), 1.65-1.69 (m,4H);
IR (KBr, cm."') 3180,2365, 1677, 1602, 1524. Example - 19
1 -[ 1 -Oxo-2-((l -Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No.18)
Yield 64.1%: m.p. 118-119° C;
Mass (m/z) 237(M++1),259(M++Na) ;
'HNMR (400 MHz, d4-MeOH)δ 4.71-4.75 (bs,lH), 3.97-4.01 (m,2H), 3.66-3.69 (m,2H), 3.48-3.52 (m,lH), 2.18-2.29 (m,4H), 1.98-2.02 (m,2H),1.80-1.85 (m,2H), 1.65-1.69 (m,4H);
IR (KBr, cm."') 3169,2241,1679,1605,1522.
Example - 20
3-[ 1 -Oxo-2-(( 1 -(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No.17)
Yield 76.9%:
Mas (m/z) 322(M++1);
'HNMR (400 MHz, d4-MeOH)δ 8.24-8.31 (dd,2H,J=8Hz 12Hz,), 7.63- 7.70(dd,2H,J=8Hz, 12Hz), 5.35-5.37 (t,lH,J=4Hz,), 4.66-4.79 (m,2H), 4.01-4.41 (m,4H), 3.37-3.38 (m,2H); IR (CC14, cm."') 3422,2338, 1655,1510.
Example - 21
3-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No.16)
Yield 64.3% ; Mass (m/z) 277(M++1),299(M++Na), 261 ; 'HNMR (400 MHz, d4-MeOH)δ : 7.35-7.46 (m,5H), 5.33-5.35 (t,lH,J=
4Hz ,), 4.43-4.49 (m,2H), 4.25 (s,2H), 3.90 (s,2H), 3.36-3.37(d,2H,J=4Hz ,); IR (KBr, cm."') : 3470, 2340, 1671, 1620, 1508.
Example - 22
3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 15)
Yield 63.7%:
Mass (m/z) 187 ( M+ +1) ;
'HNMR (400 MHz, j-MeOH) δ 5.04 (bs,lH), 4.41-4.49 (m,2H), 3.58-
3.62 (dd,2H,J=5.6Hz 4.8Hz), 3.26-3.33 (m,2H);
IR (CCl4, cm. ) 3460, 2260, 1676, 1508.
Example - 23
l-[l-Oxo-2-((l -ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 14)
Yield 38.2% ;
Mass (m/z) 197( M+ +1), 219( M+ +Na);
'HNMR (400 MHz, (it-MeOH)δ 4.82-4.84 (bs,lH),4.22-4.24 (bs,lH),3.98-4.00 (m,lH), 3.65-3.70 (m,lH),3.48-3.54 (m,lH), 3.17-3.23 (q,2H,J=8Hz), 2.13-2.3 l(m,4H), 1.26-1.30 (t,3H,J=8Hz) ;
IR (CCl4, cm."') : 3424, 2247, 1676, 1521.
Example -24
l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine (Compound No. 13)
Yield : 52.3% ; Mass (m/z) : 243( M+ +1);
'HNMR (400 MHz, d4-MeOH)δ : 5.36-5.38(t,lH,J=4Hz),4.75-4.77
(d,lH,J=8Hz), 4.61- 4.63 (d,lH,J=8Hz), 3.82-3.85 (dd,lH,J=4Hz, 4Hz), 3.75-3.78
(dd,lH,J=4Hz, 4Hz), 3.40-3.41 (d,2H,J=4Hz), 3.20-3.26 (q,4H,J=8Hz), 1.31-1.35
(t,6H,J=8Hz);
IR (CC14, cm."') 3440, 2253, 1678, 1460.
Example - 25
1 -[ 1 -Oxo-2-((l -(1 -methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 12)
Yield 38.3% ; Mass (m/z) 211( M+ +1), 233 ( M+ +Na);
'HNMR (400 MHz, d4-MeOH)δ 4.83-4.86(t,lH,J=4Hz),4.05-4.11 (m,2H), 3.67-3.72 (m,lH), 3.50-3.61 (m,2H),2.28-2.32 (m,2H), 2.16-2.23 (m,2H), 1.30-1.32 (d,6H,J=8Hz);
IR (CC14, cm."') 3280, 2250, 1675, 1522.
Example - 26
1 -[ 1 -Oxo-2-(( 1 -phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. i l)
Yield 67.6% ;
Mass (m/z) 259 ( M+ +1), 281 ( M+ +Na), 158;
'HNMR (400 MHz, d-,-MeOH)δ 7.37-7.44 (m,5H), 4.82-4.84
(t,lH,J=4Hz), 4.26 (s,2H), 3.79 (s,2H), 3.39-3.45 (m,lH), 3.27-3.32 (m,lH), 2.22- 2.27 (m,2H), 2.09-2.16 (m,2H);
IR (CC14, cm. ) 3470,2340,1676, 1451. Example - 27
l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 10)
Yield 88% ;
Mass (m/z) 225 ( M+ +1), 247 ( M+ +Na);
1HNMR (400 MHz, d4-MeOH)D 4.82-4.84 (t,lH,J=4Hz), 3.83-3.89 (m,2H), 3.64-3.69 (m,lH), 3.47-3.53 (m,lH), 2.84-2.86 (d,2H,J=8Hz), 2.25-2.30 (m,2H), 2.16-2.21 (m,2H), 1.30-1.37 (m,l H), 0.99-1.00 (d,6H,J=4Hz)
IR (CC14, cm."') 3443, 2280, 1675, 1557, 1453.
Example - 28
3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 9)
Yield 56.4% ;
Mass (m/z) 263 ( M+ +1), 285 ( M+ +Na), 235;
"HNMR (400 MHz,
Figure imgf000083_0001
7.22-7.40 (m,3H), 6.77-6.94 (m,2H),
4.95-4.97 (m,lH), 4.62-4.82 (m,2H), 4.12-4.20 (m,2H), 3.32-3.36 (m,2H); IR (CC14, cm."') 3440, 2339, 1677, 1436.
Example - 29
l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No.8)
Yield 52% ; m.p. : 107-108°C;
Mass (m/z) : 304 ( M+ +l), 326 ( M+ +Na);
'HNMR (400 MHz, αVMeOH)δ : 8.29-8.31 (d,2H,J=8Hz), 7.68-
7.70 (d,2H,J=8Hz), 4.84-4.86(t,lH,J=4Hz), 4.39 (s,2H), 3.90-3.91(d,2H,J=4Hz),3.50- 3.54 (m,2H), 2.24-2.28 (m,2H), 2.14-2.18 (m,2H);
IR (KBr, cm. ) 3420, 3180, 2339, 1675, 1604, 1515.
Example - 30
l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)] ethyl -2-cyano pyrrolidine (Compound No.7)
Yield 45.3% ;
Mass (m/z) 269 ( M+ +1), 291 ( M+ +Na), 213;
'HNMR (400 MHz, cLrMeOH)δ 4.77-4.79 (t,lH,J=4Hz),3.61-3.74 (m,3H), 3.46 -3.54 (m,lH), 2.23-2.28 (m,2H), 2.13-2.20 (m,2H), 1.46 (s.9H);
IR (CC14, cm."') 3306, 2979, 2242, 1678, 1530.
Example - 31
1 -[ 1 -Oxo-2-((2-( 1 , 1 -dimethyl ethyl oxy carbonyl))- 1 -phenyl hydrazino)] ethyl-2-cyano pyrrolidine (Compound No. 6) Yield : 53.7% ;
Mass (m/z) : 345 ( M+ +1), 367 ( M+ +Na), 267; 'HNMR (400 MHz, CDCl3)δ : 7.22-7.26(m,2H),6.75-6.89 (m,3H), 6.37
(bs,lH), 4.77-4.80(t,lH,J=8Hz), 4.07 (s,2H), 3.72-3.76 (m,lH), 3.60-3.66 (m,lH), 2.20-2.37 (m,4H), 1.35 (s,9H);
IR (CC14, cm."1) 3470, 3333, 2242, 1663, 1602, 1496.
Example - 32 3-[l-Oxo-2-((2-(l,l -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine (Compound No. 5)
Yield : 33.3% ;
Mass (m z) : 287 ( M+ +l), 309 ( M+ +Na) , 231;
'HNMR (400 MHz, CDC13) δ: 7.44-7.48(m,lH),7.20-7.24 (m,lH), 5.24-5.34
(m,lH), 4.68-4.75 (m,lH), 4.55 (s,lH), 3.84 (bs,lH), 3.46-3.56 (m,l H), 3.30-3.35
(m,2H), 1.48 (s,9H);
IR (CC14, cm."') : 3401, 2241, 1733, 1578, 1540.
Example - 33
l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 4)
Yield 42.3% ;
Mass (m/z) 168 ( M+ +1), 191 ( M+ +Na);
'HNMR (400 MHz, d4-MeOH)δ 4.79-4.8 l(m,lH), 3.88 (s,2H), 3.62-3.69
(m,2H), 2.24-2.29(m,2H), 2.12-2.20 (m,2H); IR (CC14, cm."') : 3470, 3250, 2240, 1678, 1435.
Example - 34
1 -[ 1 -Oxo-2-(( 1 -phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 3)
Yield : 96.1% ;
Mass (m/z) : 245 ( M+ +1), 267 ( M+ +Na), 228;
'HNMR (400 MHz, CDC13) δ: 7.00-7.42(m,5H), 4.78-4.80 (b,s), 4.08 (s,2H), 3.64-3.83(m,2H), 2.24-2.34 (m,4H);
IR (CC14, cm."') : 3441, 2339, 1679, 1432. Example-35
1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 34)
Yield : 97% .
Mass : 251 (M++l), 273 (M++Na);
'HNMR (CDCl3)δ : 4.70 (bs, IH), 3.97-4.01 (d, IH, J=16 Hz), 3.81-3.85 (d, IH, J=16 Hz), 3.58-3.65 (m, 2H), 3.45-3.53 (m, 2H), 3.14-3.20 (m, 3H), 2.18-2.21 (m, 4H), 1.86-1.89 (m, 4H), 1.68-1.71 (m, 2H); IR (Neat , Cm"') : 2938, 2246 and 1670
Example-36
[4-Cyano-3-(l -phenyl hydrazino)carbonyl thiazolidine trifluoroacetate] (Compound
No. 35)
Yield : 37.8%. Mass : 249 (M++l), 271 (M++Na);
'HNMR (CDC13) δ : 7.51-7.54 (d, 2H, J=12 Hz), 7.35-7.39 (dd, 2H,
J=8Hz, 8Hz), 7.19-7.23 (dd, IH, J=8Hz, 8Hz) 5.36-5.38 (d, IH, J=8Hz), 4.31-4.33 (d,
IH, J=8Hz), 4.22-4.26 (dd, IH, J=6Hz, 6Hz), 4.08 (bs, 2H), 3.33-3.37 (dd, IH,
J=8Hz, 8Hz), 3.08-3.14 (t, IH, J=12Hz); IR ( Neat, Cm"') : 2935, 2244 and 1663
Example-37 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride (Compound No. 36)
Yield : 40%. Mass : 311 (M++1); lHNMR (d4-MeOH) D : 5.60 (bs, IH), 3.71-3.74(d, IH, J=12Hz), 3.61-
3.64 (d, IH, J=12Hz), 3.01 (s,lH), 2.28-2.35 (m,7H), 1.30 (m, IH), 0.83-1.06 (m,
3H), 0.67-.0.82 (m, 10H); IR ( Neat, Cm"') : 2931 , 2497, 1654
Example-38
1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyπolidine trifluoroacetate
(Compound No. 37)
Yield : 50%. Mass : 265 (M++l), 287 (M++Na);
'HNMR (d4-McOH) δ : 4.84 (bs, IH), 4.01-4.03 (m, 2H), 3.66-
3.70 (m, IH), 3.50-3.53 (m, IH), 2.26-2.29 (m, 2H), 2.18-2.22 (m, 2H), 1.74-1.77 (m,
6H), 1.51-1.58 (m, 4H), 0.99-1.01 (d, 3H, J=8Hz);
IR (KBr, Cm"') : 3169, 2917, 2240, 1673
Example-39
l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine (Compound No. 38)
Yield 30%.
Mass 293 (M++1), 315 (M++Na) ;
'HNMR (CDC13) δ 4.75 (bs, IH), 3.85-3.87 (m, IH), 3.64-3.71 (m, 2H), 3.29-3.35 (m, 3H), 2.83-2.90 (m, 2H), 2.61-2.65 (m, 2H), 2.11- 2.22 (m, 6H), 1.78-1.88 (m, 4H), 0.96-.0.98 (d, 6H, J=8Hz);
IR ( Neat, Cm"') 3263,2924,2241, 1645
Example-40
1 -[ 1 -Oxo-2-( 1 -(4-methylcyclohexylmethyl) hydrazino)]ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 39)
Yield 5%. Mass 279 (M +1), 301 (M++Na) ; 'HNMR (CDCl3) δ 4.79 (bS, IH), 3.96-3.98 (m, IH),
3.53-3.61 (m, 2H), 3.06-3.10 (m, IH), 2.25-2.29 (m, 3H), 1.84-1.88 (m, IH), 1.72- 1.75 (m, IH), 1.51-1.55 (m, 4H), 1.35-1.37 (m, IH), 1.22-1.35 (m, 4H), 0.89-0.96 (m, 5H);
IR ( Neat, Cm"1) : 2856, 2248, 1669, 1513
Example-41
1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 40)
Yield 35.3%.
Mass 279 (M++l), 301 (M++Na);
'HNMR (CDC13) δ 7.16-7.18 (d, 2H, J=8Hz), 6.86- 6.88 (d, 2H, J-8Hz), 4.76 (bs, IH), 3.55-3.84 (m, 4H), 2.11-2.33 (m, 4H);
IR (Neat, Cm"1) : 2244, 1650, 1597
Example-42 l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate (Compound No. 41 )
Yield : 66.6%.
Mass : 211 (M++l), 233 (M++Na);
'HNMR (αVMeOH) δ : 5.01 (bs, I H), 3.62-3.64 (m, IH), 3.60-
3.61 (m, IH), 2.28-2.31 (m, 2H), 2.08-2.18 (m, 4H), 0.99-1.01 (d, 6H, J=8Hz);
IR (Neat, Cm"') : 2877, 2251, 1651, 1555
Example-43
3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 42)
Yield : 21.8%.
Mass : 311 (M++l), 333 (M++Na);
'HNMR (CDCl3) δ : 5.31-5.33 (bs, IH), 4.70-4.72 (d,
IH, J=8Hz), 4.63-4.65 (d, IH, J=8Hz), 4.02-4.15 (m, 2H), 3.30-3.42 (m, 4H), 2.14-3.12 (m, 3H), 1.82-1.90 (m, 5H), 1.32-1.42 (m, 3H), 1.05-1.08(m, 2H),
0.92-0.94 (d, 3H, J=8Hz);
IR (KBr,Cm"') : 3470, 3403, 2340, 1665, 1630.
Example-44
3-[l -Oxo-2- (l-(4-morpholinocarbonyl) hydrazino) ethyl]-4-cyanothiazolidine trifluoroacetate (Compound No. 43)
Yield 10.5%.
Mass 300 (M++l), 322 (M++Na); i HNMR (CDC13) δ 4.62 (bs, IH), 3.68-3.72 (m, 5H), 3.44-3.55 (m, 2H), 3.18-3.40 (m, 7H) IR (KBr, Cm"') 2828, 1670, 1429
Example-45 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 44)
Yield 40%. Mass 325 (M++l); "HNMR (CDC13) δ 5.28 (bs, IH), 4.57-4.59 (m, 2H),
3.88-4.10 (dd, 2H, J=16Hz, 16Hz), 3.60-3.63 (t, IH, J=6Hz), 3.22-3.33 (m, 2H), 1.96- 2.08 (m, 2H), 1.80-1.83 (m, 2H), 1.41-1.44 (t, 6H, J=5.5 Hz), 1.27-1.37 (m, 4H), 1.01-1.06 (m, 2H), 0.87-0.90 (d, 3H, J=l 1Hz);
IR (Neat, Cm"' : 2249, 1673, 1560
Example-46
l-[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyrrolidino acetyl)] hydrazino] ethyl- 2- cyanopyrrolidine trifluoroacetate (Compound No. 45)
Yield : 66.6%. Mass : 385 (M+-l);
'HNMR (CDCl3) δ : 4.84 (bs, IH), 4.76 (bs, IH),
4.05-4.19 (m, 4H), 3.98-4.01 (m, IH), 3.80-3.87 (m, IH), 3.61-3.68 (m, 7H), 1.42- 4.48 (m, 6H), 1.31-1.34 (m, 8H);
IR (Neat, Cm"1) : 2933, 2239, 1669, 1609, 1534.
Example-47
3-[l -Oxo-2- (1,2-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate (Compound No. 46)
Yield 96%. Mass 483 (M++l), 505 (M++Na);
1 HNMR(d4-MeOH) δ 8.71-8.75 (dd, 2H, J=8Hz, 8Hz),
8.44-8.52 (m, 2H), 7.85-7.99(m, 4H), 5.25(bs, IH), 4.56-4.58 (d, IH, J=8.5Hz), 3.94- 3.99 (dd, IH, J=9Hz, 9Hz), 3.61-3.66(m, 4H), 3.36-3.39(m, 3H), 3.22-3.26(m, 5H); IR (Neat, Cm"') : 2362, 1673, 1524
Example-48
3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate (Compound No. 47)
Yield : 82.2%. Mass : 325 (M++l), 347 (M++Na);
'HNMR (d4-MeOH) δ : 5.33-5.36 (t, IH, J=4Hz), 4.72-4.74 (d,
IH, J=8Hz), 4.63-4.65 (d, IH, J=8Hz), 4.06-4.09 (m, 2H), 3.47-3.51 (m, IH), 3.36-
3.40 (m, 2H), 1.95-2.10 (m, 4H), 1.04-1.21 (m, 5H), 0.90 (s, 9H);
IR (KBr, Cm"') : 3025, 2964, 2207, 1678, 1610. Example-49
1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate (Compound No. 48)
Yield : 69.4%.
Mass : 299 (M++l), 321 (M++Na);
'HNMR (CDCl3)δ : 7.47-7.51 (d, IH, J=14Hz), 7.33-7.35 (d, IH, J=8Hz), 7.19-17.21 (d, 2H, J=8Hz), 4.71 (bs, IH), 3.74-4.00 (m, 3H), 3.42-3.55 (m, 3H), 2.77-2.92 (m, 2H), 2.05-2.21 (m, 7H); IR (Neat, Cm"') : 3414, 2950, 2246, 1675
Example-50
3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 49)
Yield : 71%.
Mass : 325 (M++l), 347 (M++Na);
'HNMR(d4-MeOH) δ : 5.32-5.34 (t, IH, J=4Hz), 4.67-4.74 (dd,
2H, J=8Hz, 8Hz), 4.08-4.11 (d, 2H, J=12Hz), 3.47-3.51 (m, IH), 3.37-3.38 (d, 2H, J=4Hz), 1.95-2.05 (m, 2H), 1.57-1.60 (m, 4H), 1.32-1.38 (m, 3H), 0.90 (s, 9H); IR (KBr, Cm"') : 2942, 2867, 2247, 1662, 1498.
Example-51
> l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2- cyano pyrrolidine (Compound No. 50)
Yield : 17.7%.
Mass : 403 (M+-l); 'HNMR (CDC13) δ : 5.32 (bs, IH), 4.71-4.87 (m, 3H), 4.11-
4.23 (m, 2H), 3.75-3.79 (m, 2H), 3.51-3.64 (m, 4H), 3.27-3.36 (m, 4H), 1.86-1.90 (m, 2H), 1.77-180 (m, 4H), 1.30-1.35 (m, 5H); IR (Neat, Cm"') : 2936, 2247, 1675, 1540.
Example-52
3-[l -Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate (Compound No. 51)
Yield : 43.9%.
Mass : 312 (M++1);
'HNMR (d6-DMSO) δ : 5.32 (bS, IH), 4.58-4.80 (m, 4H), 4.28-4.49 (m, 2H), 3.93-4.05 (m, 4H), 2.99-3.01 (m, 2H), 1.24-1.25 (d, 6H, J=6Hz);
IR (KBr, Cm"1) : 2934, 2245, 1669, 1512.
Example-53
3-[l-Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate (Compound No. 52)
Yield : 55%.
Mass : 385 (M++l);
'HNMR (d4-MeOH) δ : 7.88-7.90 (d, 2H, J=8Hz), 7.71-
7.73 (d, 2H, J=8Hz), 5.31-.533 (t, IH, J=4Hz), 4.77-4.78 (d, IH, J=8Hz), 4.70-4.72 (d, IH,
J=8Hz), 4.41-4.44 (m, 3H), 4.0-4.12 (m, IH), 3.46-3.53 (m, 4H), 3.37-3.39 (m, 3H),
1.42-1.46 (m, 4H);
IR (Neat, Cm"') : 3416, 2946, 2234, 1676, 1541. Example-54
3-[l-Oxo-2-[l-(4-methylcyclohexyl)-2-(l-(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine (Compound No. 53)
Yield 45.7%.
Mass : 457 (M++l), 479 (M++Na);
'HNMR ( rMeOH) δ : 8.70-8.72 (d, 2H, J=8Hz), 8.04-8.09 (t, IH,
J=9Hz), 7.59-7.61 (t, IH, J=4Hz), 5.25-5.28 (t, IH, J=4.5Hz), 4.68-4.70 (d, IH, J=8Hz), 4.35-4.45 (m, 2H), 3.38-3.71 (m, 4H), 3.01-3.09 (m, 3H), 1.70-1.86 (m, 6H), 1.22-1.36 (m, 11H), 0.88-0.90 (d, 3H, J=8Hz);
IR (Neat, Cm"') : 3418, 2925, 2246, 1651
Example-55
3-[l -Oxo-2- [l-(4-methylcyclohexyl)-2-(l-isopropyl-4-piperidinyl)] hydrazino] ethyl - 4-cyanothiazolidine (Compound No. 54)
Yield : 36%.
Mass : 408 (M++l); 'HNMR (CDC13) δ : 5.23 (bs, IH), 4.76-4.78 (d, IH,
J=8Hz), 4.68-4.70 (d, IH, J=8Hz), 4.51-4.53 (d, IH, J=8Hz), 3.47-3.52 (m, IH), 3.30-
3.37 (m, 4H), 3.10-3.17 (m, 2H), 2.90-2.94 (m, 2H), 2.75-2.78 (m, IH), 2.64-2.68 (m, IH), 2.33-2.36 ( , IH), 2.03-2.1 1 (m, 2H), 1.75-1.86 (m, 5H), 1.41-1.43 (d, 3H, J=8Hz), 1.38-1.40 (d, 3H, J=8Hz), 1.12-1.22 (m, 4H), 0.89-0.91 (d, 3H, J=8Hz); IR (Neat, Cm"') : 3423, 2931, 2340, 1636 Example-56
3-[l-Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4- cyanothiazolidine trifluoroacetate (Compound No. 55)
Yield : 65.5%.
Mass : 424 (M++l), 446 (M++Na); 'HNMR (d4-MeOH) δ : 7.67- .69 (d, 2H, J=8Hz), 7.44-7.46 (d,
2H, J=8Hz), 5.29-5.31 (t, IH, J=4Hz), 4.67-4.69 (d, IH, J=8Hz), 4.60-4.62 (d, IH,
J=8Hz), 3.99-4.01 (d, 2H, J=8Hz), 3.75-3.78 (m, 2H), 3.36-3.37 (d, 2H, J=8Hz), 3.10-
3.16 (m, IH), 2.46 (s, 3H), 2.38-2.41 (m, 2H), 1.98-2.01 (m, 2H), 1.62-1.72 (m, 2H);
IR ( KB^Cm"1) 3464, 2842, 2111, 1672, 1606
Example-57
3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 56)
Yield : 16%.
Mass : 438 (M++l), 460 (M++Na);
'HNMR (CDC13) δ : 7.65-7.67 (d, 2H, J=8Hz), 7.33-
7.35 (d, 2H, J=8Hz), 5.24-5.26 (t, IH, J=4Hz), 4.68-4.70 (d, IH, J=8Hz), 4.58-4.60
(d, IH, J=8Hz), 3.49-3.57 (m, 5H), 3.26-3.27 (d, 2H, J=4Hz), 2.56-2.60 (m, 6H), 2.46 (s, 6H);
IR (Neat,Cm"') : 3424, 2939, 2251, 1666, 1599.
Example-58
3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris-trifluoroacetate (Compound No. 57)
Yield : 68.2%. Mass : 361 (M++l);
1HNMR(d -MeOH) δ : 8.98-9.00 (d, 2H, J=8Hz), 8.72-
8.74 (d, IH, J=8Hz), 8.23-8.29 (dd, IH, J-8Hz, 8Hz), 4.74-4.78 (t, IH, J=8Hz), 4.32-
4.35 (d, IH, J=8Hz), 4.23-4.25 (d, IH, J=8Hz), 3.42-3.70 (m, 5H), 3.02-3.10 (m, 6H), 2.17-2.20 (m, 4H);
IR (Neat, Cm"') : 3392, 2949, 2250, 1676.
Example-59
3-[l-Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 58)
Yield : 33.6%.
Mass : 399 (M++l); 'HNMR t&rMeOffj δ : 7.87-7.89 (d, 2H, J=8Hz), 7.69-7.71 (d,
2H, J=8Hz), 5.25-5.27 (t, IH, J=4Hz), 4.69-4.71 (d, 2H, J=8Hz), 4.35-4.39 (m, 2H),
3.49-3.64 (m, 4H), 3.06-3.22 (m, 2H), 3.02-3.04 (m, IH), 2.49-2.58 (m, 2H), 1.35 (s,
3H);
IR ( CC14, Cm"') : 3354, 2236, 1678.
Example-60
3-[l-Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4- cyanothiazolidine tris-trifluoroacetate (Compound No. 59)
Yield : 32.7%.
Mass : 375 (M++l); 'HNMR (CDC13) δ : 8.70-8.72 (d, 2H, J=8Hz), 8.04-
8.08 (t, IH, J=8Hz), 7.59-7.61 (t, IH, J=8Hz), 5.25-5.27 (t, lH,J=4Hz),4.68-4.70 (d, lH,J=8Hz), 4.35-4.43 (m, 3H), 3.51-3.71 (m, 2H), 3.09-3.15 (m, 3H), 2.01-2.03 (m, 4H), 1.36 (s, 3H);
IR ( CC14 , Cm"') 3358, 2142, 1678. Example-61
3-[l -Oxo-2- (l-(4-n-propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate (Compound No. 60)
Yield : 97.5%. Mass : 311 (M++l), 333 (M++Na);
'HNMR ( U-MeOH) δ : 5.33-5.35 (t, IH, J=4Hz), 4.72-4.74 (d,
IH, J=8Hz), 4.64-4.68 (d, IH, J=8Hz), 4.05-4.20 (m, 2H), 3.38-3.47 (m, 3H), 1.70-
1.74 (m, 5H), 1.52-1.60 (m, 4H), 1.33-1.39 (m, 4H), 0.92-0.96 (t, 3H, J=8Hz);
IR (KBr; Cm"') : 3461 , 2942, 2117, 1670, 1640.
Example-62 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 61)
Yield : 56%.
Mass : 405 (M++l); 'HNMR (d4-MeOH) δ : 8.35-8.37 (d, 2H, J=8Hz), 1.77-1.79 (d,
2H, J=8Hz), 5.31-5.33 (t, IH, J=4Hz), 4.78-4.80 (d, IH, J=8Hz), 4.63-4.65 (d, IH, J=8Hz), 4.45 (s, 2H), 3.44-3.50 (m, 3H), 3.37-3.38 (m, 4H), 3.1 1-3.15 (m, 2H), 188- 2.20 (m, 4H);
IR (KBr, Cm"1) : 2939, 2679 and 1652
Example-63
3-[l-Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 62)
Yield : 55.5%.
Mass : 444 (M++l); 'HNMR(d4-MeOH)δ : 7.78-7.80 (d, 2H, J=8Hz), 7.65-7.67 (d,
2H, J=8Hz), 5.29-5.31 (t, IH, J=4Hz), 4.68-4.70 (d, IH, J=8Hz), 4.60-4.62 (d, IH, J=8Hz), 4.00-4.01 (d, IH, J=8Hz), 3.77-3.81 (dd, 2H, J=4Hz, 6Hz), 3.31-3.36 (m, 2H), 3.06-3.18 (m, 2H), 2.44-2.49 (m, 2H), 1.99-2.05 (m, 2H), 1.65-1.72 (m, 2H); IR(KBr,Cm"') : 3171, 2357, 1674, 1605, 1534,
1440
Example-64
3-[l-Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 63)
Yield : 58.3%.
Mass : 281 (M++l), 303 (M++Na);
'HNMR (cU-MeOH) δ : 5.33-5.35 (t, IH, J=4Hz), 4.71-4.72 (d, IH, J=6Hz), 4.64-4.65(d, lH,J=6Hz), 3.93-3.97 (dd, 2H, J=4Hz, 8Hz), 3.50-3.54 (m, 2H), 3.37-3.39 (d, 2H, J=6Hz), 2.38-2.40 (m, IH), 2.28-2.32 (m, IH), 1.78-1.88 (m, 2H), 1.60-1.63 (m, IH), 1.42-1.54 (m, 4H); IR (KBr, Cm"1) : 2950, 216, 1675, 1628, 1511.
Example-65
3-[l -Oxo-2- (l-(4-n-propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 64)
Yield : 85.3%. Mass : 311 (M++1);
'HNMR ( t-MeOH) δ : 5.33-5.35 (t, IH, J=4Hz), 4.71-4.73 (d,
IH, J=8Hz), 4.63-4.65 (d, IH, J=8Hz), 4.11-4.16 (m, IH), 3.38-3.39 (d, 2H,J=4Hz), 3.12-3.16(m, IH), 1.92-2.05 (m, 4H), 1.39-1.41 (m, IH), 1.32-1.38 (m, 4H), 1.20-123 (m, 3H), 0.90-0.94 (t, 3H, J=8Hz);
IR (KBr, Cm"') 3496,2328, 1667,1551. Example-66
3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl -4- cyanothiazolidine trifluoroacetate (Compound No. 65)
Yield : 61%.
Mass : 394 (M++l), 416 (M++Na);
'HNMR (CDC13) δ : 5.31-5.33 (t, IH, J=4Hz), 4.68- 4.70 (d, IH, J=8Hz), 4.52-4.54 (d, IH, J=8Hz), 4.01-4.05 (m, 4H), 3.51-3.63
(m, 5H), 2.56-2.68 (m, 2H), 2.11-2.20 (m, 2H), 1.71-1.80 (m, 4H), 1.44-1.53 (m, 6H),
0.90-0.92 (d, 3H, J-8Hz);
IR (CCI4, Cm"') : 3372,2944,2240,1679.
Example-67
3-[ 1 -Oxo-2-( 1 -( 1 -acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 66)
Yield : 43%. Mass : 312 (M++l), 334 (M++Na);
1HNMR (d4-MeOH) δ : 5.32-5.35 (t, 1H,J= 4Hz), 4.71-4.73 (d,
IH, J=8Hz), 4.64-4.66 (d, IH, J=8Hz), 4.54-4.57 (m, IH), 4.05-4.15 (m, 2H), 3.38- 3.51 (m, 4H), 3.15-3.19 (m, IH), 2.70-2.83 (m, IH), 2.13 (s, 3H), 1.97-2.05 (m, 2H), 1.44-1.55 (m, IH), 1.24-1.29 (m,lH); IR (Neat, Cm"1) : 2922, 1680 and 1651
Example-68
1 , 1 -Dioxo-3-[ 1 -oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 67)
Yield : 70.5%.
Mass : 315 (M++l ), 337 (M+ +Na); lHNMR (CDC13) δ : 5.62-5.65 (dd, IH, J=4Hz,
J=4Hz), 4.95-4.97 (d, IH, J=8.Hz), 4.73-4.75 (d, IH, J=8Hz), 3.97-4.08 (m, 2H), 3.79-3.93 (m, 2H), 3.11-3.15 (m, IH), 1.98-2.05 (m, 2H), 1.85-1.89 (dd, 2H, J=4Hz, 4Hz), 1.36-1.41 (m, 3H), 1.0-1.09 (m, 2H), 0.93-0.95 (d, 3H, J=8Hz); IR ( Neat, Cm"') : 3398,2252,1678,1530.
Example-69
3-[ 1 -Oxo-2-( 1 -methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine (Compound No. 68)
Yield : 15%.
Mass : 297 (M++l), 319 (M++Na);
'HNMR (CDC13) δ : 5.32 (bs, IH), 4.64-4.66 (d, IH, J=8Hz), 4.61-4.63 (d, IH, J=1H), 3.51 (s, 3H), 3.32-3.36 (m, 3H), 2.96-2.99 (m, IH), 2.84-2.87 (m, IH), 2.03-2.06 (m, IH), 1.92-1.94 (m, IH), 1.23-1.36 (m, 5H), 1.03- 1.11 (m, 2H), 0.94-0.96 (d, 3H, J=8Hz); IR (Neat, Cm"') : 3302,2923,2244,1667.
Example-70
3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine (Compound No. 69)
Yield : 15%.
Mass : 297 (M++l ), 319 (M+ +Na);
'HNMR ( j-MeOH) δ : 5.26-5.28 (t, IH, J=4Hz), 4.75-4.77 (d,
IH, J=8Hz), 4.57-4.59 (d, IH, J=8Hz), 3.41-3.50 (m, 2H), 2.64-2.67 (m, IH), 2.54- 2.60 (m, 2H), 2.19 (s, 3H), 1.85-1.88 (m, 2H), 1.70-1.73 (m, 2H), 1.28-1.32 (m, 2H), 1.03-1.12 (m, 3H), 0.89-0.91 (d, 3H, J=8Hz);
IR ( Neat, Cm"1) : 3421, 2244, 1660. Example-71
3-[l-Oxo-2-(l-(l-(2,3-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 70)
Yield 60% Ό.
Mass 442 (M++l), 464(M++Na);
'HNMR ( -MeOH) δ 7.65-7.68 (dd, IH, J=4Hz, 4Hz), 7.42-7.45 (dd, IH, J=4Hz, 4Hz) ,7.31-7.35 (dd, IH, J=4Hz) 4Hz), 5.34 (bs, IH), 4.71- 4.73 (d, IH, J=8Hz), 4.62-4.64 (d, IH, J=8Hz), 4.02-4.08 (m, IH), 3.25-3.53 (m, 4H) 2.84-3.15 (m, 3H), 2.07-2.13 (m, IH), 1.88-1.95 (m, IH), 1.62-1.65 (m, IH), 1.48- 1.51 (m, IH), 1.21-1.31 (m, IH);
IR (Neat, Cm"1) : 3351 ,2227, 1676, 1629.
Example-72
3-[ 1 -Oxo-2-[ 1 -methyl-2-( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)]-hydrazino] ethyl-4-cyanothiazolidine (Compound No. 71)
Yield 23.5%.
Mass 458 (M++1), 480 (M++Na);
1 HNMR (CDC13) δ 7.76-7.78 (d, 2H, J=8Hz), 7.62-
7.64. (d, 2H, J=8Hz), 5.17-5.19 (t, IH, J=4Hz), 4.83-4.85 (d, IH, J=8Hz), 4.71-4.73 (d, IH, J=8Hz), 4.63 (s, IH), 4.51-4.57 (m, IH), 3.66-3.69 (d, IH, J=12Hz), 3.50-3.53 (m, IH), 3.41-3.47 (m, 4H), 3.35-3.39 (m, IH), 2.52 (s, 3H), 1.84-1.88 (m, 2H), 1.43- 1.47 (m, 2H); IR ( Neat,Cm"') : 2943, 2240, 1728, 1666, 1584. Example-73
3-[ 1 -Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis- trifluoroacetate (Compound No. 72)
Yield 52.8%. Mass 270 (M++l);
HNMR ((. -MeOH) δ 5.32-5.34 (t, IH, J=4Hz), 4.74-
4.76 (d, IH, J=8Hz), 4.62-4.64 (d, IH, J=8Hz), 3.36-3.53 (m, 8H), 2.17-2.21 (m, 3H), 1.77-1.86 (m, 2H);
IR (Neat, Cm"') 3394, 2250, 1679.
Example-74
[l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyrrolidine trifluoroacetate (Compound No. 73)
Yield 67%. Mass 426 (M++l), 448 (M++Na);
'HNMR (d-,-MeOH) δ 7.78-7.80 (d, 2H, J=8Hz), 7.65-
7.67 (d, 2H, J=8Hz), 4.79-4.81 (t, IH, J=4Hz), 3.92 (s, 2H), 3.79-3.82 (m, 2H), 3.62-
3.66 (m, IH), 3.47-3.51 (m, IH), 3.14-3.17 (m, IH), 2.43-2.49 (t, 2H, J=8Hz), 2.16-
2.29 (m, 4H), 2.01-2.03 (d, 2H, J=8Hz), 1.61-1.68 (m, 2H); IR (KBr, Cm"') : 3415, 2332, 1663, 1580.
Example-75
3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine (Compound No. 74)
Yield 47.6%. Mass 325 (M++1), 347 (M++Na);
'HNMR (CDC13) δ 5.18-5.20 (t, IH, J=4Hz), 4.76- 4.78 (d, IH, J=8Hz) 4.67-4.70 (d, IH, J=9.6Hz), 4.56-4.58 (d, I H, J=8Hz), 4.42-4.44 (d, 1H,J= 9Hz), 3.96-3.99 (m, IH), 3.81-3.92 (m, IH), 3.77-3.81 (m, 2H), 3.52-3.55 (m, 2H), 3.30-3.35 (m, 4H), 2.85-2.92 (m, IH), 2.63-2.67 (m, IH), 1.89 (s, 3H), 0.90- 0.92 (d, 3H, J=8Hz);
IR (Neat, Cm"') 3343,2248,1676,1570.
Example-76
3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 75)
Yield 38.9%.
Mass 321 (M++1), 343 (M++Na);
'HNMR (d4-MeOH) δ 5.32-5.34 (t, IH, J=4Hz), 4.70- 4.72 (d, IH, J=8Hz), 4.61-4.63 (d, IH, J=8Hz), 4.04-4.06 (d, IH, J=8Hz), 3.53 (bs, IH), 3.47-3.50 (m, I H), 3.37-3.38 (d, 2H, J=4Hz), 1.92-2.12 (m, 6H), 1.85-1.94 (m, 2H), 1.76-1.82 (m, 4H), 1.58-1.61 (m, 2H);
TR (KBr, Cm"') 2927, 2242, 1663, 1508.
Example-77
3-[l-Oxo-2-(l-(l -(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 76)
Yield : 76.4%.
Mass : 354 (M++l), 376 (M++Na);
'HNMR (d4-MeOH) δ : 5.33-5.35 (t, IH, J=4Hz), 4.76-4.78 (d,
IH, J=8Hz), 4.63-4.65 (d, IH, J=8Hz), 4.47-4.50 (d, 2H, J=12 Hz), 4.08-4.10 (d, 2H,
J=8Hz), 3.33-3.53 (m, 5H), 2.01-2.03 (m, 2H), 1.48-1.54 (m, 2H), 1.30 (s, 9H); IR (KBr, Cm"1) : 3427, 2248, 1673, 1614.
Example-78
3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate (Compound No. 77)
Yield : 63.3%.
Mass : 415 (M++l), 437 (M++Na); 1HNMR (cU-MeOH) δ : 8.36 (s, IH), 7.73-7.77 (dd, lH,J=4Hz, 8Hz), 6.94-6.96(d, lH,J=8Hz), 5.34-5.36 (t, IH, J=4Hz), 4.71-4.73 (d, IH, J=8Hz), 4.63-4.65 (d, IH, J=8Hz), 4.54-4.58 (d, 2H,J= 13Hz), 4.09-4.13 (t, 2H, J=8Hz), 3.36-3.40 (m, IH), 3.01 -3.04 (m, 3H), 2.03-2.07 (m, 2H), 1.58-1.62 (m, 2H); IR (Neat, Cm"1) : 2943, 2248 and 1672
Example-79
3- [ 1 -Oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 78)
Yield : 66.6%.
Mass : 362 (M++l), 384 (M++Na);
'HNMR (d4-MeOH) δ : 5.33-5.35 (t, IH, J=4Hz), 4.73- 4.75 (d, IH, J=8Hz), 4.59-4.61 (d, IH, J=8Hz), 4.02-4.14 (m, 2H), 3.19-3.24 (m, 4H),
2.97 (s, 3H), 2.14-2.17 (d, 2H, J=10Hz), 2.05-2.07 (d, 2H, J=8Hz), 1.36-1.44 (m, 4H);
IR (KBr, Cm"1) : 2940, 2248, 1677, 1437.
Example-80 3-[l-Oxo-2- (1 -(3, 3, 5 -trimethyl cyclohexyl)-hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 79)
Yield : 48.5%.
Mass : 311 (M++l); 1HNMR (d4-MeOH) δ : 5.34 (bs, IH), 4.73-4.75 (d, IH, J=8Hz),
4.65-4.67 (d, IH, J=8Hz), 4.04-4.14 (m, 2H), 3.61-3.64 (m, IH), 3.38-3.39 (d, 2H, J=4Hz), 1.95-1.99 (m, IH), 1.77-1.80 (m, IH), 1.62-1.65 (m, IH), 1.46-1.49 (m, 4H), 1.10-1.12 (d, 3H, J=8Hz), 0.99 (s, 6H); IR (KBr, Cm"1) : 3099, 2246, 1665, 1628, 1516. Example-81
3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 80)
Yield : 97%.
Mass : 257 (M++l), 279 (M+ +Na);
'HNMR (CDC13) δ : 5.27 (bs, IH), 4.71-4.73 (d, IH,
J=8Hz), 4.55-4.57 (d, I H, J=8Hz), 3.84-3.90 (m, 2H), 3.66-3.69 (t, IH, J=6Hz), 3.28-
3.37 (m, 4H), 1.35-1.37 (t, 3H, J=4Hz), 1.26-1.27 (d, 6H, J=6Hz); IR (Neat, Cm"1) : 2983,2251,1670.
Example-82
3-[l-Oxo-2-[l-(l-phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 81)
Yield : 56%.
Mass : 360 (M++l);
'HNMR (d4-MeOH) δ : 7.52 (bs, 5H), 5.43 (bs, IH),
4.69-4.71 (d, IH, J=8Hz), 4.61-4.63 (d, IH, J=8Hz), 4.31-4.42 (m, 2H), 4.05-4.11 (m, 2H), 3.58-3.61 (m, 2H), 3.40-3.51 ( , 3H), 3.01 -3.15 (m, 2H), 2.21-2.24 (m, 2H), 1.96-2.02 (m, 2H); IR (Neat, Cm"1) : 3411,2249,1675.
Example-83
3-[l-Oxo-2-(l-(l-(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 82)
Yield : 41%.
Mass : 458 (M++l), 480 (M+ +Na); 'HNMR (d4-MeOH) δ : 7.85-7.87 (d, 2H, J=8Hz), 7.58-
7.60 (d, 2H, J=8Hz), 5.31 (bs, IH), 4.72-4.74 (d, IH, J=8Hz), 4.60-4.62 (d, IH, J=8Hz), 3.96-4.07 (m, 2H), 3.45-3.53 (m, 2H), 3.06-3.08 (m, 2H), 1.86-1.97 (m, 4H), 1.26-1.38 (m, 4H); IR (KBr, Cm"') : 2943, 2240, 1673, 1435.
Example-84
3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine (Compound No. 83)
Yield : 30%.
Mass : 241 (M++l);
1HNMR (d4-MeOH) δ : 5.25-5.27 (t, IH, J=4Hz), 4.78-4.81 (d,
IH, J=10Hz), 4.72-4.74 (d, IH, J=8Hz), 3.50-3.56 (m, 2H), 3.30-3.37 (m, 2H), 2.95- 2.98 (t, 2H, J=5.5Hz), 2.72-2.83 (m, 2H), 1.25-1.34 (m, 4H); IR (Neat, Cm"1) : 2925,2244,1737,1663.
Example-85
3-[ 1 -Oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl)-2- isopropyl)hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 84)
Yield : 75%.
Mass : 404 (M++l ), 426 (M+ +Na); lHNMR (d4-MeOH) D : 5.32-5.34 (t, IH, J=4Hz),
4.79-4.81 (d, IH, J=8Hz), 4.65-4.67 (d, IH, J=8Hz), 4.03-4.13 (m, 2H), 3.57-3.59 (t,
IH, J=4Hz), 3.48-3.53 (q, 2H, J=8Hz), 3.38-3.39 (d, 2H, J=4Hz), 3.21-3.26 (m, IH), 2.96-2.97 (d, 3H, J=6.5Hz), 2.1 1-2.14 (m, 2H), 1.98-2.04 (m, 2H), 1.71-1.80 (m, 2H),
1.44-1.50 (m, 2H), 1.35-1.37 (d, 6H, J=8Hz); IR (KBr, Cm"1) : 2945, 2245, 1676, 1435.
Example-86
3-[ 1 -oxo-2-[ 1 -( 1 (mo holinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4-cyano- thiazolidine trifluoroacetate (Compound No. 85)
Yield : 80%
Mass : 383 (M++l), 405 (M++Na)
'HNMR (αVMeOH): δ 5.32-5.34 (t, IH), 4.71-4.73 (d, IH), 4.63-4.65 (d, IH), 4.03- 4.12 (m, 2H), 3.78-3.81 (m, 2H), 3.66-3.68 (t, 4H), 3.47-3.49 (m, IH), 3.38-3.39 (d, 2H), 3.27-3.29 (t, 4H), 2.87-2.94 (t, 2H), 1.95-2.03 (m, 2H), 1.55-1.61 (m, 2H)
IR (KBr, cm"1) : 2888, 2246, 1670, 1542
Example-87
3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 86) Yield : 70%
Mass : 348 (M++l)
'HNMR (drMeOH) δ : 5.32.-5.34 (t, 1 H), 4.72-4.74 (d, IH), 4.59-4.61 (d, IH), 4.07-4.09 (m, 2H), 3.78-3.81 (m, 2H), 3.43-3.48 (m, IH), 3.38-3.39 (d, 2H), 2.86 (S, 3H), 2.80-2.85 (m, 2H), 2.03-2.08 (m, 2H), 1.63-1.73 (m, 2H) IR (KBr, cm"1) : 3426, 2929, 2248, 21 10, 1679 Example-88
3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4- cyanothiazolidine trifluoroacetate (Compound No. 87)
Yield : 80%
Mass : 390 (M++l), 412 (M++Na)
'HNMR (( t-MeOH) δ : 5.31-5.34 (t, IH), 4.75-4.76 (d, IH), 4.58-4.61 (d, IH), 4.08-4.10 (d, 2H), 3.80-3.83 (m, 2H), 3.53-3.61 (m, IH), 3.38-3.39 (d, 2H), 2.86 (S, 3H), 3.44-3.48 (m, IH), 2.78-2.85 (m, 2H), 2.03-2.06 (m, 2H), 1.60- 1.72 (m, 2H), 1.36-1.37 (d, 6H) IR (KBr, cm"1) : 3399, 2937, 2248, 1672
Example-89
3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 88)
Yield : 80%
Mass : 376 (M++l), 398 (M++Na)
'HNMR ( -MeOH) δ : 5.31-5.34 (t, IH), 4.74-4.76 (d, IH),
4.65-4.67 (d, IH), 4.03-4.25 (m, 2H), 3.80-3.82 (m, 2H), 3.44.3.48 (m, IH), 3.25-3.29
(q, 2H), 3.38-3.39 (d, 2H), 2.86 (S, 3H), 2.80-2.85 (m, 2H), 2.03-2.05 (m, 2H), 1.64- 1.70 (m, 2H), 1.30-1.34 (t, 3H)
IR (KBr, cm"1) : 3501, 2933, 2246, 1672 Example-90
3-[ 1 -oxo-2-[ 1 -( 1 -(morpholinocarbonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl- 4- cyanothiazolidine trifluoroacetate (Compound No. 89)
Yield : 80%
Mass : 411 (M++l), 433 (M++Na)
'HNMR (d4-MeOH) δ : 5.32-5.33 (t, IH), 4:73-4.78 (d, IH),
4.64-4.66 (d, IH), 4.03-4.11 (m, 2H), 3.77-3.81 (m, 2H), 3.66-3.69 (t, 4H), 3.48-3.51 (m, IH), 3.38-3.39 (d, 2H), 3.26-3.29 (m, 6H), 2.88-2.90 (m, 2H), 1.92-1.96 (m, 2H), 1.53-1.56 (m, 2H), 1.31 -1.36 (t, 3H) IR (KBr, cm"1) : 3361, 2929, 2247, 1675
Example-91
3-[ 1 -oxo-2-[ 1 -( 1 -(N-ethylmethylaminocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoiOacetate (Compound No. 90)
Yield : 80%
Mass : 355 (M++l), 377 (M++Na) 'HNMR (cL,-MeOH) δ : 5.33-5.35 (t, IH), 4.71-4.74 (d, IH),
4.63-4.66 (d, IH), 4.08-4.12 (m, 2H), 3.71-3.74 (m, 2H), 3.44-3.48 (m, IH), 3.38-3.39 (d, 2H), 3.22-3.27 (q, 2H), 2.82-2.88 (m, 2H), 2.88 (S, 3H), 1.95-1.97 (m, 2H), 1.53- 1.62 (m,2H), 1.14-1.19 (t, 3H) IR (KBr, cm"') : 3398, 2935, 2245, 1675
Example-92
3-[l-oxo-2-[l-(l-(4-methoxyphenylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl- 4- cyanothiazolidine trifluoroacetate (Compound No. 91)
Yield : 80%
Mass : 440 (M++l), 462 (M++Na) lHNMR (d4-MeOH) D : 7.72-7.74 (d, 2H), 7.12-
7.15 (d, 2H), 5.29-5.31 (t, I H), 4.67-4.69 (d, IH), 4.59-4.61 (d, IH), 4.05-4.07 (m, 2H), 3.90 (S, 3H), 3.72-3.77 (m, 2H), 3.35-3.37 (d, 2H), 3.17-3.19 (m, IH), 2.38-2.44 (m, 2H), 1.99-2.03 (m, 2H), 1.65-1.71 (m, 2H).
IR (KBr, cm"') : 3471, 2954, 2246, 1665
Example-93
3-[ 1 -oxo-2-[ 1 -(1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate (Compound No. 92)
Yield : 90%
Mass : 453 (M++l)
'HNMR (c -MeOH) δ : 7.79-7.82 (d, 2H), 7.07-7.09 (d,
2H), 5.30-5.32 (t, IH), 4.67-4.69 (d, IH), 4.59-4.61 (d, IH), 4.01-4.03 (m, 2H), 3.36- 3.37 (d, 2H), 3.08-3.1 1 (m, IH), 2.97-3.01 (m, IH), 1.96-2.03 (m, 2H), 1.85-1.88 (m, 2H), 1.25-1.38 (m, 4H) IR (KBr, cm"1) : 2942, 2247, 1673, 1596
Example-94
3-[ 1 -oxo-2-[ 1 -(1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazol idine bis-trifluoroacetate (Compound No. 93)
Yield : 90%
Mass : 392 (M++l)
'HNMR (d4-MeOH) δ : 7.53-7.56 (t, 2H), 7.20-7.24 (t, 2H), 5.32-
5.34 (t, IH), 4.72-4.74 (d, IH), 4.63-4.65 (d, IH), 4.24-4.25 (S, 2H), 4.07-4.14 (m, 2H), 3.64-3.70 (m, IH), 3.38-3.39 (d, 2H), 3.18-3.22 (m, IH), 2.32-2.36 (m, 2H), 2.18-2.22 (m, 2H), 1.52-1.58 (m, 4H) IR (KBr, cm"') : 2963, 2248, 1673, 1513 Example-95
3-[l-oxo-2-[l-(l-(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate (Compound No. 94)
Yield : 95%
Mass : 387 (M'+l), 400 (M++Na)
'HNMR (d-4-MeOH) δ : 7.55-7.58 (t, 2H), 7.23-7.25 (t, 2H), 5.31-
5.33 (t, IH), 4.70-4.72 (d, IH), 4.59-4.61 (d, IH), 4.35 (S, 2H), 4.02-4.14 (m, 2H),
3.46.3.59 (m, 3H), 3.37-3.38 (d, 2H), 3.07-3.15 (m, 2H), 2.18-2.24 (m, 2H), 1.83-1.87
(m, 2H). IR (KBr, cm"1) : 3364, 2955, 2251, 1675
Example-96 3-[ 1 -oxo-2-[( 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate (Compound No. 95)
Yield : 87% Mass : 438 (M++l), 460 (M++Na)
1HNMR (d4-MeOH) D : 8.332-8.338 (d, IH), 8.16-
8.18 (d, IH), 7.83-7.86 (dd, IH), 5.32-5.34 (t, IH), 4.72-4.74 (d, IH), 4.64-4.66 (d, IH), 4.01-4.14 (m, 4H), 3.66-3.68 (m, 2H), 3.47-3.49(m,lH),3.37-3.38 (d, 2H), 3.21- 3.23 ( , 2H), 2.23-2.26 (m, 2H), 2.01-2.05 (m, 2H)
IR (KBr, cm"1) : 2954, 2249, 1674, 1539
Example-97
3-[l-oxo-2-[l-(l -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 96)
Yield : 90% Mass : 368 (M++l), 390 (M++Na)
'HNMR (d4-MeOH) δ : 5.53-5.35 (t, IH), 4.74-4.76 (d, IH), 4.63-4.65 (d, IH), 4.04-4.16 (m, 2H), 3.64-3.70 (m, IH), 3.38-3.41 (d, 2H), 3.18-3.22 (m, IH), 2.05-2.08 (m, 2H), 1.96-1.99 (m, 2H), 1.36-1.52 (m, 4H), 1.2 (s,9H) IR (KBr, cm"1) : 3342, 2949, 2242, 1693, 1534
Example-98
3-[ 1 -oxo-2-[ 1 -(1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl]hydrazino]ethyl- 4-cyanothiazolidine (Compound No. 97)
Yield : 45%
Mass : 390 (M++l), 412 (M++Na)
1HNMR (d4-MeOH) D : 5.27-5.28 (t, IH), 4.71-4.83 (m, 2H), 3.42-3.82 (m, 2H), 3.27-3.34 (m, 3H), 2.80 (S, 3H), 2.76-2.80 (m, 2H), 2.12-2.15 (m, 2H), 1.90-1.93 (m, 2H), 1.25-1.44 (m, 4H), 1.02-1.07 (t, 3H). IR (KBr, cm"') : 3587, 3218, 2243, 1739, 1677
Example-99
3-[l-oxo-2-[(l -(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 98)
Yield : 60%
Mass : 367 (M++l)
'HNMR (d4-MeOH) δ : 5.33-5.35 (t, IH), 4.72-4.74 (d, IH), 4.68-4.70 (d, IH), 4.02-4.15 (m, 2H), 3.76-3.80 (m, IH), 3.38-3.48 (m, IH), 3.32-3.33 (d, 2H), 1.75-1.78 (m, 8H), 1.2 (S, 9H). IR (KBr, cm"') : 3408, 2933, 2159, 1672 Example-100
3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 99)
Yield : 90%
Mass : 428 (M++l), 450 (M++Na)
'HNMR (d4-MeOH) δ : 7.80-7.83 (d, 2H), 7.73-7.75 (d, 2H),
5.53-5.35 (t, IH), 4.72-4.74 (d, IH), 4.63-4.65 (d, IH), 4.20 (S, 2H), 4.10-4.18 (m,
2H),
3.48-3.75 (m, 3H), 3.38-3.39 (d, 2H), 3.25-3.27 (m, 2H), 2.26-2.29 (m, 2H), 2.03-2.05 (m, 2H).
IR (KBr, cm"') : 3411, 2934, 2248, 1675, 1647
Example-101
3-[ 1 -oxo-2-[ 1 -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate (Compound No. 100)
Yield : 75%
Mass : 428 (M++Na)
'HNMR (c -MeOH) δ : 7.86-7.89 (t, 2H), 7.18-7.22 (t, 2H), 5.32- 5.34 (t, IH), 4.72-4.74 (d, IH), 4.60-4.62 (d, IH), 4.09-4.20 (m, 2H), 3.46-3.50 (m, 2H), 3.39-3.40 (d, 2H), 1.77-1.89 (m, 8H). IR (KBr, cm"') : 3273, 2949, 2248, 1675, 1644
Example-102
3-[l-oxo-2-[l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4-yl)]-2- ethylhydrazino]ethyl-4-cyanothiazolidine tris-hydrochloride (Compound No.101)
Yield : 87% i n Mass : 466(M++1), 488 (M++Na)
'HNMR ( U-MeOH) δ : 8.332-8.338 (d, IH), 8.16-8.18 (d, IH), 7.83-7.86 (dd, IH), 5.35-5.37 (t, 1 H), 4.64-4.82 (m, 4H), 4.05-4.24 (m, 4H), 3.78- 3.82 (m, 2H), 3.47-3.49(m,lH),3.32-3.40 (m, 4H), 2.22-2.30 (m, 3H), 2.01 -2.05 (m, 3H),1.35-1.39(t, 3H).
IR (KBr, cm"') 2946,2247, 1696, 1667
Example-103
3-[ 1 -oxo-2-[- 1 -(1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 102)
Yield : 59%
Mass : 471 (M++l)
'HNMR (d4-MeOH) δ : 7.81-7.83 (d, 2H), 7.66-7.68 (d, 2H), 5.32-5.34 (t, IH), 4.73-4.75 (d, IH), 4.65-.467 (d, IH), 4.1 (S, 2H), 4.03-4.06 (m, 2H), 3.53-3.69 (m, 2H), 3.46-3.50 (m, IH), 3.38-3.39 (d, 2H), 3.46-3.50 (m, IH), 2.23-2.26 (m, 2H), 2.01-2.05 (m, 2H) IR (KBr, cm"') : 2945, 2249, 1674, 1613
Example-104
3-[l-oxo-2-[l-(l-(2-oxo-2(-adamant-l-yl)amino ethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 103)
Yield : 53%
Mass : 461 (M++l) 'HNMR (d4-MeOH) δ : 5.32-5.34 (t, 1H), 4.71-4.73 (d,
2H), 4.63-4.65 (d, IH), 4.05-4.08 (m, 2H), 3.8 (S, 2H), 3.48-3.50 (m, 3H), 3.37-3.39 (d, 2H), 3.32-3.33 (m, 2H), 2.03-2.09 (m, 2H), 1.85-2.02 (m, 1 IH), 1.72-1.75 (m, 6H)
IR (KBr, cm"') : 2910, 1674, 1558
Example - 105
3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl)piperidin- 4-yl)]hydrazino]ethyl-4-cyano-thiazolidine bis-trifluoroacetate (Compound No. 104)
Yield : 80%
Mass : 461 (M++l):,483 (M++Na):
'HNMR (d4-MeOH) δ : 7.22-7.23 (d, IH), 6.94-6.97 (dd,
IH), 6.79-6.82 (d, 2H), 5.32-5.34 (t, IH), 4.73-4.75 (d, IH), 4.64-4.67 (d, IH), 4.24
(S, IH), 4.00-4.05 (m, 4H), 3.50-3.51 (m, 2H), 3.46-3.47 (m, IH), 3.38-3.39 (d, 2H),
3.15-3.32 (m, 2H), 2.21-2.23 (m, 2H), 2.03-2.05 (m, 2H)
IR (KBr, cm"') : 2949, 1677, 1620
Example-106
3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 105)
Yield : 60%
Mass : 437 (M++l), 459 (M++Na)
'HNMR (d4-MeOH) : 7.60-7.62 (d, 2H), 7.35-7.37 (d,
2H), 5.32-5.33 (t, IH), 4.73-4.76 (d, IH), 4.65-4.67 (d, IH), 4.07- (S, IH), 3.92-4.00 (m, 2H), 3.59-3.64 (m, 2H), 3.51-3.52 (m, IH), 3.17-3.38 (d, 2H), 3.15-3.32 (m, 2H), 2.18-2.21 (m, 2H), 1.99-2.05 (m, 2H) IR (KBr, cm"1) 2924, 1677, 1620
Example-107
3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)]hydrazino]ethyl- 4-cyanothiazolidine tris-trifluoroacetate (Compound No. 106)
Yield : 66%
Mass : 408 (M++l), 427 (M++Na)
'HNMR (d4-MeOH) δ : 8.66-8.67 (d, 2H), 7.20-7.23 (t,
IH), 5.32-5.34 (t, IH), 4.68-4.72 (d, IH), 4.63-4.67 (d, IH), 4.60-4.62 (m, 2H), 4.09- 4.19 (m, 2H), 3.72-3.74 (m, 2H), 3.47-3.53 (m, 3H), 3.38-3.39 (d, 2H), 2.25-2.28 (m, 2H), 2.03-2.05 (m, 2H)
IR (KBr, cm"') : 2978, 1678, 1517
Example-108 3-[ 1 -oxo-2-[ 1 -( 1 -(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate (Compound No. 107)
Yield : 86% Mass : 397 (M++l), 419 (M++Na)
'HNMR (d4-MeOH) δ : 5.32-5.34 (t, IH), 4.72-4.74 (d,
IH), 4.63-4.65 (d, IH), 4.28 (S, 2H), 4.02-4.14 (m, 2H), 3.70-3.71 (t, 4H), 3.61-3.63 (m, 2H), 3.47-3.51 (m, IH), 3.42-3.43 (m, 2H), 3.38-3.39 (d, 2H), 3.32 (t, 4H), 2.21- 2.24 (m, 2H), 1.99-2.03 (m, 2H)
IR (KBr, cm"') : 2977, 1676, 1539 Example-109
3[l-oxo-2-[l-(l-(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate (Compound No. 108)
Yield : 40%
Mass : 367 (M++l), 389 (M++Na)
'HNMR (d4-MeOH) δ : 5.31-5.33 (t, IH), 4.72-4.75 (d,
IH), 4.63-4.66 (d, IH), 4.01-4.09 (m, 2H), 3.87 (S, 2H), 3.51-3.53 (m, 2H), 3.48-3.50 (m, IH), 3.37-3.38 (d, 2H), 3.14-3.16 (m, 2H), 2.73-2.77 (m, IH), 2.20-2.23 (m, 2H), 2.01-2.03 (m, 2H), 0.76-0.79 (m, 2H), 0.52-0.56 (m, 2H)
IR (KBr, cm"1) 2994, 1677, 1541
Example-110
3-[l-oxo-2-[l-(l-(2-cyanobiphenyl-4-yl)methyl)piperidine-4-yl]hydrazino]ethyl- 4- cyanothiazolidine bis-trifluoroacetate (Compound No. 109)
Yield : 80%
Mass : 461 (M++l), 483 (M++Na)
'HNMR (d4-MeOH) δ : 7.59-7.90 (m, 8H), 5.31-5.33 (d,
IH), 4.71-4.73 (d, 2H), 4.61-4.64 (d, IH), 4.45 (S, 2H), 4.01-4.12 (2H), 3.59-3.66 (m, 2H), 3.50-3.53 (m, IH), 3.37-3.38 (d, 2H), 3.15-3.32 (m, 2H), 2.25-2.27 (m, 2H), 2.03-2.05 (m, 2H)
IR (KBr, cm"1) : 2944, 2247, 1676 Example-Ill
3-[l-oxo-2-[l-(l-(l-oxo-2-(morpholin-4-yl)ethyl)piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate (Compound No. 110)
Yield : 51%
Mass : 397 (M++ 1 ), 419 (M++Na)
'HNMR (d4-MeOH) δ : 5.32-5.33 (t, IH), 4.72-4.74 (d,
IH), 4.64-4.66 (d, IH), 4.51-4.54 (m, IH), 4.24-4.34 (m, 2H), 4.03-4.05 (m, 2H), 3.96 (t, 4H), 3.78-3.82 (m, IH), 3.48-3.51 (m, IH), 3.38-3.39 (d, 2H), 3.32-3.34 (t, 4H), 3.07-3.19 (m, IH), 2.84-2.90 (m, IH), 2.03-2.05 (m, 2H), 1.51-1.64 (m, 2H) IR (KBr, cm"') : 2949, 2247, 1673
Example-112
3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1- yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate (Compound No. I l l)
Yield : 66%
Mass : 452 (M++l), 474 (M++Na)
'HNMR (d4-MeOH) δ : 8.32-8.33 (d, IH), 8.14-8.16 (d,
IH), 7.83-7.85 (dd, IH), 5.32-5.33 (t, IH), 4.72-4.74 (d, IH), 4.59-4.63 (d, IH), 3.98- 4.08 (m, 4H), 3.38-3.39 (t, 2H), 3.21-3.23 (m, 2H), 2.28-2.30 (m, 2H), 2.19-2.20 (m, 2H), 1.53-1.62 (m, 4H)
IR(KBr,cm"') : 2977,1676,1539
Example-113
3-[l-oxo-2-[l-(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex-l- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No. 112)
Yield : 75%
Mass : 442 (M++l)
16 'HNMR (d4-MeOH) δ : 7.80-7.82 (d, IH), 7.72-7.74 (d,
IH), 5.32-5.33 (d, IH), 4.71 -4.73 (d, IH), 4.53-4.65 (d, IH), 4.02-4.13 (m, 4H), 3.38- 3.39 (d, 2H), 3.07-3.15 (m, 2H), 2.29-2.31 (m, 2H), 2.18-2.20 (m, 2H), 1.56-1.63 (m, 4H).
IR (KBr, cm"1) : 2946, 2226, 1676
Example-114
3-[l-oxo-2-[l-(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex-l- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate (Compound No.l 13)
Yield : 85%
'HNMR (d4-MeOH) δ : 7.60-.762 (d, 2H), 7.34-7.36 (d,
2H), 5.32-5.33 (t, IH), 4.72-4.74 (d, IH), 4.65-4.67 (d, IH), 3.98-4.09 (m, 4H), 3.37- 3.38 (d, 2H), 3.07-3.15 (m, 2H), 2.29-2.31 (m, 2H), 2.17-2.19 (m, 2H), 1.53-1.59 (m, 4H)
Mass : 451 (M++l)
IR (KBr, cm"') : 2948, 1677, 1544
Example-115
3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride (Compound No. 114)
Yield : 70%
Mass : 362 (M++l), 384 (M++Na)
'HNMR (d4-MeOH) δ : 5.33-5.35 (t, IH), 4.73-4.76 (d, IH), 4.64-4.66 (d, IH), 4.06-4.14 (m, 2H), 3.38-3.40 (d, 2H), 3.15-3.25 (m, 2H), 2.97
(S, 3H), 2.14-2.16 (m, 2H), 2.01-2.03 (m, 2H), 1.36-1.50 (m, 4H).
IR (KBr, cm"') : 2936,1664 and 1444 Example-116
3-[-l-oxo-2-[l-(l -(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride (Compound No. 115)
Yield : 70%
Mass : 438 (M++l), 460 (M++Na)
'HNMR (d4-MeOH) δ : 8.32-8.33 (d, IH), 8.18 (S, IH),
7.84-7.86 (d, IH), 5.34-5.35 (t, IH), 4.73-4.75 (d, IH), 4.66-4.68 (d, IH), 4.1 1-4.28 (m, 4H), 381 -3.83 (m, 2H), 3.67-3.69 (m, IH), 3.48-3.49 (m, 2H), 3.38-3.39 (d, IH), 2.27-2.29 (m, 2H), 2.03-2.1 1 (m, 2H) lR (KBr, cm"') : 2940,2246 and 1695
Examples of Scheme 2:
Example -117
[2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate] (Compound No. 1).
Yield 97.32% ; m.p. - 126-128°C;
Mass (m/z) 209 ( M+ +1), 231 ( M+ +Na);
'HNMR (400 MHz, d-rMeOH)δ 4.79-4.82 (m,lH),4.27-4.30 (dd,lH,J=4Hz,4Hz), 3.91-3.94 (m,lH), 3.59-3.62 (m,lH), 3.22-3.39 (m,6H), 2.19- 2.31 (m,4H); IR (KBr, cm."1) : 3000, 2364, 1673, 1430.
Example -118
[2-Cyano-l -(4-isopropyl-2-piperazinyl)-carbonyl-pyrrolidine bis trifluoroacetate]
(Compound No. 2)
Yield : 53.92% ; Mass (m/z) : 251 ( M+ +1);
'HNMR (400 MHz, d4-MeOH)δ : 4.79-4.82 (m,lH),4.28-4.30
(m,lH), 3.56-3.74 (m,2H), 2.41-3.47 (m,7H), 2.21-2.37 (m,4H), 1.31-1.33 (d,6H,J=8Hz) ; IR (CC14, cm."') 3480, 2962, 2302, 1677, 1453.
Examples of Scheme 3:
Example - 119 [4-Cyano-3-( 1 -isopropylhydrazino)carbonyl thiazolidine hydrochloride] (Compound No. 31)
Yield 52.63% ; m.p. 148-150°C (dec);
Mass (m/z) 215 ( M+ +1), 199;
'HNMR (400 MHz, d4-MeOH)δ 5.13-5.15 (d,lH,J=8Hz),4.59-
4.62 (m,lH,),4.24-4.28 (m,2H),3.42-3.46 (dd,lH,J=6Hz,4Hz), 2.96-3.00
(t,lH,J=8Hz),l .22-1.26 (t,6H,J=8Hz);
IR (KBr, cm."') 3646,2940,2355, 1649.
Example 120
[2-Cyano-l -(1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride] (Compound No. 32)
Yield 22.62% ; m.p. 160-162°C (dec);
Mass (m/z) 237 ( M+ +1), 155;
'HNMR (400 MHz, CDCl3)δ 8.75-8.77 (bs,2H),4.14-4.25
(bs,2H,),3.53-3.65 (bs,lH), 3.50-3.52 (bs,lH), 2.60-2.80 (bs,lH),2.06-2.27 (m,3H),
1.79-1.90 (m,6H), 1.65-1.68 (m,lH), 1.23-1.29 (m,3H); IR (KBr, cm."1) 3646, 3245, 2931, 2360, 1666. Example - 121
[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride] (Compound No. 33)
Yield : 32.46% m.p. 166-168°C (dec);
Mass (m/z) 255 ( M+ +1), 173;
'HNMR (400 MHz, d4-MeOH)δ 4.863-4.88(d, 1 H,J=8Hz),4.18- 4.20 (d,2H,J=8Hz),3.29-3.32(m,lH),3.16-3.20 (t,lH,J=8Hz), 2.92-2.96 (t,lH,J=8Hz), 1.66- 1.73 (m,2H), 1.54- 1.64 (m,4H), 1.49-1.53 (m,lH), 1.18-1.23 (m,2H),1.04-1.10 (m,lH); IR (KBr, cm."') : 3748, 3226, 2934, 2345, 1656.
Pharmaceutical Compositions
Pharmaceutical compositions may be prepared with a pharmaceutically effective quantity of compounds of general formula I, individually or in combination. It is common practice to administer the compounds in the form of pharmaceutical dosage forms comprising pharmaceutically acceptable excipient(s) and at least one active ingredient. These dosage forms may be administered by a variety of routes including oral, topical, transdermal, subcutaneous, intramuscular, intravenous, intranasal, pulmonary etc.
The following pharmaceutical formulations suggested are by way of example alone and in no way restrict the forms in which they can be used.
Oral formulations
Oral formulations may be administered as solid dosage forms for example pellets, powders, sachets or discreet units such as tablets or capsules and like. Other orally administered pharmaceutical preparations include monophasic and biphasic liquid dosage forms either in ready to use form or forms suitable for reconstitution such as mixtures, syrups, suspensions or emulsions. The preparations in addition may contain diluents, dispersing agents, buffers, stabilizers, solubilizers, surfactants, preservatives, chelating agents and/ or other pharmaceutical additives as are used. Aqueous or non-aqueous vehicle or their combination may be used and if desired may contain suitable sweetener, flavoring agent or similar substances. In case of suspension or emulsion a suitable thickening agent or suspending agent or emulsifying agent may be present in addition. Alternatively, the compounds may be administered as such in their pure form unassociated with other additives for example as capsules or sachets. It may also be administered with a vehicle. Pharmaceutical preparations can have a slow, delayed or controlled release of active ingredients as is provided by a matrix or diffusion controlled system.
When the present invention or its salts or suitable complexes is presented as a discrete unit dosage form like tablet, it may contain in addition medically inert excipients as are used in the art. Some example of suitable excipients include lactose, cellulose and its derivatives such as microcrystalline cellulose, methylcelulose, hydroxy propyl methyl cellulose, ethylcellulose, dicalcium phosphate, mannitol, starch, gelatin, polyvinyl pyrolidone, various gums like acadia, tragacanth, xanthan, alginates & its derivatives, sorbitol, dextrose, xylitol, magnesium stearate, talc, colloidal silicon dioxide, mineral oil, glyceryl mono stearate, glyceryl behenate, sodium starch glycolate, Cross Povidone, crosslinked carboxymethylcellulose, various emulsifiers such as polyethylene glycol, sorbitol, fattyacid esters, polyethylene glycol alkylethers, sugar esters, polyoxyethylene polyoxypropyl block copolymers, polyethoxylated fatty acid monoesters, diesters and mixtures thereof.
Preparation of oral dosage form:
A typical tablet can have the following compositions: Oral formulation
A tablet formulation may be prepared as per the following compositions.
Example - 122
Ingredients Qty. (mg / tablet)
Active ingredient of formula I 20.0 mg
Microcrystalline Cellulose 200.0 mg
Starch 50.0 mg
Magnesium Stearate 5.0 mg
Talc 2.0 mg
Example - 123 Ingredients Qty. (i mg / tablet)
Active ingredient of formula I 10 mg
Lactose 75 mg
Starch 50 mg.
Polyvinyl pyrolidone (10% solution in water) 5 mg
Sodium starch glycolate 5 mg
Magnesium Stearate 2 mg
Colloidal Silicon-dioxide 5 mg
Example 124
Ingredients Qty. (mg / tablet)
Active ingredient 5.0 mg
Microcrystalline Cellulose 80.5 mg
Starch 8.0 mg.
Talc 3.3 mg
Magnesium Stearate 1.6 mg
Colloidal Silicon-dioxide 1.6 mg Active ingredient, lactose and starch are screened through 40 # sieve and blended. The blend is then granulated with polyvinyl pyrolidone solution. Resultant mass is screened through number 16 sieve. The granules produced are then dried at 50 - 60 °C and passed through 16-mesh sieve. Sodium starch glycolate, magnesium Stearate and colloidal silicon dioxide are sifted through 60-mesh sieve and blended with the granules. The resultant blend is then compressed into tablets.
The above ingredients may be blended into tablets by any other conventional materials.
Parenteral Formulations
For parenteral administration, the compounds or their salts or suitable complexes thereof may be present in a sterile vehicle which may be an aqueous or non-aqueous vehicle or a combination thereof. The examples of vehicles are water, ethyl oleate, oils and derivatives of polyols, glycols and their derivatives. It may contain additives common in injectable preparations like stabilizers, solubilizers, pH modifiers, buffers, antioxidants, cosolvents, complexing agents, tonicity modifiers, etc.
Some suitable additives are for example tartrate, citrate or similar buffers, alcohol, sodium chloride, dextrose and high molecular weight polymers. Another alternative is sterile powder reconstitution. The compound may be administered in the form of injection for more than once daily administration, or intravenous infusion/ drip or suitable depot preparation.
For injectable administration, the active ingredient or its salt is dissolved or dispersed in a sterile vehicle. The vehicle may be aqueous or non-aqueous and may contain suitable surfactants, solubilizers, buffers, stabilizers, surfactants, antioxidants, cosolvents, chelating agents, tonicity modifiers etc. Various excipients commonly used include propylene glycol, polythene glycol, mannitol, sodium chloride, ethyloleate, polyethylene glycol fatty acid esters, polyethylene glycol castor oil, polyethylene glycol sarbitan fatty acid esters, sugar esters, various buffers such as phosphate, succinate, citrate, borate, antioxidants such as sodium metabi sulphite etc.
An injectable formulation containing the following ingredient may be prepared:
Example 125
Ingredients Qty.
Active ingredient of formula I 1 mg
Polythylene glycol 0.1 ml Isotonic Saline / WFI to 1 ml
Sodium metabisulphite
OTHER FORMULATIONS
For the dermatological application and for the buccal delivery, the recommended formulations are gel, ointment, creams, patches, liniment, lotions, oral rinse, gurgles and toothpaste containing appropriate compounds of the compounds of the general formula I.
The above examples are presented by way of illustration alone and in no way limit the scope of the invention.

Claims

1. A compound represented by general formula (I), its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, their pharmaceutically acceptable solvates
Figure imgf000126_0001
wherein
X is O, S, SO, SO2, NR7 or CHR1 ; n is null or 1 ; k is null or 1 ;
Z is O, S, and NR7 ;
Rl at two positions are independently selected from hydrogen or a substituted or unsubstituted group selected from linear or branched (Cι-Cι2)alkyl, (C2-Cι2)alkenyl, (C3-C )cycloalkyl, (C -C )cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, wherein one or more heteroatoms are independently selected from O, N or S;
R2, R3, R4 and R7 are independently selected from hydrogen, perhaloalkyl, - (CO)NR8R9, -(CO)R8,-(CO)OR8, -SO2R8, -SOR8, substituted or unsubstituted groups selected from linear or branched (Cι-Cι )alkyl, (C -Cι2)alkenyl, (C3- C )cycloalkyl, (C5-C )cycloalkenyl, bicycloalkyl, amidino bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, ' heteroaryl, heteroaralkyl, wherein one or more heteroatoms are independently selected from O, N or S;
R5 and R6 are independently selected from by hydrogen or a substituted or unsubstituted group selected from linear or branched (Cι-Ci2)alkyl, (C2-Cι2)alkenyl, (C3-C7)cycloalkyl, (C -C )cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl,aralkyl, heteroaryl,heteroaralkyl, wherein one or more heteroatoms are independently selected from O, N or S;
R8 and R9 are independently selected from hydrogen or a substituted and unsubstituted group selected from linear or branched (C|-C] )alkyl, alkoxyaryl, alkoxyalkyl, alkoxycycloalkyl, alkoxyaryl, perhaloalkyl, (C2-Cι2)alkenyl, (C3-C ) cycloalkyl, perhalocycloalkyl, haloheterocycloalkyl, cyanoheterocycloalkyl, perhaloheterocycloalkyl, (C5-C ) cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, perhaloaryl, perhaloheteroaryl ;
wherein in the groups represented by Rl, R2, R3, R4, R5, R6, R7, R8 and R9 when substituted, the substitutents are optionally and independently bridged by -(CO)-, - (CO)O, -(CO)NH-, -NH-, -NR8-, -O-, -S-, -(SO)-, -(SO2)-, -(SO2)NH-, -NH(SO2)-, - O(CO)- or -NH(CO)-; and are selected from halogen, hydroxy, nitro, cyano, amino, oxo, oxime, unsubstituted or substituted by R10 for the groups selected from linear or branched ( -C8) alkyl, (C3-C7)cycloalkyl, alkylcycloalkyl, perhaloalkyl, perhalocycloalkyl, aryl, aralkyl, alkylaryl, alkylheteroaryl, aralkoxylalkyl, perhaloaryl, alkylheterocycloalkyl, heterocycloalkyl, perhaloheterocyclyloalkyl, heteroaryl, heteroaralkyl, alkylaryl, perhaloheteroaryl, acyl, acyloxy, acylamino, alkylamino, arylamino, aralkoxy, alkoxyalkyl, alkylthio, thioalkyl, arylthio, thioaryl, carboxylic acid or its derivatives, or sulfonic acid or its derivatives wherein the groups / substituents present on same or adjacent atoms such as carbon or nitrogen, together optionally and independently may form a five or a six or a seven membered ring optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from O, N or S; and wherein
RIO is independently selected from halogen, hydroxy, nitro, cyano, amino, oxo or oxime, and pharmaceutically usable hydrates and salts thereof ;
with the proviso that,
if k is null, then R4 and R6 together form an optionally six or seven membered ring, which optionally contains two to three heteroatoms independently selected from O, S and NR7with Rl as hydrogen, and Nj is attached to hydrogen.
2.The compound as claimed in claim 1, wherein the said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b) [2-Cyano-l -(4-isopropyl-2-piperazinyl)-carbonyl-pyrrolidine bis trifluoroacetate], c) l -[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) 1 -[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-(l,l-dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) 1 -[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl- 2-cyano pyrrolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) 1 -[ 1 -Oxo-2-(( 1 -(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[ 1 -Oxo-2-(( 1 -phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, k) l-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate,
1) 1 -[ 1 -Oxo-2-((l -(1 -methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) 1 -[ 1 -Oxo-2-(( 1 -ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) 1 -[ 1 -Oxo-2-(( 1 -Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) l-[l-Oxo-2-((l -methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3 -[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, x) 1 -[1 -Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[l-Oxo-2-((l-(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine cc) trifluoroacetate, dd) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl -4-cyano thiazolidine ee) trifluoroacetate, ff) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine gg) trifluoroacetate, hh) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ii) [2-Cyano-l-(l -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride], jj) [4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride], kk) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, 11) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], mm) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine hydrochloride, nn) l-[l-Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate, oo) l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine,
pp) 1 - [ 1 -Oxo-2-( 1 -(4-methylcyclohexylmethyl) hydrazino)] ethyl-2- cyanopyrrolidine trifluoroacetate, qq) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, rr) 1 -[ 1 -Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate, ss) 3 - [ 1 -Oxo-2- ( 1 -(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, tt) 3-[ 1 -Oxo-2- (1 -(4-morpholinocarbonyl) hydrazino) ethyl]-4- cyanothiazolidine trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, vv) 1-[1 -Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyrrolidino acetyl)] hydrazino] ethyl- 2-cyanopyrrolidine trifluoroacetate, ww) 3-[l-Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, xx) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoro acetate, yy) l-[l-Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, aaa) 1-[1 -Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine, bbb) 3-[l -Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, ccc) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmefhyl)-piperidin-4-yl) hydrazino)] ethyl - 4- cyanothiazolidine bis trifluoroacetate, ddd) 3-[l-Oxo-2-[l-(4-methylcyclohexyl)-2-(l-(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, eee) 3-[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, fff) 3 -[ 1 -Oxo-2- ( 1 -( 1 -(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ggg) 3-[ 1 -Oxo-2- [ 1 -methyl-2- (1 -(4-methylphenylsulphonyl)-piperidin-4- yl)] hydrazino] ethyl -4-cyanothiazolidine trifluoroacetate, hhh) 3-[ 1 -Oxo-2- ( 1 -( 1 -(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, iii) 3-[l-Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, jjj) 3-[l -Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, kkk) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoro acetate, 111) 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[ 1 -Oxo-2- [ 1 -( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, nnn) 3-[l-Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ooo) 3-[ 1 -Oxo-2- (1 -(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate,
PPP) 3-[ 1 -Oxo-2-[ 1 -( 1 -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, qqq) 3-[l-Oxo-2-(l-(l-acetyl)-piperidin-4-yl)hydrazino] ethyl-4- cyano thiazolidine tri fluoroacetate, rrr) 1 l-Dioxo-3-[l-oxo-2-(l-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, sss) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, ttt) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, uuu) 3-[ 1 -Oxo-2-(l -(1 -(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, wv) 3-[ 1 -Oxo-2-[ 1 -methyl-2-( 1 -(4-chlorophenylsulphonyl)-piperidin-4- yl)]- hydrazino] ethyl-4-cyanothiazolidine, www) 3-[l-Oxo-2-(l-(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, xxx) [ 1 -Oxo-2-( 1 -( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyrrolidine trifluoroacetate, yyy) 3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino] ethyl-4- cyanothiazolidine, zzz) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, aaaa) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb) 3 - [ 1 -Oxo-2-( 1 -( 1 -(5 -trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, cccc) 3-[ 1 -Oxo-2-( 1 -(1 -methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l - xo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, ffff) 3-[ 1 -Oxo-2-[ 1 -(1 -phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, gggg) 3 - [ 1 -Oxo-2-( 1 -( 1 -(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, hhhh) 3 - [ 1 -Oxo-2-(pyridazin- 1 -yl)] ethyl -4-cyanothiazolidine, iiii) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, jjjj) 3-[ 1 -oxo-2-[ 1 -(1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, kkkk) 3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-
4- cyanothiazolidine trifluoroacetate, llll) 3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2- isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ 1 -oxo-2-[ 1 -( 1 -(methylsulphonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, nnnn) 3-[l-oxo-2-[l-(l-(morpholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[l-oxo-2-[l-(l-(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, pppp) 3 - [ 1 -oxo-2- [ 1 -( 1 -(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, qqqq) 3 - [ 1 -oxo-2- [ 1 -( 1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, rrrr) 3-[ 1 -oxo-2- [ 1 -(1 -(4-fluorobenzyl)aminocyclohexan-4- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate,
ssss) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, tttt) 3-[l-oxo-2-[(l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl -4-cyanothiazolidine tris-trifluoroacetate,
uuuu) 3-[ l-oxo-2-[l-(l -(trimethyl acetamido)cyclohexan-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate,
vvvv) 3-[ 1 -oxo-2- [ 1 -(1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, wwww) 3-[l -oxo-2-[(l-(trimethyl acetamido) cyclohexan-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, xxxx) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4- yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate,
yyyy) 3-[l-oxo-2-[l -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, zzzz) 3-[l-oxo-2-[l -(l-(2-oxo-2-(5-chloropyridin-2- yl)aminoethyl)piperidin-4-yl)]-2- ethylhydrazino] ethyl-4- cyanothiazolidine tris-hydrochloride,
aaaaa) 3-[l-oxo-2-[-l -(1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4- yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, ccccc) 3 -[ 1 -oxo-2- [ 1 -( 1 -(2-oxo-2(2,3 -dihydrobenzo( 14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, ddddd) 3-[ 1 -oxo-2- [ 1 -(1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate,
eeeee) 3 [2-oxo-2-[ 1 -( 1 -(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, fffff) 3-[ 1 -oxo-2-[ 1 -( 1 -(-2-oxo-2(morpholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3[ 1 -oxo-2- [ 1 -(1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4- yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3-[l-oxo-2-[l-(l-(l-oxo-2-(morpholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] jjjjj) ethyl-4-cyanothiazolidine bis-trifluoroacetate, kkkkk) 3-[ 1 -oxo-2-[ 1 -(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, lllll) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4- cyanophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino] ethyl -4- cyanothiazolidine bis-trifluoroacetate, mmmmm) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4- chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, nnnnn) 3-[l -oxo-2-(l-(l-methanesulphonylamino-4- cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and ooooo) 3-[-l-oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2- yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
3. A pharmaceutical composition comprising compound of formula (1) as defined in claim 1 , its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates in association with a pharmaceutically acceptable carrier, diluent or excepient.
4. The pharmaceutical composition as claimed in claim 3, wherein the said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b)[2-Cyano-l-(4-isopropyl-2-piperazinyl)-carbonyl-pyrrolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-( 1,1 -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyrrolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyπolidine, h) 1 -[ 1 -Oxo-2-((l -(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, k) 1 -[ 1 -Oxo-2-((l -phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate,
1) 1 -[ 1 -Oxo-2-(( 1 -( 1 -methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) 1-[1 -Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[l -Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) 1 -[ 1 -Oxo-2-((l -methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3-[ 1 -Oxo-2-((l -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, y) 3-[l-Oxo-2-((l-(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, dd) l -[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano-l -(1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride], gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate,
11) l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine, mm) 1 -[ 1 -Oxo-2-(l -(4-methylcyclohexylmethyl) hydrazino)] ethyl-2- cyanopyrrolidine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l-Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl] -4-cyanothiazolidine trifluoroacetate, π) 3-[l -Oxo-2- ( 1 -(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, ss) l-[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyπolidino acetyl)] hydrazino] ethyl- 2-cyanopyrrolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l-Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, w) 1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl-
2-cyano pyrrolidine, yy) 3-[l-Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3-[l-Oxo-2-[l-(4-methylcyclohexyl)-2-(l-(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-(l -isopropyl -4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l -Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l -Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l -Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l -Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l-Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l-Oxo-2- (l-(l -(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l -(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl - 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l -Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, 111) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l-(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3-[l-Oxo-2-(l -(l-acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) l l-Dioxo-3-[l-oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothi azol idine, rrr) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[ 1 -Oxo-2-[ 1 -methyl-2-( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l-(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyrrolidine trifluoroacetate, vw) 3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl -4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l -Oxo-2- (1 -(335 -trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, cccc)3-[ 1 -Oxo-2-[ 1 -(1 -phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l -(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3- [ 1 -Oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3-[ 1 -oxo-2-[ 1 -( 1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3 - [ 1 -oxo-2-[ 1 -( 1 -(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[l-oxo-2-[l-(l-(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[l-oxo-2-[l-(l-(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[l-oxo-2-[(l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl -4-cyanothiazolidine tris-trifluoroacetate, rπr) 3-[ 1 -oxo-2-[ 1 -(1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazol idine trifluoroacetate, ssss) 3-[ 1 -oxo-2-[ 1 -( 1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l-(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, vvw)3-[ 1 -oxo-2-[ 1 -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[ 1 -oxo-2-[- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[ l -oxo-2-[ l -( l -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(4-chlorophenyl)aminoethyl)ρiperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3 [2-oxo-2-[ 1 -( 1 -(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[l -oxo-2-[l-(l-(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3 [ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3-[ 1 -oxo-2-[ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[l -oxo-2-[l-(l-(l-oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3 -[ 1 -oxo-2- [ 1 -(4 -(2-oxo-2-(5 -chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[l -oxo-2-[l-(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex-l- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk) 3-[-l-oxo-2-[l-(l -(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
5. A method of inhibiting the enzyme DPP-IV in the body tissue of a mammal including human being which comprises administering an effective compound of compound of general formula I as defined in claim 1 or its derivatives, analogs, tautomeric forms, stereoisomers, polymoφhs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates in association with a pharmaceutically acceptable carrier, diluent or excepient to a mammal in need thereof.
6. The method as claimed in claim 5, wherein the said compound is selected from the group consisting of :
a)[2-Cyano-l-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b)[2-Cyano-l-(4-isopropyl-2-piperazinyl)-carbonyl-pyπolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate , e) 3-[l-Oxo-2-((2-( 1 ,1 -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)] ethyl -2- cyano pyrrolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, k) l-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate,
1) l-[l-Oxo-2-((l-(l-methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[ 1 -Oxo-2-((l -phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, s) 3-[ 1 -Oxo-2-(( 1 -Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) 1 -[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3-[l -Oxo-2-((l-methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l-Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[l-Oxo-2-((l-(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate , dd) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano-l -(1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride], gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride], hh) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate,
11) 1 -[ 1 -Oxo-2-(l -cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine, mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- • cyanopyrrolidine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l -Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl]-4-cyanothiazolidine trifluoroacetate, π) 3-[l-Oxo-2- (1 -(4-methyl cyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, ss) l-[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyrrolidino acetyl)] hydrazino] ethyl- 2-cyanopyrrolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl -4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, vv) 1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) 1-[1 -Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyπolidine, yy) 3-[l -Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3-[l-Oxo-2-[l-(4-methylcyclohexyl)-2-(l-(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[ 1 -Oxo-2- (1 -(1 -(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l -Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l-Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l-Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l -Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate , jjj) 3-[l -Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l -Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate,
111) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l-(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3-[ 1 -Oxo-2-( 1 -(1 -acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) 1 l-Dioxo-3-[l-oxo-2-(l-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine , rπ) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[l-Oxo-2-[l-methyl-2-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l -(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyrrolidine trifluoroacetate, vvv) 3-[ 1 -Oxo-2-(l -(4-methylcyclohexyl)-2-acetyl) hydrazino] ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(1-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[ 1 -Oxo-2-(l -(1 -(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate , aaaa) 3-[l -Oxo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[ 1 -Oxo-2-(l -isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, cccc)3-[ 1 -Oxo-2-[ 1 -(1 -phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l-(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazoli dine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[ 1 -Oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl)-2- isopropyl) . hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3-[ 1 -oxo-2-[ 1 -( 1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[ 1 -oxo-2-[ 1 -( 1 -(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[ 1 -oxo-2-[ 1 -(1 -(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[ 1 -oxo-2-[ 1 -( 1 -(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[l -oxo-2-[ 1 -(1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[ 1 -oxo-2-[( 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, rπr) 3-[ 1 -oxo-2-[ 1 -( 1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[l-oxo-2-[l-(l-(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l-(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[l-oxo-2-[l-(l-(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate , vvvv)3-[ 1 -oxo-2-[ 1 -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[l-oxo-2-[l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3 - [ 1 -oxo-2-[- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[l-oxo-2-[l-(l-(2-oxo-2(-adamant-l-yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[ 1 -oxo-2-[ 1 -(1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[ 1 -oxo-2-[ 1 -( 1 -(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3 [ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate , eeeee)3-[ 1 -oxo-2-[ 1 -(1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[ 1 -oxo-2-[ 1 -(1 -(1 -oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- l-yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[l-oxo-2-[l-(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex-l- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate , iiiii) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk)3-[-l-oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
7.A method of scavenging free radical from the body tissue of a mammal including human being which comprises administering an effective compound of compound of general formula I as defined in claim 1 or its derivatives, analogs, tautomeric forms, stereoisomers, polymoφhs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates in association with a pharmaceutically acceptable carrier, diluent or excepient to a mammal in need thereof.
8.The method as claimed in claim 7 wherein the said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b)[2-Cyano- 1 -(4-isopropyl-2-piperazinyl)-carbonyl-pyπolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-(l,l -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyrrolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate , i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, k) 1 -[ 1 -Oxo-2-((l -phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate,
1) 1 - [ 1 -Oxo-2-(( 1 -( 1 -methyl)ethyl)hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine , n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate , p) 3-[ 1 -Oxo-2-(( 1 -phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[ 1 -Oxo-2-((l -(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, s) 3-[ 1 -Oxo-2-(( 1 -Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) l-[l-Oxo-2-((l-methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, w) 3-[l-Oxo-2-((l-methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[l-Oxo-2-((l -(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate , aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate , cc) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate , dd) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride] , ff) [2-Cyano- 1 -( 1 -cyclohexyl hydrazino)carbonyl pyπolidine hydrochloride] , gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l-Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk)l-[l-Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyπOlidine trifluoroacetate ,
11) l-[l-Oxo-2-(l -cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine, mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- cyanopyπolidine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyπolidine trifluoroacetate,
pp) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l -Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl]-4-cyanothiazolidine trifluoroacetate, π) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl -4- cyanothiazolidine trifluoroacetate, ss) 1-[1 -Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyπolidino acetyl)] hydrazino] ethyl- 2-cyanopyπolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, w) 1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate , ww) 3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl-
2-cyano pyrrolidine, yy) 3-[l-Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3 - [ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -(3 -pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine , ccc) 3-[l -Oxo-2- (1-(1 -(4-methyl phenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl - 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate , eee) 3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l-Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l -Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l -Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, 111) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l-(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazol idine trifluoroacetate, n n) 3 -[ 1 -Oxo-2-( 1 -( 1 -acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) 11 -Dioxo-3-[ 1 -oxo-2-( 1 -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine , qqq) 3-[l -Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, rrr) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate , sss) 3-[ 1 -Oxo-2-[ 1 -methyl-2-( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyrrolidine trifluoroacetate, vvv) 3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothi azol i dine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[ 1 -Oxo-2-(l -( 1 -(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l-Oxo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, cccc)3-[l-Oxo-2-[l -(l-phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l-(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3-[l-oxo-2-[l -(1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazol idine trifluoroacetate, iiii) 3-[ 1 -oxo-2-[ 1 -( 1 (methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[l-oxo-2-[l-(l-(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[l-oxo-2-[l-(l-(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[l-oxo-2-[l-(l-(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[ 1 -oxo-2-[( 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl -4-cyanothiazolidine tris-trifluoroacetate, rrπ) 3-[ 1 -oxo-2-[ 1 -( 1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[ 1 -oxo-2-[ 1 -(1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine , tttt) 3-[l-oxo-2-[(l -(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[l-oxo-2-[l-(l -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, vvvv)3-[l-oxo-2-[l-(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[l-oxo-2-[l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[ 1 -oxo-2-[- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3 - [ 1 -oxo-2- [ 1 -( 1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3 [2-oxo-2-[ 1 -( 1 -(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[ 1 -oxo-2-[ 1 -( 1 -(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3[l-oxo-2-[l-(l-(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3-[ 1 -oxo-2-[ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3 -[ 1 -oxo-2- [ 1 -( 1 -( 1 -oxo-2-(moφhol in-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[ 1 -oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk)3-[-l-oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
9.A method for treatment and/or prophylaxis of disorders relating to glucose intolerance in a mammal including human being which comprises administering an effective compound of compound of general formula I as defined in claim 1 or its derivatives, analogs, tautomeric forms, stereoisomers, polymoφhs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates in association with a pharmaceutically acceptable carrier, diluent or excepient to a mammal in need thereof.
10. The method as claimed in claim 9 wherein the said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b)[2-Cyano- 1 -(4-isopropyl-2-piperazinyl)-carbonyl-pyπolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-( 1,1 -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyrrolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, k) 1 -[ 1 -Oxo-2-(( 1 -phenylmethyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate,
1) 1 -[ 1 -Oxo-2-(( 1 -( 1 -methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[ 1 -Oxo-2-(( 1 -(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate , r) l -[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, s) 3-[l -Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) 1 -[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, w) 3-[l-Oxo-2-((l -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[l-Oxo-2-((l-(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l-Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, dd) 1-[1 -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano- 1 -( 1 -cyclohexyl hydrazino)carbonyl pyπolidine hydrochloride] , gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl -4-cyanothiazolidine hydrochloride, kk) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyπolidine trifluoroacetate,
11) l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine , mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- cyanopyπolidine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l -Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl] -4-cyano thiazolidine trifluoroacetate, π) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl -4- cyanothiazolidine trifluoroacetate, ss) l-[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyπolidino acetyl)] hydrazino] ethyl- 2-cyanopyrrolidine trifluoroacetate, tt)3-[ 1 -Oxo-2- ( 12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, vv) 1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine, yy) 3-[l-Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3 - [ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -(3 -pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-(l -isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l -Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l-Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l-Oxo-2- [l-methyl-2- (l -(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l -(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l-Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate,
111) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3-[l-Oxo-2-(l-(l-acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) l l-Dioxo-3-[l-oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, πr) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[l-Oxo-2-[l-methyl-2-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyπolidine trifluoroacetate, vvv) 3-[ 1 -Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[ 1 -Oxo-2-(l -( 1 -(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l-Oxo-2- (1 -(335 -trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate , cccc)3-[l-Oxo-2-[l-(l-phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l-(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[ 1 -Oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3 - [ 1 -oxo-2- [ 1 -( 1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino] ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[ 1 -oxo-2-[ 1 -(1 (methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate , jjjj)3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[ 1 -oxo-2-[ 1 -( 1 -(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[l-oxo-2-[l-(l-(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-mefhoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3 -[ 1 -oxo-2- [ 1 -( 1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[ 1 -oxo-2-[ 1 -(1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[l-oxo-2-[l-(l-(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[l-oxo-2-[(l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl -4-cyanothiazolidine tris-trifluoroacetate, rrrr) 3-[ 1 -oxo-2-[ 1 -(1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[ 1 -oxo-2-[ 1 -(1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l -(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[l-oxo-2-[l-(l-(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, vwv)3-[ 1 -oxo-2-[ 1 -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[l-oxo-2-[l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[ 1 -oxo-2-[- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[l-oxo-2-[l-(l-(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3[2-oxo-2-[l-(l -(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[l-oxo-2-[l-(l-(-2-oxo-2(morpholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3 [ 1 -oxo-2- [ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3-[ 1 -oxo-2-[ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[l-oxo-2-[l-(l-(l-oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate , iiiii) 3-[l-oxo-2-[l-(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex-l- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[ 1 -oxo-2-( 1 -(1 -methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk)3-[-l -oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidinc trihydrochloride.
1 l.A method for treatment and/or prophylaxis of disorders associated with DPP-IV in a mammal including human being wherein the said disorders are selected from the group consisting of a) Cushing's syndrome; b) Hyperthyroidism; c) Obesity; d) Hyperglucagonemia; e) Diseases including ulcers and HIV infection; f) Disorders related to increased gastric emptying, acid secretion and hunger ; g) Autoimmune disorders including multiple sclerosis; h) Rheumatoid arthritis; i) Grave's disease ; j) Diaπhea; k) Mucosal regeneration in patients with intestinal disease; 1) Growth hormone deficiency; m) Neurological and neuropsychological disorders and n) Cancers and tumors.
12. The method as claimed in claim 11, wherein the said compound is selected from the group consisting of :-
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyπolidine bis-trifluoroacetate], b)[2-Cyano-l-(4-isopropyl-2-piperazinyl)-carbonyl-pyrrolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, e) 3-[l -Oxo-2-((2-(l,l-dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) 1 -[ 1 -Oxo-2-((2-( 1 , 1 -dimethyl ethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyπolidine, g) 1 -[ 1 -Oxo-2-((2-( 1 , 1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, k) 1 -[ 1 -Oxo-2-((l -phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate,
1) 1 -[ 1 -Oxo-2-((l -( 1 -methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) 1 -[ 1 -Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[ l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, s) 3-[ 1 -Oxo-2-((l -Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) l-[l-Oxo-2-((l-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3-[ 1 -Oxo-2-((l -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[l -Oxo-2-((l -(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) l-[l-Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, dd) 1 -[ 1 -Oxo-2- (( 1 -Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano- 1-(1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride], gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride] , hh) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate,
11) 1 -[l-Oxo-2-(l -cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine, mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- cyanopyrrolidine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate , oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l -Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl] -4-cyanothiazolidine trifluoroacetate, rr) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, ss) l-[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyrrolidino acetyl)] hydrazino] ethyl-
2-cyanopyrrolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l-Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, vv) 1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l -Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine, yy) 3-[l -Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate , zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3-[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3- [ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -isopropyl -4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l -Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl - 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l -Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l -Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l -Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l-Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l-Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate,
111) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3 - [ 1 -Oxo-2-( 1 -( 1 -acetyl)-ρiρeridin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate , ooo) l l-Dioxo-3-[l-oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine , rπ) 3-[l -Oxo-2-(l -(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[ 1 -Oxo-2-[ 1 -methyl-2-(l -(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyπolidine trifluoroacetate, vvv) 3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino] ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l -(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate , zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l-Oxo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, cccc)3-[l-Oxo-2-[l-(l-phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate , dddd) 3-[l-Oxo-2-(l-(l-(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine , ffff) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyano thiazolidine trifluoroacetate , gggg) 3-[ 1 -oxo-2-[ 1 -( 1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate , hhhh) 3-[ 1 -oxo-2-[ 1 -( 1 -(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[ 1 -oxo-2-[ 1 -( 1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[ 1 -oxo-2-[ 1 -( 1 -(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[ 1 -oxo-2-[ 1 -( 1 -(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ 1 -oxo-2-[ 1 -(1 -(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate , nnnn) 3-[l-oxo-2-[l-(l-(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[ 1 -oxo-2-[ 1 -(1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[l-oxo-2-[(l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl -4-cyanothiazolidine tris-trifluoroacetate, rπr) 3-[ 1 -oxo-2-[ 1 -( 1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[l-oxo-2-[l-(l-(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l-(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, vvvv)3-[l-oxo-2-[l-(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3 - [ 1 -oxo-2- [ 1 -( 1 -(2-oxo-2-(5 -chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[ 1 -oxo-2-[- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[l-oxo-2-[l-(l-(2-oxo-2(-adamant-l-yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l -(2-oxo-2(2, 3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate , bbbbb) 3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[l-oxo-2-[l-(l-(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3[ 1 -oxo-2-[ 1 -(1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3 - [ 1 -oxo-2- [ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[ 1 -oxo-2-[ 1 -( 1 -( 1 -oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk)3-[-l-oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
13.A method of treating a mammal including human being in disease conditions caused by accumulation of free radicals in the body cells which comprises administering an effective compound of compound of general formula I as defined in claim 1 or its derivatives, analogs, tautomeric forms, stereoisomers, polymoφhs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates in association with a pharmaceutically acceptable carrier, diluent or excepient to a mammal in need thereof.
14. The method as claimed in claim 12 wherein the said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyπolidine bis-trifluoroacetate], b)[2-Cyano- 1 -(4-isopropyl-2-piperazinyl)-carbonyl-pyπolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-( 1,1 -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l ,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyπolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbon yl))hydrazino)]ethyl-2-cyano pyrrolidine, h) l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l -[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, k) l-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, 1) l-[l-Oxo-2-((l-(l-methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) 1 -[ 1 -Oxo-2-(( 1 -ethyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[ 1 -Oxo-2-((l -(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) 1 -[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3-[l-Oxo-2-((l-methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[ 1 -Oxo-2-(( 1 -(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyπolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l -Oxo-2- ((1 -(4-methyl) cycloheχyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, dd) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano-l -(1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride], gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1 -[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl -4-cyanothiazolidine hydrochloride, kk) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate ,
11) l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine , mm) 1 -[ 1 -Oxo-2-( 1 -(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- cyanopyrrolidine trifluoroacetate , nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l -Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl]-4-cyanothiazolidine trifluoroacetate , π) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, ss) 1-[1 -Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyrrolidino acetyl)] hydrazino] ethyl-
2-cyanopyrrolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, w) 1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l -Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate. xx) 1-[1 -Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine , yy) 3-[l -Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3-[l-Oxo-2-[l-(4-methylcyclohexyl)-2-(l-(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[l -Oxo-2- [l-(4-methylcyclohexyl)-2-(l-isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l-Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l -Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l-Oxo-2- [l -methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l -Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate,
111) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3-[l-Oxo-2-(l-(l-acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) l l-Dioxo-3-[l-oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, rrr) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[l-Oxo-2-[l-methyl-2-(l -(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyπolidine trifluoroacetate, vvv) 3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl -4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[ l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate,
aaaa) 3-[l -Oxo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate,
bbbb)3 -[ 1 -Oxo-2-( 1 -isopropyl-2-ethyl)-hydrazino] -ethyl -4-cyanothiazolidine trifluoroacetate , cccc)3-[l-Oxo-2-[l-(l-phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l -(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate , eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3-[l-oxo-2-[l-(l(moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[ 1 -oxo-2-[ 1 -( 1 -(me thylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[ 1 -oxo-2-[ 1 -( 1 -(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[ 1 -oxo-2-[ 1 -( 1 -(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[l-oxo-2-[l-(l-(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[ 1 -oxo-2-[ 1 -(1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[l-oxo-2-[(l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl -4-cyanothiazolidine tris-trifluoroacetate, rπr) 3-[ 1 -oxo-2-[ 1 -( 1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazol idine trifluoroacetate , ssss) 3-[l-oxo-2-[l-(l-(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l-(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate , vvw)3-[l-oxo-2-[l-(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[l -oxo-2-[ 1 -(1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl -4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[l-oxo-2-[-l-(l -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate , yyyy) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l -oxo-2-[l -(1 -(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl -4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[l-oxo-2-[l -(l-(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate , bbbbb) 3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate , ccccc) 3-[l-oxo-2-[l-(l-(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3 [ 1 -oxo-2- [ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate , eeeee)3-[ 1 -oxo-2-[ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[l-oxo-2-[l-(l-(l-oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- l-yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[l-oxo-2-[l-(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex-l- yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk)3-[-l-oxo-2-[l -(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
15. The method as claimed in claim 13 or 14 wherein the said disease condition is selected from the group consisting of (a) Neurodegenerative disorders such as
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Motor Neuron
Disease and Prion Disease, (b) Diabetes and Diabetic Vascular Complications, (c)
Intestinal Diseases such as Intestinal Ischemia, Radiation Enmteritis, Inflammatory
Bowel Disease, Gastric and Colorectal Cancers, (d) Liver Diseases such as Alcoholic Liver Disease and Chronic Hepatitis C etc, (e) Cancers such as Lung Cancer,
Colorectal Cancer, Cervical Cancer, Breast Cancer and Malignant Melanoma, (f)
Cardiac Diseases such as Atherosclerosis, Myocardial Infarction, Ischemic Stroke and
Endothelial Dysfunction, (g) Opthalmic Disorders such as Cataract formation and
Macular degeneration, (h) HIV Diseases, (i) Respiratory Diseases such as Chronic Obstructive Pulmonary Diseases and Asthma and (j) Renal Diseases such as
Glomerulonephritis and Acute Renal Failure.
16. A process for preparation of compounds of formula 9a and 10a
R4
O
TFA . 2HN-N
NC (9a) ; X=CH2 (10a) ; X=S
wherein R4 has the same meaning as defined in claim 1 and "Boc" in process step
(a) below stands for "tertiary Butyloxy Carbonyl",
comprising the steps of :
a) reacting chloroacyl-2-cyanopyrrolidine or chloroacyl-4-cyanothiazolidine with appropriate N-substituted Boc-carbazate using aprotic solvents in presence of a base at 40-1 10°C for 8-50 hrs , wherein N-substituted Boc-carbazate obtained from alkyl halide and
b) deprotecting resulting coupled product using trifluoroacetic acid at 5-30°C for
0.25-2 hrs to obtain the desired product.
17. The process as claimed in claim 16, wherein in step (a) of the process said aprotic solvent used is selected from acetonitrile, tetrahydrofuran, dimethylformamide or dioxane and said base used is selected from tertiary amine or alkali carbonate.
18. The process as claimed in claim 17 wherein in step (a) of the process said aprotic solvent used is tetrahydrofuran and said base used is potassium carbonate in presence of catalytic amount of potassium iodide.
19. A process for preparation of compounds of formula 13 and 14
Figure imgf000181_0001
(13) ; X=CH2 (14) ; X=S
wherein
R4 has the same meaning as defined in claim 1 and "Boc" in process step (a) below stands for "tertiary Butyloxy Carbonyl",
comprising the steps of :
a) reacting chloroacyl-2-cyanopyπolidine or chloroacyl-4-cyanothiazolidine with appropriate N-substituted Boc-carbazate using aprotic solvents in presence of a base at 40-110°C for 8-50 hrs , wherein said N-substituted Boc-carbazate is obtained from aldehyde and ketone and
b) deprotecting resulting coupled product using trifluoroacetic acid at 5-30°C for 0.25-2 hrs to obtain the desired product.
20. The process as claimed in claim 19, wherein in step (a) of the process said aprotic solvent used is selected from acetonitrile, tetrahydrofuran, dimethylformamide or dioxane and said base used is selected from tertiary amine or alkali carbonate.
21. The process as claimed in claim 20 wherein in step (a) of the process said aprotic solvent used is tetrahydrofuran and said base used is potassium carbonate in presence of catalytic amount of potassium iodide.
22. A process for preparation of compounds of formula 9c and 10c
Figure imgf000182_0001
(9c) ; X=CH2 (10c) ; X=S
wherein
R4 and R2 have the same meaning as defined in claim 1 , comprising the steps of :
a) reacting N-1 -substituted hydrazinoacyl derivative of cyanothiazolidine (formula-9a) or cyanopyπolidine (formula- 10a).
Figure imgf000182_0002
NC
(9a) ; X=CH2 (10a) ; X=S
with acid chlorides/sulfonyl chloride in presence of a base in an aprotic solvent at 0-30°C for l-8 hrs and
b) isolating compounds of formula 9c or 10c thus produced.
23. The process as claimed in claim 22, wherein in step (a) of the process said base used is selected from tertiaryamine or pyridine and said aprotic solvent used is selected from acetonitrile tetrahydrofuran, dimethylformamide, dioxane, dichloromethane or chloroform.
24. The process as claimed in claim 23 wherein in step (a) of the process said base used is triethylamine and aprotic solvent used is tetrahydrofuran .
25. A process for preparation of compounds of formula 9b and 10b
Figure imgf000183_0001
(9b) ; X=CH2 (10b) ; X=S wherein
R4 and R2 have the same meaning as defined in claim 1,
comprising the steps of :
a) reacting a substituted aldehyde or ketone required to form R2 as defined in
Claim 1 with compound of formula 9a and 10a
Figure imgf000183_0002
(9a) ; X=CH2 (10a) ; X=S
at 20-70°C for 0.5-6 hrs in alcoholic solvents to give rise to corresponding Schiff base and b) reduction of the Schiff base using metal hydride in presence of catalytic amount of titanium tetrachloride in alcoholic solvent to give the coπesponding target compound.
26. The process as claimed in claim 25, wherein in step (a) of the process said alcoholic solvent used is selected from methanol, ethanol or isopropanol and in step (b) of the process said metal hydride used is selected from sodium cyanoborohydride or sodium borohydride .
27. The process as claimed in claim 25 wherein in step (a) of the process said alcoholic solvent is methanol and said schiff base used is sodium cyanoborohydride.
28. A process for preparation of compounds of formula 5a and 6a
R4
N
(5a) ;X=CH2 NC (6a) :X=S
wherein
R4 has the same meaning as defined in claim 1 and "Boc" in process step (a) below stands for "tertiary Butyloxy Carbonyl",
comprising the steps of :
a) reacting chloroacyl-2-cyanopyrrolidine or chloroacyl-4-cyanothiazolidine with
Boc-carbazate using aprotic solvents in presence of a base with catalytic amount of potassium iodide at 40-110°C for 6-50 hrs to give compound of formula 5 or 6 respectively,
Figure imgf000185_0001
(5) ;X=CH2
(6) ;X=S
b) reacting compound of formula 5 or 6 from step 1 above, with appropriate carbonyl chloride or acid chloride or sulphonyl chloride in presence of a base in an aprotic solvent at 0-30°C for 0.5-6 hrs and
c) deprotecting compounds obtained in step(b) using trifluoroacetic acid at 0- 30°C for 0.25-2 hrs to give the corresponding target compound of formula 5a or 6a respectively.
29. The process as claimed in claim 28, wherein in step (a) of the process said aprotic solvent used is selected from acetonitrile, tetrahydrofuran, dimethylformamide or dioxane and the said base used is selected from alkali or alkali earth metal carbonates or tertiaryamine and in step (b) of the process the said base used is selected from tertiaryamine, pyridine and said aprotic solvent is selected from acetonitrile, tetrahydrofuran, dimethylformamide or dioxane .
30. The process as claimed in claim 29 wherein in step (a) of the process said aprotic solvent used is tetrahydrofuron and said base used is potassium carbonate in presence of catalytic amount of potassium iodide and in step (b) of the process said base used is triethylamine and said aprotic solvent used is tetrahydrofuran.
31. A process for preparation of compounds of formula 31 and 32
Figure imgf000186_0001
21 ; X = CH} 32 ; X = S wherein
R7 has the same meaning as defined in claim 1 and the substituents "Boc" in the structural formulae 23 - 28 as given below stand for " tertiary Butyloxy Carbonyl",
comprising the steps of :
a) reacting diboc protected compound of formula 23 or 24 with trifluroacetic anhydride in aprotic solvents at 0-30°C for 1-40 hrs to give compound of formula 25 or 26 respectively,
Figure imgf000186_0002
25 ; X = CH, 27 ; X = CH, 26 : X = S 28 ; X = S
b) deprotecting compounds obtained in step(a) using trifluoroacetic acid in aprotic solvent at 0-30°C for 1-4 hrs to give compound of formula 27 or 28 as trifluoroacetate salt, respectively,
Figure imgf000187_0001
25 , X = CH, 27 , X = CH,
28 . X = S 26. X = S
c) reacting of compound of formula no. 27 or 28 with appropriate alkylhalide in aprotic solvent in presence of base to give compound of formula 29 or 30 and
Figure imgf000187_0002
29 , X = CH-
27 , X = C4 3Q . X = S
28 , X = S
d) optionally purifying by reprotecting them at N-1 of the piperazine ring using Boc-carbonate followed by deprotection of Boc group in aprotic solvents using trichloroacetic acid at 0-35°C for 1-4 hrs to yield desired product as bis- trifluoroacetate salt.
32. The process as claimed in claim 31, wherein in step (a) the said aprotic solvent used is selected from acetonitrile, tetrahydrofuran, dimethylformamide, dioxane, dichloromethane, diethylether or chloroform, in step (b) the said aprotic solvent used is selected from acetonitrile, tetrahydrofuran, dimethylformamide, dioxane, dichloromethane, chloroform or diethylether, in step ( c) the said aprotic solvent used is selected from acetonitrile, tetrahydrofuran, dimethylformamide or dioxane and the base used is selected from tertiaryamine, pyridine or alkali carbonates and in step (d) the said aprotic solvent used is selected from acetonitrile, tetrahydrofuran, dimethylformamide, dioxane, dichloromethane, diethylether or chloroform.
33. The process as claimed in claim 32 wherein in step (a) of the process said aprotic solvent used is tetrahydrofuran or dichloromethane, in step (b) of the process said aprotic solvent used is tetrahydrofiiran or acetonitile, in step ( c) of the process said aprotic solvent used is tetrahydrofuran or acetonitile and said base used is triethylamine or potassium carbonate and in step (d) of the process the said aprotic solvent used is acetonitrile.
34. A process for preparation of compounds of formula 43 and 44
Figure imgf000188_0001
44; X=S wherein
R4 has the same meaning as defined in claim 1 , comprising steps of :
a) reacting tert-butyloxycarbonyl protected formula 36 or 37 with trifluoroacetic anhydride in aprotic solvent at 10-40°C for 2-4 hrs to give coπesponding cyano compound of formula 39 or 40,
Figure imgf000189_0001
36; X=CH, 39; X=CH, 37; X=S 40; X=S
b) deprotecting compounds obtained in step (a) using trifluoroacetic acid in an aprotic solvent at 5 - 40 °C for 0.25 - 2 hrs to give compound of formula no. 41 or 42 as trifluoroacetate salt respectively and
Figure imgf000189_0002
41; X=CH2 42; X=S
c) purifying the compound so obtained by neutralizing with an aqueous alkali followed by purification of free base thus obtained by column chromatography and then converting the product thus obtained into a pharmaceutically acceptable hydrochloride salt by treating with methanolic hydrochloride at 0 - 20 °C for 0.5 - 2 hrs.
35. The process as claimed in claim 34, wherein in step (a) of the process the said aprotic solvent as used is selected from acetonitrile, tetrahydrofuran, dimethylformamide, dioxane, dichloromethane, diethyl ether or chloroform, in step (b) of the process the said aprotic solvent as used is selected from dichloromethane, diethylether, dioxane, tetrahydrofuran, acetonitrile, and in step (c) of the process the said aqueous alkali solvent as used is aqueous sodium bicarbonate and wherein steps(a) and (b) of the process are carried out at 25°C and 20°C respectively.
36. The process as claimed in claim 35 wherein in step (a) and (b) the said aprotic solvent is tetrahydrofuran.
37. Use of a compound as defined in claim 1 in the manufacture of a medicament useful in inhibiting the enzyme DPP-IV in the body cells of a mammal including human beings to enhance level of active GLP I.
38. The use as claimed in claim 37 wherein the said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b)[2-Cyano-l-(4-isopropyl-2-piperazinyl)-carbonyl -pyπolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-( 1,1 -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) 1 -[ 1 -Oxo-2-((2-( 1 , 1 -dime fhylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyrrolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) 1 -[ 1 -Oxo-2-(( 1 -(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, k) 1 -[ 1 -Oxo-2-(( 1 -phenylmethyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate,
1) l-[l-Oxo-2-((l-(l-methyl)ethyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[ 1 -Oxo-2-((l -phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) 1 -[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3-[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, y) 3-[ 1 -Oxo-2-(( 1 -(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyπolidine bis- trifluoroacetate, bb) 3-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l-Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, dd) 1-[1 -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyπolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano-l-(l -cyclohexyl hydrazino)carbonyl pyπolidine hydrochloride], gg)[4-Cyano-3-(l -cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk)l-[l-Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate,
11) 1 -[ 1 -Oxo-2-( 1 -cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyπolidine, mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- cyanopyrrolidine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl -2-cyanopyπolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyπolidine trifluoroacetate,
pp) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l -Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl]-4-cyanothiazolidine trifluoroacetate, rr) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, ss) l-[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyπolidino acetyl)] hydrazino] ethyl-
2-cyanopyπolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l-Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, vv) 1 -[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, ww) 3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) 1-[1 -Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyπolidine, yy) 3-[l-Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l-Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3 -[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -(3 -pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[l -Oxo-2- [l-(4-methylcyclohexyl)-2-(l-isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l-Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l -Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l -Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l -Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l -Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl -4-cyanothiazolidine trifluoroacetate,
111) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3-[l-Oxo-2-(l -(l-acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) 1 l-Dioxo-3-[l-oxo-2-(l-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl -4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, rrr) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[ 1 -Oxo-2-[ 1 -mefhyl-2-( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [ 1 -Oxo-2-( 1 -( 1 -(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl cyanopyπolidine trifluoroacetate, vvv) 3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l -Oxo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, cccc)3 -[ 1 -Oxo-2- [ 1 -( 1 -phenylmethyl-piperidin-4-yl)]-hydrazino] -ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l -(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl -4-cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3-[ 1 -oxo-2-[ 1 -( 1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[ 1 -oxo-2-[ 1 -( 1 (methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[ 1 -oxo-2-[ 1 -( 1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[l-oxo-2-[l-(l-(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[l-oxo-2-[l-(l-(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[l-oxo-2-[l-(l-(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -(1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[ 1 -oxo-2-[( 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, rπr) 3-[l -oxo-2-[l-(l -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[ 1 -oxo-2-[ 1 -(1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l-(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, vvvv)3-[ 1 -oxo-2-[ 1 -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[l-oxo-2-[-l-(l -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[ 1 -oxo-2- [ 1 -(1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[ 1 -oxo-2-[ 1 -(1 -(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3 [ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3-[l-oxo-2-[l-(l-(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[ 1 -oxo-2-[ 1 -( 1 -( 1 -oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex- 1 ■ yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3 - [ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate,
jjjjj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and
kkkkk) 3-[- 1 -oxo-2-[ 1 -(1 -(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
39. Use of a compound as defined in claim 1 for manufacture of medicament useful for the treatment of disorders relating to glucose intolerance in a mammal including human being.
40.The use of a compound as claimed in claim 39, wherein said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b)[2-Cyano-l-(4-isopropyl-2-piperazinyl)-carbonyl -pyrrolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-(l,l -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyrrolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyπolidine, h) 1 -[ 1 -Oxo-2-(( 1 -(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, k) 1 -[ 1 -Oxo-2-(( 1 -phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, 1) 1 -[ 1 -Oxo-2-(( 1 -( 1 -methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[l -Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) l-[l-Oxo-2-((l-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3-[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[l-Oxo-2-((l-(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) 1 -[ 1 -Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate. dd) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate,
ee) [4-Cyano-3-(l -isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano-l -(1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride], gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1-[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl -2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l -Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyπolidine trifluoroacetate,
11) l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine, mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- cyanopyrrol idine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyπolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3-[l-Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl]-4-cyanothiazolidine trifluoroacetate, π) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, ss) 1-[1 -Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyπolidino acetyl)] hydrazino] ethyl-
2-cyanopyπolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, vv) l-[l-Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l-Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine, yy) 3-[l -Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3-[ 1 -Oxo-2-[ 1 -(4-methylcyclohexyl)-2-(l -(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[l -Oxo-2- [l-(4-methylcyclohexyl)-2-(l -isopropyl -4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l -Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l-Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l -Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l-Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l-Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l-Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l -Oxo-2- (l-(l-norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate,
111) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3-[l-Oxo-2-(l-(l-acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) 1 l -Dioxo-3-[l-oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, rπ) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[l-Oxo-2-[l-methyl-2-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyπolidine trifluoroacetate, vvv) 3-[ 1 -Oxo-2-(l -(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l-Oxo-2- (1 -(335 -trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate,
bbbb)3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, cccc)3-[ 1 -Oxo-2-[ 1 -( 1 -phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l -(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3-[l-oxo-2-[l-(l(moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[l-oxo-2-[l-(l-(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[l-oxo-2-[l-(l -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[l-oxo-2-[l-(l-(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[ 1 -oxo-2-[ 1 -( 1 -(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ l-oxo-2-[ 1 -(1 -(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[l-oxo-2-[l-(l-(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[l-oxo-2-[l-(l-(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[l-oxo-2-[(l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]hydrazino]ethyl -4-cyanothiazolidine tris-trifluoroacetate, rπr) 3-[l-oxo-2-[ 1-(1 -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[ 1 -oxo-2-[ 1 -( 1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l-(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ww)3-[ 1 -oxo-2-[ 1 -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[ 1 -oxo-2-[ 1 -(1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[l-oxo-2-[- l-(l-(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[l-oxo-2-[l-(l-(2-oxo-2(-adamant-l-yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3 [2-oxo-2-[ 1 -( 1 -(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[ 1 -oxo-2-[ 1 -( 1 -(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3 [ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3-[l-oxo-2-[l-(l-(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[ 1 -oxo-2-[ 1 -( 1 -(1 -oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex-l - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate,
iiiii) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate,
jjjjj) 3-[ 1 -oxo-2-( 1 -(1 -methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk) 3-[-l-oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
41. Use of a compound as defined in claim 1 in the manufacture of a medicament useful in the treatment of a mammal including human being in disease conditions caused by accumulation of free radicals in the body cell of a mammal including human being.
42. The use of a compound as claimed in claim 41 wherein the said compound is selected from the group consisting of :-
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyπolidine bis-trifluoroacetate], b)[2-Cyano-l-(4-isopropyl-2-piperazinyl)-carbonyl-pyπolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-(l,l -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)]ethyl-2- cyano pyπolidine, g) l-[l-Oxo-2-((2-( 1,1 -dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) l-[l-Oxo-2-(l-(2-methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, k) l-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate,
1) 1 -[l-Oxo-2-((l-(l-methyl)ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l -ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[l-Oxo-2-((l-phenylmethyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, q) 3-[ 1 -Oxo-2-(( 1 -(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) 1 -[ 1 -Oxo-2-(( 1 -methylpropyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, w) 3-[ 1 -Oxo-2-((l -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, y) 3-[l-Oxo-2-((l-(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) l-[l-Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l -Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, dd) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyπolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano-l -(1 -cyclohexyl hydrazino)carbonyl pyπolidine hydrochloride], gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1 -[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l-Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk) 1 -[ 1 -Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate,
11) l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine, mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)] ethyl-2- cyanopyπolidine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl -4- cyanothiazolidine trifluoroacetate, qq) 3-[l-Oxo-2- (l-(4-moφholinocarbonyl) hydrazino) ethyl]-4-cyanothiazolidine trifluoroacetate, π) 3-[l -Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate,
ss) 1-[1 -Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l-pyπolidino acetyl)] hydrazino] ethyl- 2-cyanopyrrolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, vv) l-[l-Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l -Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) 1-[1 -Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine, yy) 3-[l -Oxo-2- (1 -isopropyl -4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l-Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine bis trifluoroacetate, aaa) 3-[l-Oxo-2-[l-(4-methylcyclohexyl)-2-(l-(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[ 1 -Oxo-2- [ 1 -(4-methylcyclohexyl)-2-( 1 -isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l-Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l-Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3 - [ 1 -Oxo-2- ( 1 -( 1 -(3 -pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l -Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l-Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l -Oxo-2- (l-(l-(4-nitrophenylrnethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[ 1 -Oxo-2- ( 1 -( 1 -norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate,
111) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3-[l-Oxo-2-(l-(l-acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) l l-Dioxo-3-[l-oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, rrr) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[l-Oxo-2-[l-methyl-2-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)] ethyl -4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyrrolidine trifluoroacetate, vvv) 3-[ 1 -Oxo-2-(l -(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine, www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l -(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazol idine trifluoroacetate, yyy)3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l -Oxo-2- (l-(335-trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[l-Oxo-2-(l-isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyanothiazolidine trifluoroacetate, cccc)3-[l-Oxo-2-[l-(l-phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l -(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazol idine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3-[ 1 -oxo-2-[ 1 -(1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[l-oxo-2-[l-(l -(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazol idine trifluoroacetate, iiii) 3-[l-oxo-2-[l-(l(methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifl uoroacetate, kkkk) 3-[ 1 -oxo-2-[ 1 -( 1 -(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[ 1 -oxo-2-[l -( 1 -(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[l-oxo-2-[l-(l-(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[ 1 -oxo-2-[ 1 -(1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[l-oxo-2-[l-(l-(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -(1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[ 1 -oxo-2-[( 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, rrrr) 3-[l-oxo-2-[l-(l -(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[ 1 -oxo-2-[ 1 -( 1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l -(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[l-oxo-2-[l-(l-(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, vvvv)3-[l-oxo-2-[l-(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[l-oxo-2-[l-(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3-[ 1 -oxo-2-[- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[l-oxo-2-[l-(l-(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3[ 1 -oxo-2-[ 1 -(1 -(2-oxo-2-(cyclopropyl)aminoethyl)ρiperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3-[ 1 -oxo-2-[ 1 -( 1 -(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[l-oxo-2-[l-(l-(l-oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[l-oxo-2-[l-(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk) 3-[-l-oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
43. Use of compound of general formula (I), as defined in claim 1 or its derivatives, analogues, tautomeric forms, stereoisomers, polymoφhs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates in the manufacture of a medicament useful in the treatment and or prophylaxis of disorders associated with DPP-IV in a mammal including human being.
44. The use of compound as claimed in claim 43, wherein the said compound is selected from the group consisting of :
a) [2-Cyano-l -(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate], b)[2-Cyano- 1 -(4-isopropyl-2-piperazinyl)-carbonyl-pyrrolidine bis trifluoroacetate], c) l-[l-Oxo-2-((l-phenyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, d) l-[l-Oxo-2-(l-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, e) 3-[l-Oxo-2-((2-( 1,1 -dimethyl ethyl oxy carbonyl))hydrazino)]ethyl-4-cyano thiazolidine, f) l-[l-Oxo-2-((2-(l,l-dimethylethyloxy carbonyl))- 1 -phenyl hydrazino)] ethyl-2- cyano pyrrolidine, g) l-[l-Oxo-2-((2-(l,l-dimethylethyl oxy carbonyl))hydrazino)]ethyl-2-cyano pyrrolidine, h) l-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, i) 3-[l-Oxo-2-((l-phenyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, j) 1 -[ 1 -Oxo-2-( 1 -(2-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, k) 1 -[1 -Oxo-2-((l -phenylmethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate,
1) l-[l-Oxo-2-((l-(l -methyl)ethyl)hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, m) l-[l-Oxo-2-((2,2-diethyl)-hydrazino)]ethyl-2-cyano thiazolidine, n) l-[l-Oxo-2-((l-ethyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, o) 3-[l-Oxo-2-(l-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, p) 3-[ 1 -Oxo-2-((l -phenylmethyl)hydrazino)] ethyl -4-cyano thiazolidine trifluoroacetate, q) 3-[l-Oxo-2-((l-(4-nitrophenylmethyl))hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, r) l-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, s) 3-[l-Oxo-2-((l-Cyclopentyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, t) l-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, u) 3-[l-Oxo-2-((l-Cyclohexyl)-hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, v) l-[l-Oxo-2-((l-methylpropyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, w) 3-[ 1 -Oxo-2-((l -methylpropyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, x) l-[l-Oxo-2-((l -Phenyl sulphonyl)hydrazino)]ethyl-2-cyano pyrrolidine trifluoroacetate, y) 3-[l-Oxo-2-((l-(4-methyl)cyclohexyl)hydrazino)]ethyl-4-cyano thiazolidine trifluoroacetate, z) l-[l-Oxo-2-((4-Methyl)cyclohexyl)hydrazino)]ethyl-2-cyano pyπolidine trifluoroacetate, aa) l-[l-Oxo-2-(l-(2-Pyridyl)-hydrazino)]ethyl-2-cyano pyrrolidine bis- trifluoroacetate, bb) 3-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, cc) 3-[l -Oxo-2- ((1 -(4-methyl) cyclohexyl)-hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, dd) l-[l-Oxo-2- ((l-Cycloheptyl)-hydrazino)] ethyl-2-cyano pyrrolidine trifluoroacetate, ee) [4-Cyano-3-(l-isopropylhydrazino)carbonyl thiazolidine hydrochloride], ff) [2-Cyano-l -(1 -cyclohexyl hydrazino)carbonyl pyrrolidine hydrochloride], gg)[4-Cyano-3-(l-cyclohexylhydrazino)carbonyl thiazolidine hydrochloride],
hh) 1 -[1 -Oxo-2- (2-cyclohexyl) hydrazino] ethyl -2-cyanopyrrolidine trifluoroacetate, ii) [4-Cyano-3-(l -phenyl hydrazino) carbonyl thiazolidine trifluoroacetate], jj) 3-[l-Oxo-2- (l-cyclohexyl-2-isopropyl) hydrazino] ethyl-4-cyanothiazolidine hydrochloride, kk)l-[l-Oxo-2-(4-methylcyclohexyl)hydrazino]ethyl-2-cyanopyrrolidine trifluoroacetate,
11) l-[l-Oxo-2-(l-cyclohexyl-2-isopropyl)hydrazino]ethyl-2-cyano pyrrolidine, mm) l-[l-Oxo-2-(l-(4-methylcyclohexylmethyl) hydrazino)]ethyl-2- cyanopyrrol idine trifluoroacetate, nn) 1-[1 -Oxo-2- (4-chlorophenyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate, oo) l-[l-Oxo-2-isopropyl-2-hydrazino] ethyl-2-cyano pyrrolidine trifluoroacetate,
pp) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-ethyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, qq) 3 - [ 1 -Oxo-2- ( 1 -(4-moφholinocarbonyl) hydrazino) ethyl] -4-cyanothiazolidine trifluoroacetate, rr) 3-[l-Oxo-2- (l-(4-methylcyclohexyl)-2-isopropyl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, ss) l -[l-Oxo-2- [(l-cyclohexyl)-2-(2-cyano-l -pyπolidino acetyl)] hydrazino] ethyl-
2-cyanopyrrolidine trifluoroacetate, tt)3-[l -Oxo-2- (12-bis- (2-(2-pyridyl) ethylaminocarbonyl) hydrazino)] ethyl-4- cyano thiazolidine bis trifluoroacetate, uu) 3-[l -Oxo-2- (l-(4-tert-butyl cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, vv) 1-[1 -Oxo-2- (1-tetralinyl) hydrazino] ethyl-2-cyanopyrrolidine trifluoroacetate,
ww) 3-[l -Oxo-2- (l-(4-tertbutylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xx) l-[l-Oxo-2- (l-cyclohexyl)-2-(4-cyano-3-thiazolidino acetyl)] hydrazino] ethyl- 2-cyano pyrrolidine, yy) 3-[l-Oxo-2- (l-isopropyl-4-piperidinyl) hydrazino)] ethyl-4-cyano thiazolidine trifluoroacetate, zz) 3-[l -Oxo-2- (l-(l-(4-cyanophenylmethyl)-piperidin-4-yl) hydrazino)] ethyl -4- cyanothiazolidine bis trifluoroacetate, aaa) 3-[ 1 -Oxo-2-[ 1 -(4-methylcyclohexyl)-2-( 1 -(3-pyridinylmethyl)-4- piperidinyl)]hydrazino]ethyl-4-cyanothiazolidine, bbb)3-[l -Oxo-2- [l-(4-methylcyclohexyl)-2-(l-isopropyl-4-piperidinyl)] hydrazino] ethyl-4-cyanothiazolidine, ccc) 3-[l-Oxo-2- (l-(l-(4-methylphenylsulphonyl)-4-piperidinyl)-hydrazino)] ethyl- 4-cyanothiazolidine trifluoroacetate, ddd) 3-[l -Oxo-2- [l-methyl-2- (l-(4-methylphenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, eee) 3-[l -Oxo-2- (l-(l-(3-pyridinemethyl)-4-piperidinyl) hydrazino)] ethyl-4- cyanothiazolidine tris trifluoroacetate, fff) 3-[l -Oxo-2- [l-methyl-2- (l-(4-cyanophenylmethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis trifluoroacetate, ggg) 3-[l -Oxo-2- [l-methyl-2- (l-(3-pyridinylmethyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine tris trifluoroacetate, hhh) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoro acetate, iii) 3-[l -Oxo-2- (l-(l-(4-nitrophenylmethyl)-piperidin-4-yl) hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, jjj) 3-[l -Oxo-2- [l-(l -(4-chlorophenylsulphonyl)-piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, kkk) 3-[l-Oxo-2- (1-(1 -norcamphoranyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, 111) 3-[l -Oxo-2- (l-(4-n propylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, mmm) 3-[l-Oxo-2-[l-(l -(4-methylcyclohexyl carbonyl)-piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, nnn) 3 - [ 1 -Oxo-2-( 1 -( 1 -acetyl)-piperidin-4-yl)hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, ooo) l l-Dioxo-3-[l-oxo-2-(l -(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, ppp) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, qqq) 3-[l-Oxo-2-(l-methyl-2-(4-methylcyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine, πr) 3-[l-Oxo-2-(l-(l-(23-dichlorophenyl carbonyl)-piperidin-4-yl) hydrazino) ] ethyl-4-cyanothiazolidine trifluoroacetate, sss) 3-[l-Oxo-2-[l-methyl-2-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)]- hydrazino] ethyl-4-cyanothiazolidine, ttt) 3-[l-Oxo-2-(l -(4-piperidinyl) hydrazino)]ethyl-4-cyanothiazolidine bis trifluoroacetate, uuu) [l-Oxo-2-(l-(l-(4-chlorophenylsulphonyl)-piperidin-4-yl)-hydrazino)] ethyl -2- cyanopyπolidine trifluoroacetate, vvv) 3-[l-Oxo-2-(l-(4-methylcyclohexyl)-2-acetyl) hydrazino]ethyl-4- cyanothiazolidine , www) 3-[l-Oxo-2-(l-(l-adamantanyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, xxx) 3-[l-Oxo-2-(l-(l-(tert-butyl carbonyl)-piperidin-4-yl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, yyy)3-[l-Oxo-2-(l-(l-(5-trifluoromethyl-2-pyridinyl)-piperidin-4-yl) hydrazino)] ethyl-4-cyano thiazolidine bis trifluoroacetate, zzz) 3-[l-Oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, aaaa) 3-[l-Oxo-2- (1 -(335 -trimethyl cyclohexyl)-hydrazino)] ethyl-4- cyanothiazolidine trifluoroacetate, bbbb)3-[ 1 -Oxo-2-( 1 -isopropyl-2-ethyl)-hydrazino]-ethyl-4-cyano thiazolidine trifluoroacetate, cccc)3-[ 1 -Oxo-2-[ 1 -( 1 -phenylmethyl-piperidin-4-yl)]-hydrazino]-ethyl-4- cyanothiazolidine trifluoroacetate, dddd) 3-[l-Oxo-2-(l-(l-(4-chlorophenyl sulphonylamino-4-cyclohexyl) hydrazino)] ethyl-4-cyanothiazolidine trifluoroacetate, eeee) 3-[l-Oxo-2-(pyridazin-l-yl)] ethyl-4-cyanothiazolidine, ffff) 3-[ 1 -Oxo-2-( 1 -( 1 -methanesulphonylamino-4-cyclohexyl)-2- isopropyl) hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, gggg) 3 -[ 1 -oxo-2-[ 1 -(1 (moφholinocarbonyl)-piperidin-4-yl)]hydrazino] ethyl-4- cyano- thiazolidine trifluoroacetate, hhhh) 3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, iiii) 3-[ 1 -oxo-2-[ 1 -( 1 (methylsulphonyl)-piperidin-4-yl)-2-isopropyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, jjjj)3-[ 1 -oxo-2-[ 1 -(1 -(methylsulphonyl)-piperidin-4-yl)-2-ethyl]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, kkkk) 3-[ 1 -oxo-2-[ 1 -( 1 -(moφholinocarbonyl)-piperidin-4-yl)-2- ethyl]hydrazino]ethyl- 4-cyanothiazolidine trifluoroacetate, llll) 3-[ 1 -oxo-2-[ 1 -( 1 -(N-ethylmethylaminocarbonyl)-piperidin-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trifluoroacetate, mmmm) 3-[ 1 -oxo-2-[ 1 -(1 -(4-methoxyphenylsulphonyl)-piperidin-4- yl)]hydrazino] ethyl- 4-cyanothiazolidine trifluoroacetate, nnnn) 3-[ 1 -oxo-2-[ 1 -( 1 -(4-methoxyphenylsulphonyl)aminocyclohexan-4-yl)] hydrazino] ethyl-4-cyanothiazolidine trifluoroacetate, oooo) 3-[l -oxo-2-[l-(l-(4-fluorobenzyl)aminocyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, pppp) 3-[ 1 -oxo-2-[ 1 -(1 -(4-fluorobenzyl)-piperidin-4-yl)]hydrazino]ethyl-4- cyanothiazolidine bis-trifluoroacetate, qqqq) 3-[l-oxo-2-[(l -(l-(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, rπr) 3-[l-oxo-2-[l-(l-(trimethyl acetamido)cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, ssss) 3-[ 1 -oxo-2-[ 1 -(1 -(methanesulphonyl)aminocyclohexan-4-yl)-2-ethyl] hydrazino] ethyl-4-cyanothiazolidine, tttt) 3-[l-oxo-2-[(l-(trimethyl acetamido) cyclohexan-4-yl)]hydrazino]ethyl-4- cyanothiazolidine trifluoroacetate, uuuu) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(4-cyanophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, vvvv)3-[ 1 -oxo-2-[ 1 -(4-fluorobenzoyl)aminocyclohexan-4-yl)]hydrazino] ethyl-4- cyanothiazolidine trifluoroacetate, wwww) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidin-4- yl)]-2- ethylhydrazino] ethyl-4-cyanothiazolidine tris-hydrochloride, xxxx) 3 -[ 1 -oxo-2- [- 1 -( 1 -(2-oxo-2(4-trifluorophenyl)aminoe thyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, yyyy) 3-[ 1 -oxo-2-[ 1 -(1 -(2-oxo-2(-adamant- 1 -yl)amino ethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, zzzz) 3-[l-oxo-2-[l-(l-(2-oxo-2(2,3-dihydrobenzo(14)dioxan-6- yl)aminoethyl) piperidin-4-yl)] hydrazino] ethyl-4-cyano-thiazolidine bis-trifluoroacetate, aaaaa) 3-[ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2(4-chlorophenyl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine bis-trifluoroacetate, bbbbb) 3[2-oxo-2-[l-(l-(2-oxo-2(pyrimidin-2-yl)aminoethyl)piperidin-4-yl)] hydrazino] ethyl -4-cyanothiazolidine tris-trifluoroacetate, ccccc) 3-[l-oxo-2-[l-(l-(-2-oxo-2(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl- 4-cyanothiazolidine bis-trifluoroacetate, ddddd)3 [ 1 -oxo-2-[ 1 -( 1 -(2-oxo-2-(cyclopropyl)aminoethyl)piperidin-4-yl)]hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, eeeee)3-[l-oxo-2-[l-(l-(2-cyanobiphenyl-4-yl)methyl)piperidine-4- yl]hydrazino]ethyl- 4-cyanothiazolidine bis-trifluoroacetate, fffff) 3-[l-oxo-2-[l-(l-(l-oxo-2-(moφholin-4-yl)ethyl)piperidin-4-yl)] hydrazino] ethyl-4-cyanothiazolidine bis-trifluoroacetate, ggggg) 3-[ 1 -oxo-2-[ 1 -(4 -(2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)amino cyclohex- 1 -yl)]hydrazino]ethyl-4-cyanothiazolidine tris-trifluoroacetate, hhhhh) 3-[ 1 -oxo-2-[ 1 -(4-(2-oxo-2-(4-cyanophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, iiiii) 3 - [ 1 -oxo-2- [ 1 -(4-(2-oxo-2-(4-chlorophenyl)aminoethyl)aminocyclohex- 1 - yl)]hydrazino]ethyl-4-cyanothiazolidine bis-trifluoroacetate, jjjjj) 3-[l-oxo-2-(l-(l-methanesulphonylamino-4-cyclohexyl)hydrazino)]ethyl-4- cyanothiazolidine hydrochloride and kkkkk) 3-[-l-oxo-2-[l-(l-(-2-oxo-2-(5-chloropyridin-2-yl)aminoethyl)piperidine-4- yl)]hydrazino]ethyl-4-cyanothiazolidine trihydrochloride.
PCT/IB2003/001330 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors WO2003084940A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2003214534A AU2003214534B2 (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
MXPA04009784A MXPA04009784A (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors.
KR10-2004-7015994A KR20040105853A (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhobitors
EP03710113A EP1492777A1 (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidase inhibitors
BR0308816-2A BR0308816A (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogs and their uses as dipeptide peptide inhibitors
CA002481995A CA2481995A1 (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
JP2003582137A JP2005532283A (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitrile and the like and their use as dipeptidyl-peptidase inhibitors
TW092127020A TW200511994A (en) 2002-04-08 2003-09-30 Novel compounds and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37022402P 2002-04-08 2002-04-08
US60/370,224 2002-04-08

Publications (2)

Publication Number Publication Date
WO2003084940A1 true WO2003084940A1 (en) 2003-10-16
WO2003084940B1 WO2003084940B1 (en) 2003-12-24

Family

ID=28792036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/001330 WO2003084940A1 (en) 2002-04-08 2003-04-03 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors

Country Status (13)

Country Link
US (1) US7138416B2 (en)
EP (1) EP1492777A1 (en)
JP (1) JP2005532283A (en)
KR (1) KR20040105853A (en)
CN (1) CN1633420A (en)
AU (1) AU2003214534B2 (en)
BR (1) BR0308816A (en)
CA (1) CA2481995A1 (en)
MX (1) MXPA04009784A (en)
PL (1) PL372814A1 (en)
RU (1) RU2004132719A (en)
WO (1) WO2003084940A1 (en)
ZA (1) ZA200407295B (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075421A1 (en) * 2004-02-05 2005-08-18 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
EP1684786A1 (en) * 2003-10-24 2006-08-02 Merck & Co., Inc. Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
US7205323B2 (en) 2004-10-12 2007-04-17 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
WO2007072083A1 (en) 2005-12-23 2007-06-28 Prosidion Limited Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
US7238724B2 (en) 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
US7348346B2 (en) 2004-03-08 2008-03-25 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
US20110152342A1 (en) * 2008-08-14 2011-06-23 Hiroshi Uchida Stabilized pharmaceutical composition
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
US11453621B2 (en) 2015-12-11 2022-09-27 Electrophoretics Limited Isobaric mass labels having n',n'-dimeihyl piperazine-2-carboxylic acid reporter moieties

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ZA200602051B (en) 2003-08-13 2007-10-31 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
KR20170005163A (en) 2003-11-17 2017-01-11 노파르티스 아게 Use of dipeptidyl peptidase iv inhibitors
CN1902184A (en) * 2003-11-18 2007-01-24 田纳西大学研究基金会 Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof
EP2165703A3 (en) 2004-01-20 2012-03-28 Novartis Pharma AG Direct compression formulation and process
CN1922139B (en) * 2004-02-18 2010-12-29 杏林制药株式会社 Bicyclic amide derivatives
JP4689599B2 (en) * 2004-02-27 2011-05-25 杏林製薬株式会社 Bicyclo derivative
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127053A (en) 2004-03-15 2011-07-20 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
US20070232586A1 (en) * 2004-04-21 2007-10-04 Kazuyuki Ohmoto Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof
FR2870538B1 (en) * 2004-05-19 2006-07-14 Servier Lab NOVEL DERIVATIVES OF PYRROLIDINES AND THIAZOLIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2006239929B2 (en) * 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
EP1926487A2 (en) * 2005-07-19 2008-06-04 University of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
AU2011202574B2 (en) * 2005-09-20 2012-02-02 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events
AU2006292377B2 (en) 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events
JP5101489B2 (en) * 2006-03-08 2012-12-19 杏林製薬株式会社 Process for producing aminoacetylpyrrolidinecarbonitrile derivative and its production intermediate
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2369341A3 (en) 2006-04-11 2012-01-04 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20081150A1 (en) * 2006-09-13 2008-10-03 Takeda Pharmaceutical DIPETHYLPEPTIDASE INHIBITORS
JP5571387B2 (en) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド Compounds and methods for the treatment of cancer
JPWO2008114857A1 (en) * 2007-03-22 2010-07-08 杏林製薬株式会社 Process for producing aminoacetylpyrrolidinecarbonitrile derivative
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
PT2959900T (en) * 2008-06-16 2017-06-22 Univ Tennessee Res Found Compound for treatment of cancer
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2010016584A1 (en) * 2008-08-07 2010-02-11 杏林製薬株式会社 Process for production of bicyclo[2.2.2]octylamine derivative
DK2344519T3 (en) 2008-11-07 2017-01-23 Massachusetts Gen Hospital C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
CN101445492B (en) * 2008-12-16 2012-05-30 天津药物研究院 Amide thiazole derivant, preparation method and use thereof
AT509045B1 (en) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H COMPOUNDS FOR THE TREATMENT OF ASTHMA BRONCHIALE
CN102883607B (en) 2010-03-01 2015-07-22 Gtx公司 Compounds for treatment of cancer
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
CN105601584A (en) * 2013-01-06 2016-05-25 天津市汉康医药生物技术有限公司 Thiazolidine derivatives, and preparation method and applications thereof
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
US6172081B1 (en) * 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010052488A (en) * 1998-06-03 2001-06-25 쥐피아이 엔아이엘 홀딩스 인코포레이티드 Aza-heterocyclic compounds used to treat neurological disorders and hair loss
CA2424475A1 (en) 2000-10-27 2002-05-02 Probiodrug Ag Method for the treatment of neurological and neuropsychological disorders
AU2002321135B2 (en) 2001-06-27 2007-11-08 Probiodrug Ag Dipepitdyl peptidase IV inhibitors and their uses as anti-cancer agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
US6172081B1 (en) * 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637546B2 (en) 2002-09-19 2014-01-28 Abbvie Inc. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV)
US8119664B2 (en) 2002-09-19 2012-02-21 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7238724B2 (en) 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1684786A1 (en) * 2003-10-24 2006-08-02 Merck & Co., Inc. Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
EP1684786A4 (en) * 2003-10-24 2007-12-12 Merck & Co Inc Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US7754757B2 (en) 2004-02-05 2010-07-13 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
US8053465B2 (en) 2004-02-05 2011-11-08 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
AU2005210285B2 (en) * 2004-02-05 2008-01-24 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
WO2005075421A1 (en) * 2004-02-05 2005-08-18 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
CN1918119B (en) * 2004-02-05 2011-08-31 杏林制药株式会社 Bicycloester derivative
US7671076B2 (en) 2004-03-08 2010-03-02 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7348346B2 (en) 2004-03-08 2008-03-25 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7205323B2 (en) 2004-10-12 2007-04-17 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation
US7538128B2 (en) 2004-10-12 2009-05-26 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them
US7524844B2 (en) 2004-10-12 2009-04-28 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007072083A1 (en) 2005-12-23 2007-06-28 Prosidion Limited Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20110152342A1 (en) * 2008-08-14 2011-06-23 Hiroshi Uchida Stabilized pharmaceutical composition
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11453621B2 (en) 2015-12-11 2022-09-27 Electrophoretics Limited Isobaric mass labels having n',n'-dimeihyl piperazine-2-carboxylic acid reporter moieties
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
MXPA04009784A (en) 2004-12-13
RU2004132719A (en) 2005-08-27
US20030225102A1 (en) 2003-12-04
ZA200407295B (en) 2006-02-22
WO2003084940B1 (en) 2003-12-24
AU2003214534B2 (en) 2006-08-31
BR0308816A (en) 2005-03-22
EP1492777A1 (en) 2005-01-05
KR20040105853A (en) 2004-12-16
US7138416B2 (en) 2006-11-21
PL372814A1 (en) 2005-08-08
CA2481995A1 (en) 2003-10-16
JP2005532283A (en) 2005-10-27
CN1633420A (en) 2005-06-29
AU2003214534A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
US20030225102A1 (en) Novel compounds and therapeutic uses thereof
US20040106802A1 (en) Novel compounds and therapeutic uses thereof
JP3909056B2 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EP1406872B1 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
EP1245568B1 (en) Sulfonyl derivatives of amino acids and their use as inhibitors of dipeptidyl-peptidase IV (DPP IV)
US7125863B2 (en) Inhibitors of dipeptidyl peptidase IV
US20040235752A1 (en) 3-fluoro-pyrrolidines as antidiabetic agents
US20050131019A1 (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20070265302A1 (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2005058849A1 (en) New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
CZ20021520A3 (en) Derivatives of 1-(2 -aminoacyl)-2-cyanpyrrolidine, pharmaceutical preparation, method for treating disorder of glucose tolerance or diabetes mellitus of type 2 and use of these derivatives
JP2005500321A (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
CA2441092A1 (en) Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
BG107799A (en) Cyanopyrrolidine derivatives
MXPA04008278A (en) Glutaminyl based dpiv inhibitors.
KR20050016551A (en) Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
CN101970402A (en) Pyrrolidine derivatives
EP1732918A1 (en) Novel pyrrolidine-3,4-dicarboxamide derivatives
WO2005033106A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
US4482725A (en) S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics
Sankaranarayanan Novel compounds and therapeutic uses thereof
MXPA06002950A (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
KR20060086404A (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Free format text: 20030920

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004/07295

Country of ref document: ZA

Ref document number: 200407295

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003214534

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003710113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 372814

Country of ref document: PL

Ref document number: PA/A/2004/009784

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2481995

Country of ref document: CA

Ref document number: 1020047015994

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038077345

Country of ref document: CN

Ref document number: 2003582137

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 01580/KOLNP/2004

Country of ref document: IN

Ref document number: 1580/KOLNP/2004

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004132719

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047015994

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003710113

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003214534

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2003710113

Country of ref document: EP